

Cochrane Database of Systematic Reviews

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review)

Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL

Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database of Systematic Reviews* 2017, Issue 10. Art. No.: CD001146. DOI: 10.1002/14651858.CD001146.pub5.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	6
OBJECTIVES	6
METHODS	6
RESULTS	8
Figure 1	9
Figure 2	17
Figure 3	18
Figure 4	19
Figure 5	20
DISCUSSION	25
AUTHORS' CONCLUSIONS	26
ACKNOWLEDGEMENTS	26
REFERENCES	27
CHARACTERISTICS OF STUDIES	35
DATA AND ANALYSES	63
Analysis 1.1. Comparison 1 Mortality, Outcome 1 Neonatal mortality (up to 28 days).	64
Analysis 1.2. Comparison 1 Mortality, Outcome 2 Mortality at 36 weeks.	64
Analysis 1.3. Comparison 1 Mortality, Outcome 3 Mortality to hospital discharge.	65
Analysis 1.4. Comparison 1 Mortality, Outcome 4 Mortality at latest reported age.	66
Analysis 2.1. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 1 BPD (28 days of life).	68
Analysis 2.2. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 2 BPD (36 weeks' postmenstrual age).	69
Analysis 2.3. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 3 BPD at 36 weeks' postmenstrual age in survivors.	70
Analysis 2.4. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 4 Late rescue with corticosteroids.	71
Analysis 2.5. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 5 Survivors who had late rescue with corticosteroids.	72
Analysis 2.6. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 6 Survivors discharged home on oxygen.	72
Analysis 3.1. Comparison 3 Death or bronchopulmonary dysplasia (BPD), Outcome 1 Death or BPD at 28 days of life.	74
Analysis 3.2. Comparison 3 Death or bronchopulmonary dysplasia (BPD), Outcome 2 Death or BPD at 36 weeks' postmenstrual age.	74
Analysis 4.1. Comparison 4 Failure to extubate, Outcome 1 Failure to extubate by third day.	76
Analysis 4.2. Comparison 4 Failure to extubate, Outcome 2 Failure to extubate by seventh day.	76
Analysis 4.3. Comparison 4 Failure to extubate, Outcome 3 Failure to extubate by 14th day.	77
Analysis 4.4. Comparison 4 Failure to extubate, Outcome 4 Failure to extubate by 28th day.	77
Analysis 5.1. Comparison 5 Complications during primary hospitalisation, Outcome 1 Infection.	80
Analysis 5.2. Comparison 5 Complications during primary hospitalisation, Outcome 2 Hyperglycaemia.	81
Analysis 5.3. Comparison 5 Complications during primary hospitalisation, Outcome 3 Hypertension.	82
Analysis 5.4. Comparison 5 Complications during primary hospitalisation, Outcome 4 Hypertrophic cardiomyopathy.	82
Analysis 5.5. Comparison 5 Complications during primary hospitalisation, Outcome 5 Growth failure.	83
Analysis 5.6. Comparison 5 Complications during primary hospitalisation, Outcome 6 Pulmonary air leak.	83
Analysis 5.7. Comparison 5 Complications during primary hospitalisation, Outcome 7 Patent ductus arteriosus (PDA).	84
Analysis 5.8. Comparison 5 Complications during primary hospitalisation, Outcome 8 Severe IVH.	85
Analysis 5.9. Comparison 5 Complications during primary hospitalisation, Outcome 9 Severe intraventricular haemorrhage (IVH) in infants examined.	86
Analysis 5.10. Comparison 5 Complications during primary hospitalisation, Outcome 10 Periventricular leukomalacia (PVL).	86
Analysis 5.11. Comparison 5 Complications during primary hospitalisation, Outcome 11 PVL in infants with cranial ultrasound scans.	87
Analysis 5.12. Comparison 5 Complications during primary hospitalisation, Outcome 12 PVL in survivors seen at follow-up Analysis 5.13. Comparison 5 Complications during primary hospitalisation, Outcome 13 Necrotising enterocolitis (NEC)	87 88
Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review)	i



Analysis 5.14. Comparison 5 Complications during primary hospitalisation, Outcome 14 Gastrointestinal bleeding.	89
	89
	90
	91
(ROP).	
Analysis 5.18. Comparison 5 Complications during primary hospitalisation, Outcome 18 Severe ROP.	91
Analysis 5.19. Comparison 5 Complications during primary hospitalisation, Outcome 19 Severe ROP in survivors	92
Analysis 6.1. Comparison 6 Long-term follow-up, Outcome 1 Bayley Mental Developmental Index (MDI) <-2 SD	96
Analysis 6.2. Comparison 6 Long-term follow-up, Outcome 2 Bayley MDI <-2 SD in tested survivors.	96
Analysis 6.3. Comparison 6 Long-term follow-up, Outcome 3 Bayley Psychomotor Developmental Index (PDI) <-2 SD	97
Analysis 6.4. Comparison 6 Long-term follow-up, Outcome 4 Bayley PDI <-2 SD in tested survivors	97
Analysis 6.5. Comparison 6 Long-term follow-up, Outcome 5 Developmental delay (criteria not specified).	97
Analysis 6.6. Comparison 6 Long-term follow-up, Outcome 6 Developmental delay (criteria not specified) in tested survivors.	97
Analysis 6.7. Comparison 6 Long-term follow-up, Outcome 7 Blindness.	98
Analysis 6.8. Comparison 6 Long-term follow-up, Outcome 8 Blindness in survivors assessed.	98
Analysis 6.9. Comparison 6 Long-term follow-up, Outcome 9 Deafness.	99
Analysis 6.10. Comparison 6 Long-term follow-up, Outcome 10 Deafness in survivors assessed.	99
Analysis 6.11. Comparison 6 Long-term follow-up, Outcome 11 Cerebral palsy.	99
Analysis 6.12. Comparison 6 Long-term follow-up, Outcome 12 Death before follow-up in trials assessing cerebral palsy 1	100
Analysis 6.13. Comparison 6 Long-term follow-up, Outcome 13 Death or cerebral palsy.	101
Analysis 6.14. Comparison 6 Long-term follow-up, Outcome 14 Cerebral palsy in survivors assessed.	102
Analysis 6.15. Comparison 6 Long-term follow-up, Outcome 15 Major neurosensory disability (variable criteria - see individual 1 studies).	102
Analysis 6.16. Comparison 6 Long-term follow-up, Outcome 16 Death before follow-up in trials assessing major neurosensory 1 disability (variable criteria).	103
Analysis 6.17. Comparison 6 Long-term follow-up, Outcome 17 Death or major neurosensory disability (variable criteria) 1	104
Analysis 6.18. Comparison 6 Long-term follow-up, Outcome 18 Major neurosensory disability in survivors examined (variable 1 criteria).	104
Analysis 6.19. Comparison 6 Long-term follow-up, Outcome 19 Abnormal neurological exam (variable criteria - see individual 1 studies).	105
	105
	106
	106
Analysis 6.23. Comparison 6 Long-term follow-up, Outcome 23 Intellectual impairment (IQ < 70).	107
	107
Analysis 6.25. Comparison 6 Long-term follow-up, Outcome 25 "Major neurosensory impairment" - blindness or deafness 1	107
Analysis 6.26. Comparison 6 Long-term follow-up, Outcome 26 "Major neurosensory impairment" - blindness or deafness - in 1 survivors assessed.	107
Analysis 6.27. Comparison 6 Long-term follow-up, Outcome 27 Behaviour abnormalities.	108
Analysis 6.28. Comparison 6 Long-term follow-up, Outcome 28 Behaviour abnormalities in 3-year-old survivors assessed 1	108
Analysis 6.29. Comparison 6 Long-term follow-up, Outcome 29 Abnormal EEG	108
	109
Analysis 6.31. Comparison 6 Long-term follow-up, Outcome 31 Rehospitalisation in infancy.	109
Analysis 6.32. Comparison 6 Long-term follow-up, Outcome 32 Rehospitalisation in infancy in survivors	109
APPENDICES	109
	111
HISTORY	111
CONTRIBUTIONS OF AUTHORS	113
DECLARATIONS OF INTEREST	113
SOURCES OF SUPPORT	113
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	113



INDEX TERMS

113	

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants

Lex W Doyle¹, Jeanie L Cheong², Richard A Ehrenkranz³, Henry L Halliday⁴

¹Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Australia. ²Newborn Research Centre and Neonatal Services, The Royal Women's Hospital, Melbourne, Australia. ³Department of Pediatrics, Yale University, New Haven, Connecticut, USA. ⁴Retired Honorary Professor of Child Health, Queen's University, Belfast, UK

Contact address: Lex W Doyle, Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, 3052, Australia. lwd@unimelb.edu.au.

Editorial group: Cochrane Neonatal Group. **Publication status and date:** Edited (no change to conclusions), published in Issue 1, 2018.

Citation: Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database of Systematic Reviews* 2017, Issue 10. Art. No.: CD001146. DOI: 10.1002/14651858.CD001146.pub5.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Bronchopulmonary dysplasia remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to prevent or treat bronchopulmonary dysplasia because of their potent anti-inflammatory effects.

Objectives

To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia.

Search methods

For the 2017 update, we used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 2013 to 21 February 2017). We also searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi-randomised trials.

Selection criteria

For this review, we selected RCTs examining systemic postnatal corticosteroid treatment within the first seven days of life (early) in highrisk preterm infants. Most studies evaluated the use of dexamethasone, but we also included studies that assessed hydrocortisone, even when used primarily for management of hypotension.

Data collection and analysis

We used the GRADE approach to assess the quality of evidence.

We extracted and analysed data regarding clinical outcomes that included mortality, bronchopulmonary dysplasia, death or bronchopulmonary dysplasia, failure to extubate, complications during primary hospitalisation, and long-term health outcomes.



Main results

We included 32 RCTs enrolling a total of 4395 participants. The overall risk of bias of included studies was probably low, as all were RCTs, and most trials used rigorous methods. Investigators reported significant benefits for the following outcomes overall: lower rates of failure to extubate, decreased risks of bronchopulmonary dysplasia both at 28 days of life and at 36 weeks' postmenstrual age, death or bronchopulmonary dysplasia at 28 days of life and at 36 weeks' postmenstrual age, patent ductus arteriosus, and retinopathy of prematurity (ROP), including severe ROP. Researchers found no significant differences in rates of neonatal or subsequent mortality; they noted that gastrointestinal bleeding and intestinal perforation were important adverse effects, and that risks of hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure were increased. The 13 trials that reported late outcomes described several adverse neurological effects at follow-up examination, including cerebral palsy. However, study authors indicated that major neurosensory disability was not significantly increased, either overall in the eight studies for which this outcome could be determined, or in the two individual studies in which rates of cerebral palsy or abnormal neurological examination were significantly increased. Moreover, data show that rates of the combined outcomes of death or cerebral palsy, or of death or major neurosensory disability, were not significantly increased. Two-thirds of studies used dexamethasone (n = 21). Subgroup analyses by type of corticosteroid revealed that most of the beneficial and harmful effects of treatment were attributable to dexamethasone. However, as with dexamethasone, hydrocortisone was associated with reduced rates of patent ductus arteriosus, mortality, and the combined outcome of mortality or chronic lung disease, but with increased occurrence of intestinal perforation. Results showed that hydrocortisone was not associated with obvious longer-term problems.

Use of the GRADE approach revealed that the quality of evidence was high for the major outcomes considered, but review authors downgraded quality one level for several outcomes (mortality at latest age, bronchopulmonary dysplasia at 36 weeks, and death or bronchopulmonary dysplasia at 36 weeks) because of weak evidence of publication bias or moderate heterogeneity (death or cerebral palsy).

Authors' conclusions

Benefits of early postnatal corticosteroid treatment (≤ 7 days), particularly dexamethasone, may not outweigh adverse effects associated with this treatment. Although early corticosteroid treatment facilitates extubation and reduces risk of bronchopulmonary dysplasia and patent ductus arteriosus, it causes short-term adverse effects including gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure. Long-term follow-up studies report increased risk of abnormal findings on neurological examination and increased risk of cerebral palsy. However, the methodological quality of studies examining long-term outcomes is limited in some cases: Surviving children have been assessed predominantly before school age; no study has been sufficiently powered to detect important adverse long-term neurosensory outcomes; and no study has been designed with survival free of adverse long-term neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. Hydrocortisone reduced rates of patent ductus arteriosus, of mortality, and of the combined outcome of mortality or bronchopulmonary dysplasia, without causing any obvious long-term harm. However, gastrointestinal perforation was more frequent in the hydrocortisone group. Longer-term follow-up into late childhood is vital for assessment of important effects or other effects that cannot be assessed in early childhood, such as effects of early hydrocortisone treatment on higher-order neurological functions, including cognitive function, academic performance, behaviour, mental health, and motor function. Further randomised controlled trials of early hydrocortisone should include longer-term survival free of neurodevelopmental disability as the main outcome.

PLAIN LANGUAGE SUMMARY

Early (up to seven days) systemic postnatal corticosteroids for preventing bronchopulmonary dysplasia in preterm infants

Review objective: To determine the relative benefits and harms of treatment with drugs that suppress inflammation, called corticosteroids, given to babies born too early during the first week after birth to prevent lung injury, known as bronchopulmonary dysplasia (sometimes also called chronic lung disease).

Background: Corticosteroids can reduce lung inflammation in newborn babies with bronchopulmonary dysplasia but may produce major adverse effects. Bronchopulmonary dysplasia is a major problem for newborn babies in neonatal intensive care units. Persistent inflammation of the lungs is the most likely cause. Corticosteroid drugs have been used to prevent or treat bronchopulmonary dysplasia through their strong anti-inflammatory effects.

Study characteristics: We reviewed all clinical trials in preterm babies in which corticosteroids had been given as a medication during the first week after birth, and from which data on the rate of bronchopulmonary dysplasia later in the newborn period were available.

Key results: This review of trials revealed that the benefits of giving systemic corticosteroids to infants starting up to seven days after birth may not outweigh the known adverse effects. However, a particular corticosteroid called hydrocortisone shows promise in improving short-term outcomes without adversely affecting long-term neurodevelopment. Beneficial effects of systemic corticosteroids overall included shorter time on the ventilator and less bronchopulmonary dysplasia, but adverse effects included higher blood pressure, bleeding from the stomach or bowel, perforation of the bowel, excessive glucose in the bloodstream, and increased risk of cerebral palsy at follow-up,

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



particularly in those treated with dexamethasone - another type of corticosteroid. Early use of corticosteroids, especially dexamethasone, to treat or prevent bronchopulmonary dysplasia should be curtailed until additional research has been performed.

Quality of evidence: Overall, the quality of evidence supporting our conclusions was high.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants

Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants

Patient or population: preventing bronchopulmonary dysplasia in preterm infants

Setting: neonatal intensive care units

Intervention: early systemic postnatal corticosteroids

Comparison: placebo or no treatment

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No. of partici- pants	Quality of the evidence	Comments
	Risk with placebo or no treatment	Risk with early systemic postnatal corticosteroids		(studies)	(GRADE)	
Mortality at 36 weeks	Study population		RR 1.01 - (0.89 to 1.14)	3733 (20 RCTs)	⊕⊕⊕⊕ HIGH	
	211 per 1000	213 per 1000 (188 to 241)		(201013)	mon	
Mortality at latest reported age	Study population		RR 0.95 – (0.85 to 1.06)	4373 (31 RCTs)	⊕⊕⊕⊙ MODERATEª	
	232 per 1000	221 per 1000 (197 to 246)	- (0.03 to 1.00)			
BPD (36 weeks)	Study population		RR 0.79 - (0.72 to 0.87)	3929 (24 RCTs)	⊕⊕⊕⊝ MODERATE ^b	
	322 per 1000	254 per 1000 (232 to 280)	(0.12 (0.001)			
Death or BPD at 36 weeks	Study population		RR 0.88 – (0.83 to 0.93)	3960 (25 RCTs)	⊕⊕⊕⊝ MODERATE ^b	
	531 per 1000	467 per 1000 (441 to 494)	- (0.03 (0 0.33)			
Gastrointestinal perforation	Study population			3040 ⊕⊕⊕⊕ (16 RCTs) HIGH	⊕⊕⊕⊕ HIGH	
	43 per 1000	74 per 1000 (56 to 99)	_ (1.23 to 2.30)			
Cerebral palsy	Study population		RR 1.42 (1.06 to 1.91)	1973 (13 RCTs)	⊕⊕⊕⊕ HIGH	

Early (~ 0		74 per 1000	106 per 1000 (79 to 142)			
davel	Death or cerebral palsy	Study population		RR 1.03 - (0.91 to 1.16)	1973 (13 RCTs)	⊕⊕⊕⊝ MODERATE ^c
evetamic n		335 per 1000	345 per 1000 (305 to 389)	(0.51 (0 1.10)		MODERATE

*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio; RR: risk ratio.

GRADE Working Group grades of evidence.

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

^{*a*}Downgraded one level for serious study limitations owing to weak evidence for publication bias, particularly for studies of hydrocortisone. ^{*b*}Downgraded one level for serious study limitations owing to weak evidence for publication bias, for both dexamethasone and hydrocortisone studies. ^{*c*}Downgraded one level for serious study limitations owing to moderate heterogeneity, particularly for studies of dexamethasone. Cochrane Library

Trusted evidence. Informed decision Better health.



BACKGROUND

Description of the condition

Advances in neonatal care, including use of antenatal corticosteroids and surfactant therapy, have improved the outcomes of preterm infants with respiratory distress syndrome, but risk of chronic lung disease or bronchopulmonary dysplasia (BPD) has been only modestly reduced (Egberts 1997). The terms 'chronic lung disease' and 'bronchopulmonary dysplasia' are often used interchangeably; for the purposes of this review, we have decided to use 'bronchopulmonary dysplasia' to describe the condition of infants with oxygen dependency at 28 days of life or at 36 weeks' postmenstrual age. More infants with BPD are now cared for in neonatal intensive care units (NICUs), and management of their condition is both time-consuming and costly. Bronchopulmonary dysplasia refers to injury and maldevelopment of the lung that follows preterm birth and is a major problem in NICUs. Persistent inflammation in the lungs is the most likely underlying pathogenesis.

Description of the intervention

Postnatal corticosteroid treatment has been shown to have some beneficial acute effects on lung function in infants with established BPD, especially among those who are ventilator-dependent (CDTG 1991; Mammel 1983). However, clinicians have been concerned that the benefits of corticosteroids might not outweigh associated adverse effects, which include hypertension, hyperglycaemia, intestinal perforation, and extreme catabolism (Anonymous 1991; Ng 1993).

Corticosteroids have been used to try to prevent BPD by treating atrisk preterm infants, starting within the first four days of life. They are given parenterally or enterally. It is not clear whether early use of corticosteroids provides long-term benefits, nor is it clear whether adverse neurological outcomes observed in animal studies do not apply to the immature human newborn infant.

How the intervention might work

Corticosteroids might prevent BPD through their potent antiinflammatory effects.

Why it is important to do this review

Multiple systematic reviews have examined the use of postnatal corticosteroids in infants with or at risk of BPD (Arias-Camison 1999; Bhuta 1998; Doyle 2000; Doyle 2010a; Doyle 2010b; Doyle 2010c; Doyle 2014a; Doyle 2014b; Halliday 1997; Halliday 1999; Tarnow-Mordi 1999). Other systematic reviews have explored early versus late use of inhaled corticosteroids and comparisons of systemic versus inhaled steroids for prevention or treatment of BPD (Onland 2017; Shah 2007b; Shah 2012a; Shah 2012b; Shah 2017).

Two existing Cochrane reviews have reviewed separately trials in which postnatal corticosteroids were started before 8 days of birth or after the first 7 days following birth (Doyle 2014a; Doyle 2014b). This review examines the outcomes of trials in which preterm infants were treated with corticosteroids up to seven days after birth. It is an update of previous Cochrane reviews and includes long-term outcome data from 13 trials (Doyle 2014a; Halliday 2000; Halliday 2010).

OBJECTIVES

To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia.

METHODS

Criteria for considering studies for this review

Types of studies

We sought to identify randomised controlled trials (RCTs) of systemic postnatal corticosteroid therapy in preterm infants at risk of developing BPD, who were enrolled within the first seven days of life (early postnatal corticosteroids). We included trials that provided hydrocortisone in the first days of life, even if it had been used primarily to treat or prevent hypotension.

Types of participants

Preterm infants at risk of developing BPD, including those who are ventilator-dependent.

Types of interventions

Intravenous or oral corticosteroids versus control (placebo or no treatment). We did not include in this review trials of inhaled corticosteroids.

Types of outcome measures

Primary outcomes

- Mortality
- Bronchopulmonary dysplasia (at 28 days of life, at 36 weeks' postmenstrual age, and at 36 weeks' postmenstrual age in survivors)
- Death or bronchopulmonary dysplasia (at 28 days of life and at 36 weeks' postmenstrual age)
- Long-term outcomes (including blindness, deafness, cerebral palsy, and major neurosensory disability)

Secondary outcomes

- Failure to extubate
- Late rescue with corticosteroids (in all infants and in survivors)
- Need for home oxygen therapy
- Complications during primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus, severe intraventricular haemorrhage, periventricular leukomalacia, necrotising enterocolitis, gastrointestinal bleeding, intestinal perforation, and severe retinopathy of prematurity)

Search methods for identification of studies

Electronic searches

We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane Neonatal search strategy for specialized register).

We conducted a comprehensive search that included the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1) in



the Cochrane Library; MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 2013 to 21 February 2017), using the following search terms: (adrenal cortex hormones OR dexamethasone OR betamethasone OR hydrocortisone OR steroid OR corticosteroid), plus database-specific limiters for RCTs and neonates (see Appendix 1 for full search strategies for each database). We did not apply language restrictions.

We searched clinical trials registries for ongoing or recently completed trials (clinicaltrials.gov; the World Health Organization International Trial Registry and Platform (www.whoint/ictrp/search/en/); and the ISRCTN Registry).

See Appendix 2 for search strategies used previously.

Searching other resources

We also searched the reference lists of all published trials to identify trials overlooked during the electronic literature search.

Data collection and analysis

We used methods of the Cochrane Neonatal Group for data collection and analysis.

Selection of studies

We included all randomised and quasi-randomised controlled trials that fulfilled the selection criteria described in the previous section. Two review authors (LWD and JC) independently reviewed results of the updated search and selected studies for inclusion. We resolved disagreements by discussion.

Data extraction and management

For each trial, we sought information regarding methods of randomisation, blinding, stratification, and reporting of outcomes for all infants enrolled, and whether the trial used a single-centre or multi-centre setting. Information on trial participants included birth weight, gestational age, severity of respiratory distress syndrome, need for mechanical ventilation and surfactant, and sex. We analysed information on clinical outcomes for mortality, survival without BPD, BPD defined at 28 days of life and at 36 weeks' postmenstrual age, failure to extubate, pneumothorax, infection, hyperglycaemia, hypertension, severe retinopathy of prematurity, patent ductus arteriosus, severe intraventricular haemorrhage, periventricular leukomalacia, necrotising enterocolitis, gastrointestinal bleeding, intestinal perforation, and need for late corticosteroid treatment, as well as long-term outcomes such as developmental delay, blindness, deafness, cerebral palsy, and major neurosensory disability.

For each study, one review author entered final data into Review Manager (RevMan) 5 software (RevMan 2014); a second review author checked the data for accuracy. We resolved discrepancies through discussion or by consultation with a third assessor.

We attempted to contact authors of the original reports to request further details when information regarding any of the above was unclear.

Assessment of risk of bias in included studies

Two review authors (LWD, JC) independently assessed risk of bias (low, high, or unclear) of all included trials using the Cochrane 'Risk of bias' tool for the following domains (Higgins 2011).

- Sequence generation (selection bias).
- Allocation concealment (selection bias).
- Blinding of participants and personnel (performance bias).
- Blinding of outcome assessment (detection bias).
- Incomplete outcome data (attrition bias).
- Selective reporting (reporting bias).
- Any other bias.

We resolved disagreements by discussion or by consultation with a third assessor. See Appendix 3 for a more detailed description of risk of bias for each domain.

Measures of treatment effect

We used standard methods of the Cochrane Neonatal Group when analysing data.

We performed statistical analyses using RevMan 5. We analysed dichotomous data using risk ratio (RR), risk difference (RD), and the number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH). We reported 95% confidence intervals (CIs) for all estimates.

We included no continuous outcomes in this review. If included, we planned to analyse continuous data using the mean difference (MD) or the standardised mean difference (SMD) to combine trials that measure the same outcome using different methods.

Unit of analysis issues

For clinical outcomes such as episodes of sepsis, we analysed the data as proportions of neonates having one or more episodes.

Dealing with missing data

For included studies, we noted levels of attrition. If we had concerns regarding the impact of including studies with high levels of missing data in the overall assessment of treatment effect, we planned to explore this concern via sensitivity analysis.

We conducted all outcome analyses on an intention-to-treat basis, that is, we included in the analyses all participants randomised to each group. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.

Assessment of heterogeneity

We examined heterogeneity between trials by inspecting forest plots and by quantifying the impact of heterogeneity using the l^2 statistic. If noted, we planned to explore possible causes of statistical heterogeneity by conducting prespecified subgroup analyses (e.g. differences in study quality, participants, intervention regimens, or outcome assessments).

Assessment of reporting biases

We assessed possible publication bias and other biases by examining symmetry/asymmetry of funnel plots.

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

For included trials that were recently performed (and therefore were prospectively registered), we explored possible selective reporting of study outcomes by comparing primary and secondary outcomes described in the reports against primary and secondary outcomes proposed at trial registration, using the websites www.clinicaltrials.gov and www.controlled-trials.com. If we found such discrepancies, we planned to contact the primary investigators to request missing outcome data on outcomes prespecified at trial registration.

Data synthesis

Quality of evidence

We used the GRADE approach, as outlined in the *GRADE Handbook*, to assess the quality of evidence for the following (clinically relevant) outcomes: mortality, BPD, death or BPD, intestinal perforation, and cerebral palsy (Schünemann 2013).

Two review authors independently assessed the quality of evidence for each of the outcomes above. We considered evidence from RCTs as high quality but downgraded evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. We used the GRADEproGDT Guideline Development Tool to create a 'Summary of findings' table to report the quality of evidence (GRADEpro GDT).

Through the GRADE approach, we assessed the quality of a body of evidence by assigning one of four grades.

- High: We are very confident that the true effect lies close to that of the estimate of the effect.
- Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

- Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
- Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

When we judged meta-analysis to be appropriate, we carried out the analysis using RevMan 5, as supplied by Cochrane. We used the Mantel-Haenszel method to obtain estimates of typical risk ratio and risk difference. We included no continuous outcomes in this review. We planned to use the inverse variance method to analyse continuous measures, if included.

We used the fixed-effect model for all meta-analyses.

Subgroup analysis and investigation of heterogeneity

We performed subgroup analyses by type of corticosteroid used (dexamethasone or hydrocortisone) when we identified sufficient numbers of trials to make such subgroup analyses meaningful.

Sensitivity analysis

We planned to perform sensitivity analyses for situations that might affect interpretation of significant results (e.g. when risk of bias is associated with the quality of some included trials, when we note missing outcome data). We thought no such analyses were necessary for this review.

RESULTS


Description of studies

Results of the search

Thirty-two studies qualified for inclusion in this review (Figure 1). Most of these trials enrolled low birth weight infants with respiratory distress syndrome who were receiving mechanical ventilation.



Figure 1. Study flow diagram: review update.



Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Figure 1. (Continued)

quantitative synthesis (meta-analysis)

Included studies

See Characteristics of included studies.

The corticosteroid that was usually administered was dexamethasone, and the most common treatment regimen consisted of 0.50 mg/kg/d for three days followed by 0.25 mg/kg/d for three days, then 0.12 mg/kg/d for three days followed by 0.05 mg/kg/d for three days. However, trialists described considerable variation in treatment regimens, including short courses of one to two days and longer courses of up to four weeks. Eleven studies used hydrocortisone (Baden 1972; Batton 2012; Baud 2016; Biswas 2003; Bonsante 2007; Efird 2005; Hochwald 2014; Ng 2006; Peltoniemi 2005; Watterberg 1999; Watterberg 2004). In some cases, when low (almost physiological) doses were used, the indication was management of hypotension (see under Description of studies).

Anttila 2005 was a multi-centre, double-blind, placebo-controlled trial of infants with birth weight of 500 grams to 999 grams, gestation less than 32 weeks, and respiratory failure by four hours of age. Investigators randomised 109 infants to receive four doses of dexamethasone (0.25 mg/kg at 12-hour intervals) or saline placebo.

Baden 1972 included 44 infants with respiratory distress syndrome, mild hypoxia and hypercapnia, and a chest radiograph compatible with respiratory distress syndrome. Researchers randomised infants to receive hydrocortisone 15 mg/kg on admission and 12 hours later intravenously, or placebo. Birth weights ranged from 800 grams to 2805 grams, and gestational ages from 26 to 36 weeks.

Batton 2012 was a pilot study of infants at 23 to 26 weeks' gestation with low blood pressure in the first 24 hours of life. Investigators compared dopamine and hydrocortisone versus placebo using a factorial design. The dose of hydrocortisone was 1 mg/kg loading, then 0.5 mg/kg 12-hourly for six doses (total dose, 3.5 mg/kg). The trial was stopped early because of slow recruitment after only 10 infants were enrolled.

Baud 2016 was a multi-centre double-blind randomised controlled trial of 523 infants at 24 to 27 weeks' gestational age who were recruited from 21 French centres with NICU facilities in the first 24 hours after birth between 25 May 2008 and 31 January 2014. The treatment group received hydrocortisone hemisuccinate 1 mg/kg/d divided into two doses for seven days, then 0.5 mg/kg/d once per day for three days (total dose, 8.5 mg/kg). Control infants were given an equivalent volume of 5% glucose placebo. The trial was halted early because of lack of funding.

Biswas 2003 was a multi-centre randomised trial of 253 infants of less than 30 weeks' gestational age. Investigators mechanically ventilated infants and entered them into the study within nine hours of birth. They gave all infants surfactant during the first 24 hours of life. Trialists randomised those in the treatment group (n = 125) to receive an infusion of hydrocortisone 1 mg/kg/d and triiodothyronine (T3) 6 μ g/kg/d for five days, then hydrocortisone 0.5 mg/kg/d and T3 3 μ g/kg/d for two days. The placebo group (n = 128) received an equal volume of 5% dextrose.

Bonsante 2007 enrolled a total of 50 infants of birth weight less than 1250 grams or at 24 to 30 weeks' gestation who were less than 48 hours old and were ventilator-dependent after surfactant treatment. Exclusion criteria were cardiopulmonary malformations, perinatal asphyxia, death within 12 hours after recruitment, or use of steroids for any reason within 12 days after birth. Researchers excluded no infants for these latter two reasons. They stratified infants by birth weight (not specified), gestational age (not specified), and antenatal steroid exposure, then randomly allocated infants to a 12-day course of hydrocortisone (1.0 mg/ kg for nine days, then 0.5 mg/kg/d for three days) (n = 25) or an equivalent volume of 0.9% saline placebo (n = 25). Study authors based the sample size calculation on the results of Watterberg 1999, resulting in an estimate of 138 infants to be recruited. The study was stopped early when 50 infants had been enrolled because of reports from other trials of spontaneous intestinal perforation with early hydrocortisone treatment.

Efird 2005 was a randomised controlled trial of hydrocortisone to prevent hypotension in infants of birth weight less than 1000 grams and gestation of 24 to 28 weeks. Trialists randomised 34 infants to receive 1 mg/kg of intravenous hydrocortisone 12-hourly for two days, followed by 0.3 mg/kg 12-hourly for three days, or a normal saline placebo.

Garland 1999 reported a prospective, multi-centre, randomised trial comparing a three-day course of dexamethasone therapy, beginning at 24 to 48 hours of life, versus placebo. Researchers enrolled 241 preterm infants (dexamethasone n = 118, placebo n = 123) who weighed between 500 grams and 1500 grams, had received surfactant therapy, and were at significant risk for BPD or death, using a predictive model at 24 hours. Trial authors gave dexamethasone to infants in a three-day tapering course at 12-hour intervals. The first two doses were 0.4 mg/kg, the third and fourth doses were 0.2 mg/kg, and the fifth and sixth doses were 0.1 mg/kg and 0.05 mg/kg, respectively. They gave a similar volume of normal saline to placebo-treated infants at similar time intervals.

Halac 1990 was a randomised trial undertaken to determine if prenatal corticosteroid therapy would reduce the incidence of necrotising enterocolitis. Investigators randomised women to prenatal betamethasone or placebo when they were admitted in preterm labour and were expected to deliver within 24 hours. They then randomised infants of mothers who had received placebo to postnatal dexamethasone or placebo; we included in this review only infants who were randomised to postnatal therapy. Study infants weighed less than 1501 grams at birth or were born at less than 34 weeks' gestation and had evidence of "birth asphyxia" (oneminute Apgar score < 5, prolonged resuscitation, and metabolic acidosis (bicarbonate < 15 mmol/L within one hour of birth)). Trialists assigned study groups via a table of random numbers. The treatment group (n = 130) received 2 mg/kg/d of dexamethasone



phosphate intravenously for seven days; the control group (n = 118) received an equal volume of 10% dextrose. The major endpoint of this study was necrotising enterocolitis.

Hochwald 2014 reported a single-centre randomised trial conducted to determine the effects of hydrocortisone on vasopressor dosing in hypotensive infants at < 31 weeks' gestation or with birth weight < 1251 grams during the first 48 hours after birth. Researchers randomly allocated 22 infants to hydrocortisone 2 mg/kg for one dose and 1 mg/kg for three doses, six hours apart, then 0.5 mg/kg for four doses, six hours apart (total dose, 7 mg/kg), or an equal volume of saline placebo.

Kopelman 1999 was a prospective blinded randomised controlled trial of 70 infants who required mechanical ventilation at less than 28 weeks' gestation. Thirty-seven infants received dexamethasone 0.20 mg/kg at delivery, and 33 infants received placebo consisting of an equal volume of saline.

Lauterbach 2006 presented a single-centre randomised trial to determine the effects of two active drugs on occurrence of BPD at 36 weeks. The two active drugs were nebulised pentoxifylline diluted in distilled water and intravenous dexamethasone. Infants weighing < 1251 grams at birth who were receiving supplemental oxygen on the fourth day after birth were eligible if they did not have a grade 3 or 4 intraventricular haemorrhage. Study authors randomly allocated a total of 150 infants to nebulised pentoxifylline every six hours for three days, intravenous dexamethasone 0.25 mg/kg/12-hourly for three days, or nebulised saline placebo every six hours for three days. Study drugs could be repeated every seven days if the infant was still ventilator- or oxygen-dependent and a diagnosis of BPD had not been established. Trialists did not report the number of repeat doses for any group. Researchers entered only data from the dexamethasone group and the control group into the meta-analysis.

Lin 1999 was a randomised trial with a sequential design involving infants weighing 500 grams to 1999 grams. Investigators stratified infants by birth weight into three groups: 500 grams to 999 grams, 1000 grams to 1500 grams, and 1501 grams to 1999 grams. Within each group, equal numbers of dexamethasone-treated or control cards were placed into envelopes for random selection of the first infant of each pair. The next infant of the appropriate birth weight stratum was enrolled for the match. A pharmacist opened the envelope, and investigators administered dexamethasone or saline placebo blind. Entry criteria included the presence of severe radiographic respiratory distress syndrome, the need for assisted ventilation within six hours of birth, and receipt of one dose of surfactant. Treated infants were given dexamethasone starting within 12 hours of birth at 0.25 mg/kg/dose 12-hourly for seven days, 0.12 mg/kg/dose 12-hourly for seven days, 0.05 mg/kg/dose 12-hourly for seven days, and 0.02 mg/kg/dose 12-hourly for seven days, resulting in a total of four weeks of treatment. Trialists presented results for 20 treated and 20 control infants.

Mukhopadhyay 1998 reported a randomised trial that included untreated controls. Study authors did not describe the method of randomisation used. Treated infants received dexamethasone 0.5 mg/kg/dose 12-hourly for three days, beginning within six hours of birth. Researchers included 19 infants at less than 34 weeks' gestation and weighing less than 2000 grams who could be provided with mechanical ventilation. These infants had severe respiratory distress syndrome but were not given surfactant. Ng 2006 was a double-blind randomised controlled trial of a "stress dose" of hydrocortisone for treatment of refractory hypotension. Investigators randomised 48 infants of birth weight less than 1500 grams to receive hydrocortisone 1 mg/kg eight-hourly for five days, or an equivalent volume of isotonic saline.

Peltoniemi 2005 enrolled a total of 51 infants weighing less than 1251 grams at birth or born at less than 31 weeks' gestation, who were under 36 hours old and were ventilator-dependent. Investigators conducted this trial at three collaborating centres in Finland. They stratified infants by centre and by birth weight (501 grams to 749 grams, 750 grams to 999 grams, and 1000 grams to 1250 grams) and randomly allocated them to a 10-day tapering course of hydrocortisone (2 mg/kg/d for two days, 1.5 mg/kg/d for two days, 0.75 mg/kg/d for six days) (n = 25) or an equivalent volume of 0.9% saline placebo (n = 26). Researchers based the sample size calculation on detecting an increase in survival without BPD from 50% to 70% and required inclusion of 160 participants per study arm (alpha and beta error 0.05 and 0.20, respectively). This study was stopped early at 51 infants because two of the hydrocortisone-treated infants had intestinal perforation and other RCTs of early hydrocortisone had reported the same complication. Trialists followed up with children at two years and at five to seven years of age. Long-term outcomes included in the meta-analysis pertain to the five- to seven-year follow-up study only.

Rastogi 1996 recruited 70 infants with birth weight of 700 grams to 1500 grams who had severe respiratory distress syndrome (assisted ventilation with at least 40% oxygen and/or 7 cmH₂O mean airway pressure, alveolar/arterial (a/A) partial pressure of oxygen (PO₂) ratio \leq 0.24) and had been treated with surfactant before entry. Infants were less than 12 hours old, and trialists excluded them if they had major malformations, chromosome abnormalities, five-minute Apgar scores <3, or severe infection. The intervention group received dexamethasone intravenously every 12 hours according to the following schedule: 0.50 mg/kg/d on days one to three, 0.30 mg/kg/d on days four to six, 0.20 mg/kg/d on days seven to nine, and finally 0.10 mg/kg/d on days 10 to 12. The control group received a saline placebo intravenously.

Romagnoli 1999 was a randomised trial that used numbered, sealed envelopes involving 25 dexamethasone-treated infants and 25 untreated controls. Entry criteria were birth weight < 1251 grams, gestational age < 33 weeks, ventilator- and oxygendependent at 72 hours, and high risk of BPD based on a local scoring system that predicted 90% risk. Treated infants were given dexamethasone beginning on the fourth day at a dose of 0.5 mg/kg/d for three days, 0.25 mg/kg/d for three days, and 0.125 mg/kg/d for one day.

Sanders 1994 enrolled 40 infants at less than 30 weeks' gestation who had respiratory distress syndrome diagnosed by clinical and radiographic signs, required mechanical ventilation at 12 to 18 hours of age, and had received at least one dose of surfactant. Exclusion criteria at entry included a strong suspicion of sepsis or pneumonia, congenital heart disease, chromosome abnormalities, and receipt of an exchange transfusion. Trialists randomised infants to receive dexamethasone 0.50 mg/kg at between 12 and 18 hours of age and a second dose 12 hours later, or a saline placebo. They administered both treatments intravenously.



Shinwell 1996 reported a multi-centre trial that randomised 248 infants of birth weight 500 grams to 2000 grams if they had clinical and radiographic evidence of respiratory distress syndrome, required mechanical ventilation with more than 40% oxygen, were less than 12 hours old, and had no contraindications to corticosteroid treatment, such as a bleeding tendency, hypertension, hyperglycaemia, or active infection. Investigators excluded infants with lethal congenital malformations. The intervention group received dexamethasone 0.25 mg/kg intravenously every 12 hours for a total of six doses. The control group received intravenous saline.

Sinkin 2000 was a multi-centre randomised double-blind trial that included 384 infants of less than 30 weeks' gestation with respiratory distress syndrome. A total of 189 infants received dexamethasone 0.50 mg/kg at 12 to 18 hours of age and a second dose 12 hours later, and 195 infants received an equal volume of saline placebo.

Soll 1999 described a multi-centre randomised double-blind controlled trial that compared dexamethasone given at 12 hours of age versus selective late dexamethasone therapy in premature infants weighing 501 grams to 1000 grams (early dexamethasone n = 272, late selective therapy n = 270). Infants required assisted ventilation, had received surfactant therapy, were physiologically stable, had no obvious life-threatening congenital anomaly, had blood cultures obtained, and had started antibiotic therapy. Trialists randomly assigned infants to early dexamethasone therapy or saline placebo. They administered intravenous dexamethasone for 12 days according to the following schedule: 0.5 mg/kg/d for three days, 0.25 mg/kg/d for three days, 0.1 mg/kg/d for three days, and 0.05 mg/kg/d for three days. Infants in either group could receive late postnatal corticosteroids beginning on day 14 if they needed assisted ventilation with supplemental oxygen greater than 30%.

Stark 2001 was a randomised multi-centre controlled trial conducted to compare a tapering course of stress-dose corticosteroid started on the first day versus placebo. Infants with birth weight 501 grams to 1000 grams needing mechanical ventilation before 12 hours of age were eligible for the study. Infants with birth weight over 750 grams also needed to have received surfactant and required an oxygen concentration of 30% or greater. The initial dose of dexamethasone was 0.15 mg/kg/d for three days, then tapered over seven days. After enrolling 220 infants (sample size was 1200), the trial was halted because of an excess of intestinal perforations in the dexamethasone-treated group. Researchers randomised 111 infants to receive dexamethasone and 109 to receive placebo.

Subhedar 1997 reported a randomised trial that enrolled infants into one of four treatment groups using a factorial design. Investigators compared both inhaled nitric oxide (iNO) and early dexamethasone separately versus controls. They randomised 42 infants: 10 to receive iNO alone, 11 dexamethasone alone, 10 both treatments, and 11 neither treatment. Researchers compared 21 infants receiving dexamethasone versus 21 controls. Infants were eligible for entry into the trial at 96 hours of age if they met the following criteria: gestational age less than 32 weeks, mechanical ventilation from birth, had received surfactant therapy, and were thought to be at high risk of developing BPD based on a scoring system (Ryan 1996). Exclusion criteria were major congenital anomaly, structural cardiac defect, significant ductus shunting, culture-positive sepsis, intraventricular haemorrhage with parenchymal involvement, pulmonary or gastrointestinal haemorrhage, disordered coagulation, and platelet count < 50,000. Infants received dexamethasone intravenously at 12-hourly intervals for six days: 0.50 mg/kg/dose for six doses and 0.25 mg/kg/dose for a further six doses. Control infants did not receive a placebo.

Suske 1996 randomised 26 infants with gestational age of 24 to 34 weeks who had respiratory distress syndrome and had been treated with surfactant. Trialists excluded infants with known septicaemia during the first week of life, haemodynamically relevant cardiac anomalies except for patent ductus arteriosus, or malformations of the lung or central nervous system (CNS). They performed randomisation by drawing lots before the age of two hours. The intervention group received dexamethasone 0.50 mg/ kg intravenously in two divided doses for five days, and controls received no placebo.

Tapia 1998 was a multi-centre double-blind placebo-controlled trial of 109 preterm infants with respiratory distress syndrome and birth weight between 700 grams and 1600 grams who were treated with mechanical ventilation and surfactant. Researchers randomised 55 infants to receive dexamethasone 0.50 mg/kg/d for three days, followed by 0.25 mg/kg/d for three days, followed by 0.12 mg/kg/d for three days, then 0.06 mg/kg/d for three days. A total of 54 control infants received an equal volume of saline.

Vento 2004 enrolled 20 neonates with birth weight less than 1251 grams and gestation less than 33 weeks who were oxygen- and ventilator-dependent on the fourth day of life and randomised them to receive dexamethasone 0.50 mg/kg/d for three days, 0.25 mg/kg/d for three days, and 0.125 mg/kg/d for one day (total dose 2.375 mg/kg), or no corticosteroid treatment.

Wang 1996 reported a randomised trial of a 21-day course of dexamethasone or saline placebo given in a double-blind fashion. Study authors did not state the method of randomisation used. Entry criteria were birth weight 1000 grams to 1999 grams, appropriate for gestational age, clinical and radiological severe respiratory distress syndrome, mechanical ventilation, and age less than 12 hours. Surfactant was not given, as it was not commercially available in Taiwan at the time of the study. Treated infants were given dexamethasone 0.25 mg/kg/dose 12-hourly for seven days, 0.125 mg/kg/dose 12-hourly for seven days, and 0.05 mg/kg/dose 12-hourly for seven days, for a total course of 21 days. The first dose of dexamethasone was given during the first 12 hours of life. Participants included 34 infants in the dexamethasone group and 29 in the placebo control group.

Watterberg 1999 described a randomised double-masked placebocontrolled pilot study conducted to compare early treatment with low-dose hydrocortisone (1.0 mg/kg/d for nine days, then 0.5 mg/ kg/d for three days), begun before 48 hours of age, versus placebo. Researchers enrolled at two centres 40 infants weighing between 500 grams and 999 grams who were mechanically ventilated: 20 hydrocortisone-treated infants and 20 placebo controls.

Watterberg 2004 was a multi-centre masked randomised trial of hydrocortisone to prevent early adrenal insufficiency. Investigators randomised 360 infants with birth weight of 500 grams to 999 grams who were mechanically ventilated to receive hydrocortisone 1 mg/kg/d for 12 days, then 0.5 mg/kg/d for three days, or saline



Cochrane

placebo. They enrolled infants at between 12 and 48 hours of life. The trial was stopped because of an increase in spontaneous gastrointestinal perforation in the hydrocortisone group.

Yeh 1990 enrolled 57 infants whose birth weight was < 2000 grams and who had severe respiratory distress syndrome diagnosed on the basis of a chest radiograph and the need for mechanical ventilation within four hours after birth. Absence of infection was also required for inclusion. Trialists randomly assigned infants to receive dexamethasone 0.50 mg/kg/dose 12-hourly from days one to three, then 0.25 mg/kg/dose 12-hourly from days four to six, then 0.12 mg/kg/dose 12-hourly from days seven to nine, and finally 0.05 mg/kg/dose 12-hourly from days 10 to 12. Researchers administered all doses intravenously and gave a saline solution to infants in the placebo group.

Yeh 1997 reported a multi-centre randomised double-blind clinical trial of 262 preterm infants (< 2000 grams) who had respiratory distress syndrome and required mechanical ventilation from shortly after birth. The treated group received dexamethasone 0.25 mg/kg/dose 12-hourly intravenously from day one to day seven; 0.12 mg/kg/dose 12-hourly intravenously from day 8 to day 14; 0.05 mg/kg/dose 12-hourly intravenously from day 15 to day 21; and 0.02 mg/kg/dose 12-hourly intravenously from day 22 to day 28. Control infants received a saline placebo.

Excluded studies

We excluded 25 studies. See Characteristics of excluded studies.

We excluded studies for several reasons. In one study, the primary outcome was the need for an epinephrine infusion 12 hours after treatment (Gaissmaier 1999). Study authors reported no long-term outcomes. Another study was not an RCT (Tsukahara 1999). This study included 26 study infants and 12 historical controls.

We included studies of late postnatal corticosteroids in the review titled "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants." We excluded these studies from this review and included the following studies: Ariagno 1987; Avery 1985; Brozanski 1995; CDTG 1991; Cummings 1989; Doyle 2006; Durand 1995; Harkavy 1989; Kari 1993; Kazzi 1990; Kothadia 1999; Kovacs 1998; Noble-Jamieson 1989; Ohlsson 1992; Papile 1998; Parikh 2013; Romagnoli 1997; Scott 1997; Vento 2004; Vincer 1998; and Walther 2003.

Investigators in one trial randomised 120 very low birth weight infants to both hydrocortisone and caffeine as active treatments, compared with treatment described in "standard guidelines", which presumably meant no hydrocortisone or caffeine (Dobryansky 2012). Major outcomes reported were BPD and BPD combined with death. As caffeine alone reduces BPD, the independent effect of hydrocortisone cannot be determined (Schmidt 2006).

Although researchers in another trial randomly allocated 29 very low birth weight infants to dexamethasone or placebo before six hours of age, they reported none of the outcomes that are applicable to this review (Yaseen 1999). Outcomes reported comprised only changes in mean values over the first five days for oxygenation, blood pressure and serum creatinine, and urea and glucose - not rates of BPD, hypertension, or hypoglycaemia, for example. We found no studies that are currently awaiting further assessment.

Risk of bias in included studies

The overall risk of bias was low for most studies. All were randomised controlled trials, although the method of random allocation was not always clear. Allocation concealment applied to most studies. Blinding of investigators and others was achieved most often through the use of placebo, usually saline solution. Follow-up reporting for short-term outcomes was mostly complete but was more variable for long-term outcomes beyond discharge and later into childhood. Most studies reported primary outcomes as specified in their methods.

Anttila 2005 carried out randomisation in the pharmacy of the co-ordinating centre using coded vials, with blinding of study investigators. Open-label dexamethasone was allowed when deemed necessary by the attending neonatologist, but its use was discouraged. Trialists performed intention-to-treat analysis and reported no follow-up component.

Baden 1972 performed randomisation by using vials and a table of random numbers. Clinical personnel were not aware of the content of any vial. Study authors reported outcomes for all enrolled infants. Follow-up consisted of the following: One paediatrician and one psychologist saw survivors at 12 months of age, corrected for prematurity. A neurologist saw all children with abnormal neurological signs. Observers were blinded to treatment group allocation. The follow-up rate of survivors was 93% (25/27). Study authors did not specify criteria for the diagnosis of cerebral palsy, nor did they provide specific criteria for blindness or deafness (children were tested by free-field pure-tone audiometry). Psychological assessment consisted of the Griffiths Scales. Study authors did not report major neurosensory disability (Fitzhardinge 1974).

Batton 2012 did not state the method of randomisation used. Trialists administered an identical placebo and reported no followup component.

Baud 2016 generated the randomisation sequence electronically using nQuery. After enrolment, researchers assigned treatment through a secure study website after verifying eligibility and consent status. They electronically randomised all infants before they reached 24 completed hours after birth and reported shortterm outcomes for all but two participants who were randomised. They followed up on 93% of survivors at 22 months' corrected age, although only 75% were given the full neurodevelopmental assessment battery. Investigators maintained double-blinding through all aspects of the study.

Biswas 2003 conducted randomisation as performed by the Perinatal Trials Unit in Oxford, with stratification for centre and gender, and the study pharmacist held the code. Controls received an equal infusion rate of 5% dextrose. One pharmacy made the syringes and transported them to individual study centres. Trialists reported short-term outcomes for all enrolled infants. Study authors reported no follow-up component.

Bonsante 2007 conducted centralised randomisation using a computer-generated random number sequence. Researchers stratified infants into six risk groups to ensure a homogeneous number of infants with regard to birth weight, gestation, and antenatal corticosteroid administration. They prepared drugs each

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



day in the pharmacy, and the care team, parents, and personnel collecting data had no knowledge of the random assignment at any time. Study authors reported results of follow-up at two years of age (follow-up component) in conjunction with data from another study but did not describe clinical criteria for various outcomes (Peltoniemi 2009). Study authors reported follow-up data for 92% (33/36) of survivors up to hospital discharge.

Efird 2005 performed randomisation by opening sequentially numbered, opaque envelopes containing preassigned treatment designations. Investigators randomised infants of multiple gestations as separate participants and blinded clinicians to treatment identity. If hypotension persisted, the randomisation assignment could be unblinded and hydrocortisone administered if the infant had been assigned to the placebo group. Study authors reported no follow-up component.

Garland 1999 randomised infants at each centre within each of four strata on the basis of birth weight (≤ 1000 grams, > 1000 grams) and a/A ratio before surfactant (\leq 0.15, > 0.15). Study pharmacists at each centre maintained randomisation codes. Investigators, caregivers, and parents were blinded to treatment allocation. The first interim analysis (n = 75) showed increased risk of gastrointestinal perforation in the dexamethasone group. After adjustment for severity of illness, the difference was not sufficiently statistically significant to stop enrolment. However, to ensure participant safety, the Data Monitoring Committee recommended that the dexamethasone dose should be reduced. Investigators changed the dosing schedule to four doses of 0.25 mg/kg/dose every 12 hours, begun at 24 to 48 hours, followed by doses of 0.125 mg/kg and 0.05 mg/kg at the next two 12-hour periods, respectively. After the first interim analysis, all enrolled infants received ranitidine therapy during the first three days of the study. It appears that study authors reported outcome measures for all 241 infants enrolled in the study and included no follow-up component.

Halac 1990 used a table of random numbers for randomisation, along with placebo blinding. Study authors stated that they had excluded from the study deaths before 10 days of age; they reported a total of five early deaths from sepsis, but it was not clear how often this occurred in each group. Apart from these infants, investigators provided outcome data for all remaining enrolled infants. They reported limited follow-up to six months of age but provided no follow-up results (apart from a statement that "growth and development were not hampered in any of these patients").

Hochwald 2014 did not state methods used for random sequence generation, allocation concealment, blinding of personnel and families, and blinding of outcomes, apart from use of a placebo, and reported no follow-up component.

Kopelman 1999 performed randomisation in the pharmacy after stratifying infants for treatment with antenatal corticosteroids. The blinded clinical team provided care. Study authors provided outcome data for all enrolled infants and reported no follow-up component.

Lauterbach 2006 used a computer-generated random number table for randomisation. Investigators allocated infants to groups by opening numbered containers on the fourth day of life. They provided no placebo for the dexamethasone arm and hence reported no blinding of dexamethasone treatment. Study authors reported no follow-up component. Lin 1999 performed randomisation by opening sealed envelopes in the pharmacy. This study used a sequential analysis design and paired 12 infants successfully. Study authors reported outcome measures for all 40 enrolled infants, including those who remained unpaired. They described no follow-up component.

Mukhopadhyay 1998 did not state the method of randomisation used. Investigators were able to provide ventilation for only 28 of 43 eligible infants and subsequently excluded eight infants owing to non-availability of blood gases due to a technical fault, and excluded one baby because of congenital heart block. This left 19 infants included in the study: 10 received intravenous dexamethasone, and nine received no drug treatment. Study authors did not mention placebo. They reported outcome measures for these 19 infants and described no follow-up component.

Ng 2006 performed randomisation by using computer-generated random numbers and opening sequentially numbered, sealed, opaque envelopes in the pharmacy. They assigned infants in blocks of six, and once an envelope was opened, an infant would be irrevocably entered into the trial. To ensure effective blinding of medications, both types of trial drug were colourless and odourless and were filled to the same volume before they were sent to the ward. Study authors reported no follow-up component.

In the Peltoniemi 2005 study, non-clinical staff achieved randomisation centrally, independent of the chief investigators, using random variation in block sizes of two to eight, separately for each centre. Study authors did not specify the method used for randomisation. Researchers had syringes prepared and labelled identically in the pharmacy department of the centre, thereby concealing allocation from study site investigators and caregivers of the infant. Open-label corticosteroids were discouraged after randomisation but were not prohibited; some infants may have received both a second course of their initially allocated study drug and open-label corticosteroids. No one apart from the pharmacist at study sites had access to the treatment codes. Study authors reported short-term outcomes for all enrolled infants. Followup consisted of the following: Investigators assessed surviving children at 24 months of age, corrected for prematurity, and at five to seven years of age, when it was not stated that age was corrected for prematurity. Paediatricians, paediatric neurologists, speech therapists, and psychologists at individual study sites were blinded to treatment group allocation. At two years, children were considered to have a major neurosensory impairment if they had cerebral palsy, blindness (inability to see any objects, with the exception of light), deafness (failure to pass an evoked otoacoustic emission test during the neonatal period and no response in brainstem auditory evoked potentials), or developmental delay (defined as a Mental Developmental Index (MDI) on the Bayley Scales of Infant Development < 70 (< -2 standard deviations (SDs)) or a developmental quotient < 70 on the Griffiths Cognitive Scales). Researchers assessed cognitive development of children at five to seven years of age by using the Wechsler Presechool and Primary Scale of Intelligence - Revised (WPPSI-R). They diagnosed minor neurological dysfunction on the basis of the number of dysfunctional domains. Speech assessment included the Reynell Developmental Language Scale III (RDLS III). Study authors did not provide the criteria for blindness or deafness and reported the follow-up rate of survivors at two years (98%; 45/46) and at five to seven years of age (80%; 37/46) (Peltoniemi 2009; Peltoniemi 2016).

Rastogi 1996 performed randomisation in the pharmacy, using a random number list after stratifying infants for birth weight into three groups: 700 grams to 999 grams, 1000 grams to 1249 grams, and 1250 grams to 1500 grams. The clinical team and other study personnel were blinded to assignments until the study was completed, and they recorded all outcome variables for all infants. Study authors reported no follow-up component.

Romagnoli 1999 achieved randomisation through random number allocation by opening numbered, sealed envelopes. Trialists excluded infants with prenatal infections, congenital malformations, and evidence of sepsis at randomisation. They did not mention placebo and reported outcome measures for all 50 enrolled infants. Follow-up consisted of the following: One paediatrician and one neurologist saw survivors at 34 to 42 months of age, corrected for prematurity, and observers were blinded to treatment group allocation. The follow-up rate of survivors was 100% (45/45). The neurologist diagnosed cerebral palsy, but study authors did not specify the criteria used for this, nor for the diagnosis of blindness or deafness. Psychological assessment included the Stanford-Binet 3rd Revision, and intellectual impairment comprised an IQ < 70. Major neurosensory impairment consisted of either blindness or deafness (Romagnoli 2002).

Sanders 1994 randomised participants in the pharmacy after opening sealed envelopes. Trialists dispensed dexamethasone or placebo via labelled syringes. Clinical personnel were not aware of assignment of the intervention. Study authors reported outcomes for all 40 enrolled infants. Follow-up consisted of the following: A paediatrician, a neurologist, and a psychologist saw survivors at mean ages of 64 (SD 8) months (dexamethasone) and 61 (SD 4) months (controls), not corrected for prematurity, with observers blinded to treatment group allocation. Researchers sought additional data from parents and teachers. The followup rate of survivors was 100% (31/31). The criterion for the diagnosis of cerebral palsy was a fixed motor deficit diagnosed by the neurologist. Blindness comprised visual acuity < 6/60 in the better eye, and study authors defined deafness as the need for a hearing aid. Psychological assessment was based on the Wechsler Scales (Wechsler Intelligence Scale for Children (WISC) and WPPSI-R) - intellectual impairment comprised a full-scale IQ < 70. Study authors did not specify major neurosensory disability and planned further follow-up at 15 years of age (Sinkin 2002 (personal communication follow-up to Sanders 1994)).

Shinwell 1996 supplied each participating unit with numbered sets of syringes containing dexamethasone or physiological saline. Syringes containing dexamethasone were not distinguishable from those containing saline. Trialists numbered syringe sets according to a random number list and stratified randomisation by centre and by two birth weight groups: 500 grams to 1000 grams, and 1001 grams to 2000 grams. No investigators knew the drug assignment until after the three-month observation period of the last enrolled infant. Study authors reported outcomes for 248 of 255 enrolled infants. The seven infants subsequently excluded from analysis included three with major congenital abnormalities (two with myotonic dystrophy and one with cyanotic congenital heart disease), three with errors in drug administration, and one randomised after the age of 12 hours. Follow-up consisted of the following: Survivors were seen at a mean age of 53 (SD 18; range 24 to 71) months, presumably not corrected for prematurity. Multiple paediatricians saw these children in multiple follow-up clinics, with observers blinded to treatment group allocation. The follow-up rate of survivors was 83% (159/190). Trialists did not specify criteria for the diagnosis of cerebral palsy, but neurologists made the diagnosis in all cases. Study authors did not specify criteria for blindness but defined deafness as the need for hearing aids. Study personnel performed no formal psychological assessments, and multiple assessors assigned the judgement of developmental delay. Major neurosensory disability comprised any of non-ambulant cerebral palsy, global retardation (not specified), blindness, or deafness. Researchers planned further follow-up at school age (Shinwell 2002).

Sinkin 2000 performed randomisation with stratification by centre, using a set of sealed envelopes in the pharmacy. It appears that study authors provided outcome data for all enrolled infants. Follow-up consisted of the following (Sinkin 2002 (personal communication follow-up to Sinkin 2000)): Researchers obtained data from one of the four original centres in the study, from followup clinic appointments, and from questionnaires completed by parents and paediatricians. A paediatrician, a neurologist, and a psychologist saw survivors at approximately 12 months of age, corrected for prematurity, with observers blinded to treatment group allocation. The follow-up rate of survivors was 13% (41/311) at 36 weeks' postmenstrual age overall but was confined to one of four individual study centres, within which the follow-up rate was 100% (41/41). The criterion for the diagnosis of cerebral palsy was a fixed motor deficit diagnosed by the neurologist. Blindness comprised visual acuity < 6/60 in the better eye, and study authors defined deafness as the need for a hearing aid. Psychological assessment included the Bayley Scales of Infant Development. Investigators did not specify major neurosensory disability.

Soll 1999 performed randomisation in hospital pharmacies after opening opaque, sealed envelopes supplied by the Vermont Oxford Neonatal Network. The study was stopped before sample size goals were met owing to concern regarding adverse effects in the early corticosteroid therapy group. It appears that outcome measures were reported for most of the 542 enrolled infants. Study authors reported no follow-up component.

Stark 2001 performed random allocation in hospital pharmacies using a random number scheme. This study used a factorial design so that infants were also randomised to routine ventilator management or to a strategy of minimal ventilator support aimed at reducing mechanical lung injury. After 220 infants were enrolled from a sample size estimate of 1200, the trial was halted. It appears that study authors have reported outcome measures for all 220 participants enrolled in the trial. Follow-up consisted of the following: Trained developmental observers blinded to treatment group allocation saw survivors at 18 to 22 months of age, corrected for prematurity. The follow-up rate of survivors was 88% (144/164). Criteria for the diagnosis of cerebral palsy included non-progressive abnormalities of tone in at least one limb and abnormal control of movement and posture. Study authors defined blindness as no useful vision in either eye, and deafness as disability with bilateral hearing amplification. Psychological assessment included the MDI and the Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development-II (Bayley 1993). Major neurosensory disability comprised any of moderate or severe cerebral palsy (sitting independently with support or worse), blindness, deafness, or an MDI or PDI < -2 SD (Stark 2014).

Subhedar 1997 performed block randomisation by using computergenerated random numbers and sealed envelopes. Researchers used no placebo and provided no evidence of blinding of clinicians. Study authors reported outcome measures for all enrolled infants. Follow-up consisted of the following (Subhedar 2002 (personal communication follow-up to Subhedar 1997)): One developmental paediatrician who was blinded to treatment group allocation saw survivors at 30 months of age, corrected for prematurity. The follow-up rate of survivors was 95% (21/22). Study authors specified criteria for the diagnosis of cerebral palsy but not for deafness; an ophthalmologist diagnosed blindness. Psychological assessment included the MDI and the PDI of the Bayley Scales of Infant Development. Major neurosensory disability comprised any of cerebral palsy, an MDI or PDI < 71, blindness, or deafness.

Suske 1996 performed randomisation by drawing lots; lot numbers corresponded to numbers on non-transparent envelopes. A neutral, uninvolved person drew random lots and envelopes. This was considered a pilot trial conducted before a multi-centre study was begun, and researchers planned that the trial would be stopped if they found a statistically significant difference between groups. A total of 41 infants met the inclusion criteria. Owing to lack of co-operation and co-ordination at the beginning of the study, investigators did not randomise nine infants. They excluded four infants after randomisation because they showed definite signs of septicaemia. Study authors reported results for 26 of the 28 remaining infants and described no follow-up component.

Tapia 1998 achieved random assignment at each centre using ampoules of dexamethasone and saline prepared in the hospital pharmacy at one of the centres. Researchers reported outcomes for 109 of 113 enrolled infants. They excluded two infants from the dexamethasone group - one because of congenital cystic adenomatoid malformation, and another because of early sepsis. Investigators also excluded two patients from the placebo group one because of early sepsis, and the other because of transfer to another hospital at two weeks of age. Study authors did not provide further data on outcomes and reported no follow-up component.

Vento 2004 did not state the method of randomisation used. Whether clinicians caring for infants were blinded to treatment allocation remains unclear. Control infants did not receive a placebo, and study authors reported no follow-up component.

Wang 1996 reported that random allocation was double-blind but did not describe the exact method used. Study authors reported outcome measures for all 63 infants enrolled in the study and reported no follow-up component.

Watterberg 1999 randomised Infants at each centre by using a constant block design with four participants per block to minimise imbalance over time. Investigators used separate randomisation tables for infants exposed to antenatal corticosteroids. Hospital pharmacies prepared hydrocortisone doses and the placebo of normal saline. Study authors reported outcome measures for all of the 40 infants enrolled in the trial. Follow-up consisted of the following (Watterberg 2002 (personal communication follow-up to Watterberg 1999): A neonatologist and a physiotherapist saw survivors at a regular follow-up clinic for one of the two study sites at a mean age of 11 (SD 2) months, corrected for prematurity, with observers blinded to treatment group allocation. The follow-up rate of survivors was 53% (18/34) for the study overall, but 86% (18/21) for the study centre with

follow-up data. Researchers specified criteria for the diagnosis of cerebral palsy, which comprised abnormal tone and movement. An ophthalmologist diagnosed blindness, and investigators screened participants for deafness in early infancy and at follow-up. They performed no formal psychological testing and did not define major neurosensory disability.

Watterberg 2004 performed randomisation centrally, stratifying infants for birth weight (500 grams to 749 grams, and 750 grams to 999 grams) and by centre, using permuted block sizes of six within each stratum. Only pharmacists at individual sites who prepared the drug were aware of group assignment. All other personnel were masked. Trialists randomised twins together to the same study arm. They reported mortality for all enrolled infants but described other short-term outcomes for all but three infants who were withdrawn from the study. Follow-up consisted of the following: Assessors at individual study sites who were blinded to treatment group allocation assessed surviving children at 18 to 22 months of age, corrected for prematurity. They considered children to have a neurodevelopmental (neurosensory) impairment if they had cerebral palsy (criteria included abnormalities of tone, movement, and posture), functional blindness (inability to complete the Bayley Scales of Infant Development - Second Edition (BSID-II) because of visual impairment), functional deafness (inability to complete BSID-II because of hearing impairment), developmental delay (defined as MDI on the BSID-II < 70 (< -2 SD), or motor delay (defined as a Psychomotor Developmental Index on the BSID-II < 70 (< -2 SD)) (Bayley 1993). The follow-up rate of survivors at 18 to 22 months was 86% (252/294), or 87% (252/291) when three children whose families had withdrawn consent were excluded (Watterberg 2007).

Yeh 1990 performed randomisation in the pharmacy using balanced blocks of 10. Personnel working in the pharmacy labelled vials, and clinical staff were unaware of assignment. Trialists included 60 infants in the study and subsequently withdrew three: one because of death from *Haemophilus influenzae* septicaemia six hours after enrolment, and two because of an error in measurement of birth weight (581 grams and 2200 grams). Study authors did not report outcomes for these three infants and described no follow-up component.

Yeh 1997 completed randomisation in the central pharmacy using an assignment list. Investigators calculated sample size on the basis of an expected 50% reduction in the incidence of BPD with early dexamethasone, allowing a 5% chance of a type I error, and a 10% chance of a type II error. Study authors reported short-term outcome data for all 262 enrolled infants and described the study as double-blind. Follow-up consisted of the following: In 1998, researchers reported that one neurologist and one psychologist saw survivors at a mean age of 25 months, corrected for prematurity, with observers blinded to treatment group allocation (Yeh 1998). The follow-up rate of survivors was 81% (133/164). Study authors did not specify criteria for the diagnosis of cerebral palsy, blindness, or deafness. Psychological assessment included the MDI and the PDI of the Bayley Scales of Infant Development. Major neurosensory disability comprised severe motor dysfunction (child non-ambulant) or an MDI or PDI < -2 SD. In 2004, investigators in the Yeh trial reported that trial personnel reassessed survivors at seven to nine years of age (Yeh 2004). The follow-up rate of survivors was 92% (146/159). Assessors were blind to treatment allocation. A paediatric neurologist evaluated children for cerebral palsy, assessing motor skills using the Movement ABC, and IQ using



the WISC-III. Trial personnel formally evaluated vision and hearing. Major neurological disability comprised any of cerebral palsy, vision worse than 20/60, deafness requiring hearing aids, or an IQ < 5th centile. Whether age was corrected for prematurity remained unclear. We used data for cerebral palsy at eight years in the meta-analysis, as the diagnosis of cerebral palsy is more certain at eight years than at two years of age, and because the follow-up rate was higher when participants were eight years of age. Trialists measured blood pressure, height, weight, and head circumference at eight years of age but did not report these as standardised scores (SD or Z-scores), to enable pooling of data for meta-analysis.

Effects of interventions


See: Summary of findings for the main comparison Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants


Results of meta-analysis

Meta-analysis of these 32 studies of early postnatal corticosteroid treatment yielded the following results.

Mortality

No evidence suggests that early postnatal corticosteroid treatment reduced mortality at 28 days of life (typical risk ratio (RR) 1.02, 95% confidence interval (CI) 0.88 to 1.19, 19 studies, 2950 infants; Analysis 1.1), at 36 weeks' gestational age (OR 1.01, 95% CI 0.89 to 1.14, 20 studies, 3733 infants; Analysis 1.2), before discharge (typical RR 0.95, 95% CI 0.85 to 1.07, 30 studies, 4273 infants; Analysis 1.3), or at the latest age possible to determine the outcome (typical RR 0.95, 95% CI 0.85 to 1.06, 31 studies, 4373 infants; Analysis 1.4). We found weak evidence of publication bias for mortality at latest age, particularly for studies examining treatment with hydrocortisone (Figure 2).





Bronchopulmonary dysplasia


Early corticosteroids reduced the incidence of BPD, defined as needing oxygen supplementation at 28 days of life (typical RR 0.87, 95% CI 0.81 to 0.93; typical RD (RD) -0.07, 95% CI -0.10 to -0.03; 17 studies, 2874 infants; Analysis 2.1) or at 36 weeks' postmenstrual age (typical RR 0.79, 95% CI 0.72 to 0.87; typical RD -0.07, 95% CI -0.09 to -0.04; 24 studies, 3929 infants; Analysis 2.2). We found weak evidence of publication bias for oxygen supplementation at 36

weeks (Figure 3) and a reduction in BPD at 36 weeks' postmenstrual age among survivors (typical RR 0.81, 95% CI 0.74 to 0.88; typical RD -0.08, 95% CI -0.11 to -0.05; 21 studies, 2970 infants; Analysis 2.3). Early corticosteroids reduced the need for later corticosteroid treatment overall (typical RR 0.75, 95% CI 0.68 to 0.82; typical RD -0.11, 95% CI -0.15 to -0.07; 14 studies, 2483 infants; Analysis 2.4) and among survivors (typical RR 0.77, 95% CI 0.67 to 0.89; typical RD -0.11, 95% CI -0.77 to -0.05; seven studies, 895 infants; Analysis 2.5). Results of analysis showed no significant reduction in



fewer studies were able to determine this outcome (typical RR 0.72, 95% CI 0.51 to 1.03, six studies, 691 infants; Analysis 2.6).







Death or bronchopulmonary dysplasia

Early corticosteroids reduced the incidence of death or BPD, defined as needing oxygen supplementation at 28 days of life (typical RR 0.92, 95% CI 0.88 to 0.96; typical RD -0.06, 95% CI -0.09

to -0.03; 15 studies, 2546 infants; Analysis 3.1) or at 36 weeks' postmenstrual age (typical RR 0.88, 95% CI 0.83 to 0.93; typical RD -0.06, 95% CI -0.09 to -0.03; 25 studies, 3960 infants; Analysis 3.2). We found weak evidence of publication bias for mortality or BPD at 36 weeks (Figure 4).







Failure to extubate

Early corticosteroids reduced rates of failure to extubate at three days (typical RR 0.85, 95% CI 0.75 to 0.95; typical RD -0.09, 95% CI -0.16 to -0.03; four studies, 887 infants; Analysis 4.1), seven days (typical RR 0.76, 95% CI 0.68 to 0.85; typical RD -0.12, 95% CI - 0.17 to -0.07; eight studies, 1448 infants; Analysis 4.2), 14 days (typical RR 0.77, 95% CI 0.62 to 0.97; typical RD -0.10, 95% CI -0.19 to -0.02; four studies, 443 infants; Analysis 4.3), and 28 days of life (typical RR 0.84, 95% CI 0.72 to 0.98; typical RD -0.07, 95% CI -0.13 to -0.01; seven studies, 902 infants; Analysis 4.4).

Complications during primary hospitalisation

Metabolic complications

Early corticosteroids increased risks of hyperglycaemia (typical RR 1.33, 95% CI 1.20 to 1.47; typical RD 0.11, 95% CI 0.07 to 0.15; 13 studies, 2167 infants; Analysis 5.2) and hypertension (typical RR 1.85, 95% CI 1.54 to 2.22; typical RD 0.10, 95% CI 0.07 to 0.13; 11 studies, 1993 infants; Analysis 5.3).

Gastrointestinal complications

Early corticosteroids increased risks of gastrointestinal bleeding (typical RR 1.86, 95% CI 1.35 to 2.55; typical RD 0.05, 95% CI 0.03 to 0.08; 12 studies, 1816 infants; Analysis 5.14) and gastrointestinal perforation (typical RR 1.72, 95% CI 1.29 to 2.30; typical RD 0.03,

95% CI 0.02 to 0.05; 16 studies, 3040 infants; Analysis 5.15), but we found no evidence of an effect on the incidence of necrotising enterocolitis (typical RR 0.90, 95% CI 0.74 to 1.11; 25 studies, 4050 infants; Analysis 5.13).

Other effects

Early corticosteroids increased risks of hypertrophic cardiomyopathy (RR 4.33, 95% CI 1.40 to 13.4; RD 0.40, 95% CI 0.17 to 0.63; one study, 50 infants; Analysis 5.4) and growth failure (RR 6.67, 95% CI 2.27 to 19.6; RD 0.68, 95% CI 0.48 to 0.88; one study, 50 infants; Analysis 5.5) in one study in which these were reported. Early corticosteroids reduced the risk of patent ductus arteriosus (typical RR 0.78, 95% CI 0.72 to 0.85; typical RD -0.09, 95% CI -0.12 to -0.06; 24 studies, 4013 infants; Analysis 5.7). Results showed no significant effects on infection (typical RR 1.05, 95% CI 0.96 to 1.15; 25 studies, 4101 infants; Analysis 5.1), pulmonary air leaks (typical RR 0.91, 95% CI 0.74 to 1.13; 16 studies, 3225 infants; Analysis 5.6), severe intraventricular haemorrhage (typical RR 0.96, 95% CI 0.83 to 1.11; 26 studies, 4103 infants; Analysis 5.8), periventricular leukomalacia (typical RR 1.07, 95% CI 0.78 to 1.46; 15 studies, 2807 infants; Analysis 5.10), or pulmonary haemorrhage (typical RR 1.16, 95% CI 0.87 to 1.54; 10 studies, 1820 infants; Analysis 5.16). Early corticosteroids reduced any retinopathy of prematurity (typical RR 0.88, 95% CI 0.80 to 0.97; nine studies, 1345 infants; Analysis 5.17) and both severe retinopathy of prematurity (typical RR 0.81, 95% CI 0.66 to 0.98; RD -0.03, 95% CI -0.05 to -0.00; 14 studies,



2577 infants; Analysis 5.18) and severe retinopathy of prematurity among survivors (typical RR 0.77, 95% CI 0.64 to 0.94; RD -0.05, 95% CI -0.09 to -0.01; 12 studies, 1575 infants; Analysis 5.19).

Follow-up data

Follow-up studies are few compared with the total number of studies: Of 32 studies, 13 provided follow-up data.

Developmental delay


Corticosteroids increased developmental delay in one study of dexamethasone, but criteria for the diagnosis were not explicit (RR 1.68, 95% CI 1.08 to 2.61; RD 0.14, 95% CI 0.03 to 0.24; one study, 248 infants; Analysis 6.5). Results showed no significant differences when developmental delay was determined by formal

developmental assessments (Analysis 6.1; Analysis 6.2; Analysis 6.3; Analysis 6.4).

Cerebral palsy

Corticosteroids increased cerebral palsy (typical RR 1.42, 95% CI 1.06 to 1.91; typical RD 0.02, 95% CI 0.00 to 0.05; 13 studies, 1973 infants; Analysis 6.11), but results showed little difference in the combined outcome, death or cerebral palsy (typical RR 1.03, 95% CI 0.91 to 1.16; 13 studies, 1973 infants; Analysis 6.13). We noted moderate heterogeneity ($I^2 = 52\%$) for the combined outcome, death or cerebral palsy, among the dexamethasone studies and little evidence of publication bias for the outcome of cerebral palsy (Figure 5).





Major neurosensory disability

Results showed few effects on major neurosensory disability (typical RR 1.09, 95% CI 0.89 to 1.33; eight studies, 1754 infants; Analysis 6.15) and on the combined outcome, death or major neurosensory disability (typical RR 0.97, 95% CI 0.88 to 1.08; eight studies, 1754 infants; Analysis 6.17).

Abnormal neurological examination

Results showed a significant increase in the rate of abnormal neurological examination findings (typical RR 1.81, 95% CI 1.33 to 2.47; typical RD 0.10, 95% CI 0.05 to 0.15; five studies, 829

infants; Analysis 6.19) and in the combined outcome, death or abnormal neurological examination (typical RR 1.23, 95% CI 1.06 to 1.42; typical RD 0.10, 95% CI 0.03 to 0.16; five studies, 829 infants; Analysis 6.21). Although criteria for this diagnosis were vague and varied between studies, the size of the difference in this outcome in trials for which data were available was similar to the size of the difference in cerebral palsy in the corresponding study. Yeh 1997 provided data for cerebral palsy obtained at age eight to nine years, whereas investigators obtained abnormal examination data from earlier in childhood - at two years of age.



Other long-term outcomes

Results showed no significant effects on other long-term outcomes of blindness, deafness, formal psychometric testing, abnormal electroencephalogram (EEG), behaviour problems, or rehospitalisation in infancy.

Subgroup analysis by type of corticosteroid used

Mortality

Data show little difference in the effects of dexamethasone or hydrocortisone on mortality at 28 days of life (typical RR dexamethasone 1.06, 95% CI 0.90 to 1.24; 16 studies, 2603 infants; hydrocortisone 0.78, 95% CI 0.50 to 1.23; three studies, 347 infants; P value for interaction = 0.22; Analysis 1.1), or of dexamethasone on mortality at 36 weeks' postmenstrual age (typical RR 1.08, 95% CI 0.94 to 1.25; 14 studies, 2487 infants; Analysis 1.2), before discharge (typical RR 1.03, 95% CI 0.90 to 1.18; 19 studies, 2840 infants; Analysis 1.3), or at the latest age possible to determine the outcome (typical RR 1.02, 95% CI 0.90 to 1.16; 20 studies, 2940 infants; Analysis 1.4). However, hydrocortisone reduced mortality to discharge (typical RR hydrocortisone 0.80, 95% CI 0.65 to 0.98; 11 studies, 1433 infants; P value for interaction = 0.04; Analysis 1.3) and at the latest age possible to determine the outcome (typical RR hydrocortisone 0.80, 95% CI 0.65 to 0.99; 11 studies, 1433 infants; P value for interaction = 0.05; Analysis 1.4), and had a borderline effect on mortality at 36 weeks (typical (RR 0.83, 95% CI 0.65 to 1.06; six studies, 1246 infants; P value for interaction = 0.07; Analysis 1.2).

Bronchopulmonary dysplasia

Most of the benefit of early corticosteroids in reducing the incidence of BPD was provided by dexamethasone, with little effect of hydrocortisone, regardless of the definition of BPD: needing oxygen supplementation at 28 days of life (typical RR dexamethasone 0.85, 95% CI 0.79 to 0.92; typical RD -0.07, 95% CI -0.11 to -0.04; 16 studies, 2621 infants; hydrocortisone 1.00, 95% CI 0.85 to 1.18; one study, 253 infants; Analysis 2.1), or needing oxygen at 36 weeks' postmenstrual age (typical RR dexamethasone 0.71, 95% CI 0.62 to 0.81; typical RD -0.08, 95% CI -0.12 to -0.05; 16 studies, 2584 infants; hydrocortisone 0.91, 95% CI 0.80 to 1.05; eight studies, 1345 infants; Analysis 2.2). Benefit in reducing the need for late rescue with postnatal corticosteroids also was largely confined to the dexamethasone group (typical RR dexamethasone 0.72, 95% CI 0.65 to 0.80; typical RD -0.14, 95% CI -0.18 to -0.10; 10 studies, 1974 infants; hydrocortisone 1.01, 95% CI 0.73 to 1.40; four studies, 509 infants; Analysis 2.4). Strong evidence showed subgroup differences for some of these outcomes, with low P values for Analysis 2.2, Analysis 2.3, and Analysis 2.4. We noted substantial or moderate heterogeneity for some of these comparisons (2.1, 2.3, and 2.4), suggesting that results should be interpreted with caution.

Death or bronchopulmonary dysplasia

Most of the benefit of early corticosteroids in reducing the incidence of the combined outcome of death or bronchopulmonary dysplasia at 28 days of life was provided by dexamethasone, with little effect of hydrocortisone (typical RR dexamethasone 0.91, 95% CI 0.86 to 0.96; typical RD -0.07, 95% CI -0.10 to -0.03; 14 studies, 2293 infants; hydrocortisone 1.00, 95% CI 0.90 to 1.12; one study, 253 infants; Analysis 3.1), but both agents reduced the combined outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age (typical RR dexamethasone 0.87, 95% CI 0.80 to 0.94; typical RD -0.07, 95% CI -0.10 to -0.03; 16 studies, 2581 infants; hydrocortisone 0.90, 95% CI 0.82 to 0.99; typical RD -0.06, 95% CI -0.11 to -0.01; nine studies, 1379 infants; Analysis 3.2). Heterogeneity was substantial for one of these comparisons (Analysis 3.1) and was moderate for the other (Analysis 3.2), suggesting the need for caution when results are interpreted.

Complications during primary hospitalisation

Some of the short-term complications observed with corticosteroids were related more to dexamethasone than to hydrocortisone, including hyperglycaemia (typical RR dexamethasone 1.35, 95% CI 1.21 to 1.49; typical RD 0.11, 95% CI 0.08 to 0.15; 12 studies, 2117 infants; hydrocortisone 0.92, 95% CI 0.50 to 1.67; one study, 50 infants; Analysis 5.2), hypertension (typical RR dexamethasone 1.84, 95% CI 1.53 to 2.21; typical RD 0.10, 95% CI 0.07 to 0.13; 10 studies, 1943 infants; hydrocortisone RR 3.00, 95% CI 0.33 to 26.92; one study, 50 infants; Analysis 5.3), and gastrointestinal haemorrhage (typical RR dexamethasone 1.87, 95% CI 1.35 to 2.58; typical RD 0.05, 95% CI 0.03 to 0.08; 10 studies, 1725 infants; hydrocortisone 1.53, 95% CI 0.27 to 8.74; two studies, 91 infants; Analysis 5.14). However, both types of corticosteroid were associated with greater gastrointestinal perforation (typical RR dexamethasone 1.73, 95% CI 1.20 to 2.51; typical RD 0.03, 95% CI 0.01 to 0.05; nine studies, 1936 infants; hydrocortisone 1.70, 95% CI 1.07 to 2.70; typical RD 0.03, 95% CI 0.00 to 0.06; seven studies, 1104 infants; Analysis 5.15) and lower rates of patent ductus arteriosus (typical RR dexamethasone 0.76, 95% CI 0.69 to 0.84; typical RD -0.10, 95% CI -0.13 to -0.06; 17 studies, 2706 infants; hydrocortisone 0.82, 95% CI 0.71 to 0,95; typical RD -0.07, 95% CI -0.12 to -0.02; seven studies, 1307 infants; Analysis 5.7). Only dexamethasone was associated with reductions in the rates of any retinopathy of prematurity (typical RR dexamethasone 0.84, 95% CI 0.72 to 0.99; eight studies, 1042 infants; hydrocortisone 0.93, 95% CI 0.84 to 1.04; one study, 303 infants; Analysis 5.17), severe retinopathy of prematurity (typical RR dexamethasone 0.77, 95% CI 0.60 to 0.99; eight studies, 1507 infants; hydrocortisone 0.87, 95% CI 0.63 to 1.21; six studies, 1070 infants; Analysis 5.18), and severe retinopathy of prematurity among survivors (typical RR dexamethasone 0.75, 95% CI 0.59 to 0.95; 10 studies, 1238 infants; hydrocortisone 0.83, 95% CI 0.60 to 1.17; two studies, 337 infants; Analysis 5.19).

Follow-up data

Cerebral palsy and the combined outcome of death or cerebral palsy were more common with dexamethasone than with hydrocortisone (cerebral palsy: typical RR dexamethasone 1.75, 95% CI 1.20 to 2.55; typical RD 0.05, 95% CI 0.01 to 0.09; seven studies, 921 infants; typical RR hydrocortisone 1.05, 95% CI 0.66 to 1.66; six studies, 1052 infants; Analysis 6.11; death or cerebral palsy: typical RR dexamethasone 1.17, 95% CI 1.00 to 1.37; typical RD 0.07, 95% CI 0.00 to 0.13; seven studies, 921 infants; typical RR hydrocortisone 0.86, 95% CI 0.71 to 1.05; typical RD -0.04, 95% CI -0.09 to 0.01; six studies, 1052 infants; Analysis 6.13).

We noted that some subgroup analyses included few studies and small sample sizes for the hydrocortisone subgroup; hence the power to detect beneficial or harmful effects of hydrocortisone was limited under these circumstances.

Results of individual trials

Anttila 2005: The primary outcome was survival without BPD, intraventricular haemorrhage (grade 3 or 4), or periventricular leukomalacia, and although this tended to be greater in the



dexamethasone group, differences compared with controls were not statistically significant. The risk ratio for death or BPD at 36 weeks' postmenstrual age was 0.78 (95% CI 0.54 to 1.13) overall, and 0.61 (95% CI 0.33 to 1.11) in the subgroup with birth weight 750 grams to 999 grams. We noted no detectable trends in mortality, severe intraventricular haemorrhage, or periventricular leukomalacia. Rates of patent ductus arteriosus, retinopathy of prematurity, or sepsis did not differ between groups. Mean arterial blood pressures were increased in the dexamethasone group during the first week (P = 0.015), and the dexamethasone group tended to need more insulin therapy (49% vs 39%; P = 0.25).

Baden 1972: Results of this study showed no significant effects on blood gases, pH, oxygen requirement, need for assisted ventilation, or survival. Data indicate no significant differences in rates of cerebral palsy or deafness among survivors, in mean scores on Griffiths Scales, or in the combined rate of death or cerebral palsy (Fitzhardinge 1974).

Batton 2012: Data show minimal effects on rates of death during primary hospitalisation, BPD (undefined), intraventricular haemorrhage, periventricular leukomalacia, or necrotising enterocolitis.

Baud 2016: Death or BPD at 36 weeks' gestational age occurred in 40% (102/255) of the hydrocortisone group compared with 49% (130/266) of the placebo group (OR 0.82, 95% CI 0.67 to 0.99). Rates of any neurodevelopmental impairment (NDI) among assessed survivors were similar in the two groups (hydrocortisone 27% (53/194); placebo 30% (55/185)), as were rates of moderate to severe impairment (hydrocortisone 7% (14/194); placebo 11% (21/185)). The combined outcome of death or moderate severe impairment in all randomised infants was lower in the hydrocortisone group than in the control group (hydrocortisone 24% (62/255); placebo 33% (88/266); OR 0.73, 95% CI 0.56 to 0.97).

Biswas 2003: Results showed no significant effects of infusion of hydrocortisone and T3 on the primary endpoint of death or failure to extubate by seven days, or death or oxygen dependency at 14 days. Patent ductus arteriosus was significantly reduced in the treatment group (41/125 vs 60/128; RR 0.70, 95% CI 0.51 to 0.96), but data show no other significant differences in secondary outcomes.

Bonsante 2007: Oxygen-free survival was significantly greater in the hydrocortisone group than in the control group (64% vs 32%; P = 0.023). The effect of hydrocortisone was particularly evident in the subgroup not exposed to prenatal corticosteroids. Four infants in the hydrocortisone group died compared with 10 in the control group (16% vs 40%; P = 0.05). Duration of ventilation, patent ductus arteriosus, severe retinopathy of prematurity, severe intraventricular haemorrhage, and periventricular leukomalacia were not different between groups.

Efird 2005: Vasopressor was used less in the hydrocortisonetreated group, significantly so on the second day of life. Results showed no significant differences in cortisol levels between groups at any time point, and no significant differences in mortality, duration of ventilation, BPD (oxygen at 36 weeks' postmenstrual age), nosocomial infections, necrotising enterocolitis, spontaneous intestinal perforations, or intraventricular haemorrhage. No infants were treated or removed from the study as a result of hypertension. Data show no differences in the rate of glucose intolerance between groups, but two infants in the hydrocortisone group received insulin for five days.

Garland 1999: Early dexamethasone-treated infants were more likely than placebo-treated controls to survive without BPD (83/118 vs 71/123; P = 0.03). They also were less likely to develop BPD if they survived to 28 days of life (16/99 vs 27/98; P = 0.042). Mortality rates were not significantly different. Subsequent dexamethasone therapy was used less often among early dexamethasone-treated infants who survived (68/99 vs 81/98; P = 0.01). Intestinal perforation was more common, but not significantly so, among dexamethasone-treated infants (12/118 vs 7/122; P = 0.20); during the first week of life, the difference was significant (9/118 vs 1/122; P = 0.009). Infants in the dexamethasone group also spent less time receiving oxygen (median days 43 vs 50; P = 0.04). Any grade of intraventricular haemorrhage (36% vs 52%; P = 0.02) and of patent ductus arteriosus ligation (14% vs 28%; P = 0.01) was also less common in the dexamethasone group. Hypertension (P<0.001) and treatment with insulin (P=0.007) ocurred more often for dexamethasone-treated infants than controls.

Halac 1990: Investigators reported no substantial or statistically significant effects of dexamethasone on neonatal mortality, mortality to hospital discharge, necrotising enterocolitis, sepsis, patent ductus arteriosus, or severe intraventricular haemorrhage.

Hochwald 2014: Data show no statistically significant effects of hydrocortisone on mortality to hospital discharge, BPD, death or BPD, necrotising enterocolitis, or sepsis.

Kopelman 1999: Intermittent mandatory ventilation (IMV) rate and ventilation index improved more rapidly in the dexamethasone-treated group. Mean blood pressure was higher in the dexamethasone group after the first day. Patent ductus arteriosus was less common in dexamethasone-treated infants (13/37 vs 19/33; P = 0.08), and fewer received indomethacin (8/37 vs 15/33; P = 0.03). At the study hospital, where early extubation was practised, more dexamethasone-treated infants were extubated during the first week (10/22 vs 2/16, P < 0.03). Results show no difference in intraventricular haemorrhage and no occurrence of adverse effects.

Lin 1999: For the endpoint of BPD at 28 days of life, statistical significance favouring dexamethasone was reached when analysis of 12 consecutive pairs in which one infant had BPD and the other did not showed that 10 pairs favoured dexamethasone and two pairs favoured control. Data presented for 40 infants (20 in each group) show a lower incidence of BPD at 28 days of life in the dexamethasone group (n = 4) than in the control group (n = 11; P < 0.05). Duration of oxygen therapy was also shorter in the dexamethasone group, at 7 ± 6 days versus 13 ± 12 days (P < 0.05). Among survivors, 12 of 15 in the dexamethasone group were extubated compared with 9 of 16 in the control group at the end of the study. Infants in the treated group had transient hyperglycaemia and hypertension, but data showed no differences between groups for mortality, incidence of sepsis, or intraventricular haemorrhage.

Mukhopadhyay 1998: Oxygen requirement was lower in the treated group than in the control group on days three, four, and five, although differences were not statistically significant. Mean duration of ventilation was shorter in the dexamethasone group (87 \pm 42 hours) than in the control group (120 \pm 46 hours; P value not given). Study authors reported one case of culture-positive sepsis

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



in the dexamethasone group, and two in the control group. None of the infants developed BPD (definition not given). Four infants in the dexamethasone group developed a pneumothorax versus three in the control group. Survival was 60% in the treated group and 55% in the control group.

Ng 2006: Nineteen infants (79%) in the hydrocortisone group were weaned from vasopressor support within 72 hours compared with eight controls (33%) (P < 0.001). Cumulative doses of dopamine and dobutamine after randomisation were significantly lower in the hydrocortisone group. Duration of ventilation, duration of oxygen, and incidence of BPD (oxygen at 36 weeks' postmenstrual age) were not significantly different between groups. Results showed no differences between groups for highest serum glucose, culture-proven sepsis, necrotising enterocolitis, intestinal perforation, duration of hospitalisation, and mortality. However, significantly more hydrocortisone-treated infants had glycosuria (P = 0.029).

Peltoniemi 2005: Hydrocortisone-treated infants did not show a significant increase in survival without BPD (64% vs 54% placebo) or a significant decrease in BPD among survivors (odds ratio (OR) 0.53, 95% CI 0.17 to 1.71). However, the study enrolled only 16% of its intended sample size. Two infants in the hydrocortisone group and three in the placebo group died. During the first week of life, infants in the hydrocortisone group needed lower mean airway pressures than infants in the placebo group (P = 0.03). Patent ductus arteriosus (36% vs 73%; P = 0.01) and duration of oxygen therapy (34 vs 62 days; P = 0.02) occurred less often in the hydrocortisone group, but intraventricular haemorrhage, cystic periventricular leukomalacia, retinopathy of prematurity, sepsis, necrotising enterocolitis, gastrointestinal haemorrhage, open corticosteroid treatment, and duration of intubation and of hospitalisation were not different between groups. Risk of gastrointestinal perforation was increased in the hydrocortisone group (16% vs 0%; P = 0.05). Data showed no differences in the rate of hyperglycaemia requiring insulin nor in blood pressures (diastolic and systolic). At six-year follow-up, data showed no substantial differences between groups in rates of cerebral palsy, blindness, deafness, or intellectual impairment (IQ < 69; steroid group 8% (2/25) vs placebo group 4% (1/26)).

Rastogi 1996: Ventilator variables at 5 to 14 days were significantly improved among infants who received dexamethasone compared with infants who received placebo. The effect seemed to be more marked in infants weighing less than 1250 grams at birth. Significantly more infants could be extubated by 14 days in the dexamethasone group (26/32 vs 14/32; P = 0.004). Dexamethasone therapy reduced the incidence of BPD at 28 days of life (OR 0.10, 95% CI 0.03 to 0.30) and eliminated BPD at 36 weeks' postmenstrual age. Dexamethasone-treated infants were more likely to show weight loss at 14 days (12.9% vs 3.7%; P = 0.01) and higher blood pressure from days 3 to 10. However, data showed no differences in time to regain birth weight, hypertension (one infant in each group), or incidence of intraventricular haemorrhage.

Romagnoli 1999: The incidence of BPD at 28 days of life and at 36 weeks' postmenstrual age was significantly lower in the dexamethasone group than in the control group (P < 0.001). Infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (P < 0.001). Hyperglycaemia, hypertension, growth failure, and hypertrophy of the left ventricle were transient side effects of early corticosteroid administration. Data show no significant differences in rates of cerebral palsy, blindness, deafness, intellectual impairment, or mean IQ, or in the combined rate of death or cerebral palsy (Romagnoli 2002).

Sanders 1994: The dexamethasone group required less ventilatory support (mean airway, peak inspiratory and end-expiratory pressures, and IMV) and supplemental oxygen after study day 4 (all P < 0.05). Improved tidal volume in the dexamethasone group, as assessed by pulmonary function testing of infants who remained intubated, was seen on study day 7 (P = 0.02). The dexamethasone group required a shorter time in hospital (median 95 days vs 106 days; P = 0.01). Survival in the dexamethasone group was 89% versus 67% in the placebo group (P = 0.08). Survival without BPD was 68% in the dexamethasone group versus 43% in the placebo group (P = 0.14). Mean blood pressure was elevated on study days 4 to 7. Data show no differences in rates of hyperglycaemia, incidence or severity of intraventricular haemorrhage, or days to regain birth weight, and no significant differences in rates of cerebral palsy, blindness, deafness, or intellectual impairment, nor in the combined rate of death or cerebral palsy (Sinkin 2002 (personal communication follow-up to Sanders 1994)).

Shinwell 1996: Results showed no differences in any outcome variable, except for a reduction in the need for mechanical ventilation at three days in dexamethasone-treated infants (54/122, 44% vs 71/106, 67%; P = 0.001). Gastrointestinal haemorrhage, hypertension, and hyperglycaemia were more common among treated infants, but no life-threatening complications, such as gastrointestinal perforation, were encountered. Follow-up of survivors at two to six years showed no significant differences in rates of blindness, deafness, or major neurosensory disability, nor in the combined rate of death or major neurosensory disability. However, data showed significant increases in rates of abnormal neurological examination findings, developmental delay, and cerebral palsy, and a significant increase in the combined rate of death or cerebral palsy (Shinwell 2002).

2000: Results showed no differences between Sinkin dexamethasone and placebo groups, respectively, for the primary outcomes of survival (79% vs 83%), survival without oxygen at 36 weeks' postmenstrual age (both 59%), and survival without oxygen at 36 weeks' postmenstrual age without late corticosteroids (46% vs 44%). We noted no significant differences between groups for median time in oxygen (50 vs 56 days), ventilation (20 vs 27 days), time to regain birth weight (15.5 vs 15.0 days), nor length of stay (88 vs 89 days). Infants given early dexamethasone were less likely to receive late corticosteroids for BPD during their hospital stay (25% vs 35%; P = 0.042). We noted no clinically significant side effects in the dexamethasone group, although transient elevations in blood glucose and blood pressure with return to baseline were evident by study day 10. Among infants who died (40 vs 33), data show no differences in median days on oxygen, ventilation, or length of hospital stay. However, among survivors (149 vs 162), we observed the following: median days on oxygen 37 vs 45, ventilation 14 vs 19 days, and length of stay 79 vs 81 days, for dexamethasone versus placebo groups, respectively. Data show no significant differences in rates of cerebral palsy, in the combined rate of death or cerebral palsy, or in mean Bayley scores (Sinkin 2002 (personal communication follow-up to Sinkin 2000).

Soll 1999: Results showed no differences in the primary outcome of BPD or death at 36 weeks' postmenstrual age (early therapy 135/272 vs 143/267; RR 0.93, 95% CI 0.79 to 1.09). Infants who



received early corticosteroid therapy were less likely to need late treatment (114/270 vs 164/267; RR 0.69, 95% CI 0.58 to 0.81). They also had a lower risk of patent ductus arteriosus (92/272 vs 117/269; RR 0.78, 95% 0.63 to 0.96) and were less likely to receive indomethacin therapy (132/273 vs 176/269; RR 0.74, 95% CI 0.64 to 0.86). However, infants who received early corticosteroid therapy were more likely to have complications such as hyperglycaemia (200/271 vs 151/263; RR 1.29, 95% CI 1.13 to 1.46) and to require insulin therapy (168/271 vs 102/267; RR 1.62, 95% CI 1.36 to 1.94). Data show trends towards increased gastrointestinal haemorrhage (33/271 vs 21/267; RR 2.55, 95% CI 0.92 to 2.61) and gastrointestinal perforation (31/271 vs 20/267; RR 1.53, 95% CI 0.89 to 2.61). Infants who had cranial ultrasound scans showed a trend towards an increase in periventricular leukomalacia in the early corticosteroid group (18/252 vs 8/250; RR 2.23, 95% CI 0.99 to 5.04). Infants who received early corticosteroid therapy received fewer days of supplemental oxygen but experienced poorer weight gain.

Stark 2001: Corticosteroid-treated infants had a lower incidence of the primary outcome, death or BPD at 36 weeks' postmenstrual age (63% vs 69%; P < 0.05). Fewer infants in the corticosteroid group had pulmonary interstitial emphysema (9% vs 23%; P < 0.05), required oxygen at 28 days of life (78% vs 94%; P < 0.05), or received subsequent corticosteroid treatment (34% vs 51%; P < 0.05). Rates of severe intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, and nosocomial infection were similar. Hypertension and hyperglycaemia were more frequent in the corticosteroid group (27% vs 4% and 23% vs 12%, respectively; both with P < 0.05). During the first 14 days, 14/111 (13%) infants in the corticosteroid group and 3/109 (3%) in the placebo group had spontaneous gastrointestinal perforation without necrotising enterocolitis (P < 0.05). Spontaneous perforation was also associated with indomethacin treatment (P = 0.005), as was an interaction between indomethacin and corticosteroid therapy (P = 0.04). Data showed no significant differences in rates of cerebral palsy, developmental delay, or major neurosensory disability, in the combined rate of death or cerebral palsy, or in the combined rate of death or major neurosensory disability (Stark 2001).

Subhedar 1997: Results showed no differences in the combined incidence of BPD and/or death before discharge from hospital between infants treated with dexamethasone and control infants (RR 0.95, 95% CI 0.79 to -1.18) or between those treated with inhaled nitric oxide and controls (RR 1.05, 95% CI 0.84 to 1.25). Data showed no significant differences in rates of cerebral palsy, blindness, deafness, developmental delay, the combined rate of death or cerebral palsy, or the combined rate of death or major neurosensory disability (Subhedar 2002 (personal communication follow-up to Subhedar 1997)).

Suske 1996: Infants in the dexamethasone group were extubated earlier (6.6 days vs 14.2 days; P < 0.02) and required less time in supplemental oxygen (4.2 days vs 12.5 days; P < 0.02). Pulmonary complications tended to be fewer in the dexamethasone group (1/14 vs 4/12), and retinopathy of prematurity tended to occur less frequently (2/14 vs 6/12; P < 0.05).

Tapia 1998: Results showed no significant differences in mortality and/or BPD between groups. The number of infants requiring oxygen at 36 weeks' postmenstrual age was significantly reduced in the dexamethasone group (8% vs 33%; P < 0.05). Stepwise logistic regression analysis with oxygen dependency at 36 weeks as the dependent variable, and birth weight, gestational age, gender, prenatal corticosteroids, and study treatment as the independent variables, showed that study treatment was the only variable significantly associated with oxygen dependency at 36 weeks. Data showed no differences between groups in the number of days of mechanical ventilation and oxygen treatment, and no differences in the incidence of major morbidity and possible complications related to corticosteroid administration, except for a lower incidence of necrotising enterocolitis in the dexamethasone group.

Vento 2004: Seven dexamethasone-treated infants and two control infants were extubated during the study period of seven days. Data showed no differences between groups for respiratory distress syndrome, patent ductus arteriosus, or severe intraventricular haemorrhage (grade 3 or 4). Dexamethasone-treated infants had lower absolute cell count and proportion of polymorphs in tracheal aspirate fluid compared with control infants as early as day 1 of treatment. They also had significantly higher dynamic compliance values compared with control infants (P < 0.01) as early as day 2 of treatment. Inspired oxygen concentrations were significantly lower on day 2 (0.24 vs 0.31; P < 0.05), and mean airway pressure on day 5 (4.8 vs 7.2 cmH₂O; P < 0.05).

Wang 1996: Dexamethasone treatment decreased fractional inspired oxygen concentration, arterial carbon dioxide tension, and mean airway pressure, and facilitated successful weaning from mechanical ventilation. Surfactant protein (SP)-A concentrations in tracheal aspirates were increased at days 7 and 14, and SP-D concentrations were increased from days 3 to 14 in the dexamethasone-treated group, compared with the control group.

Watterberg 1999: In this study, more infants treated with hydrocortisone survived without supplemental oxygen at 36 weeks' postmenstrual age (12/20 vs 7/20; P = 0.023). Hydrocortisone treatment was also associated with a reduction in duration of oxygen > 40% (7 vs 28 days; P = 0.06), duration of oxygen > 25% (48 vs 69 days; P = 0.02), and duration of mechanical ventilation (25 vs 32 days; P = 0.03). Data show no differences in rates of death, sepsis, patent ductus arteriosus, necrotising enterocolitis, gastrointestinal perforation, intraventricular haemorrhage, or retinopathy of prematurity, and no significant differences in rates of cerebral palsy, blindness, or deafness, or in the combined rate of death or cerebral palsy (Watterberg 2002 (personal communication follow-up to Watterberg 1999)).

Watterberg 2004: Results showed no differences in primary outcomes between groups (hydrocortisone vs placebo): survival without BPD (35% vs 34%), death before 36 weeks' postmenstrual age (15% vs 16%), and death before discharge (16% vs 17%). In a subgroup of infants exposed to chorioamnionitis, the hydrocortisone-treated group had significantly improved survival without BPD (38% vs 24%; P = 0.005) and lower mortality at 36 weeks' postmenstrual age (10% vs 18%; P = 0.02) and before discharge (12% vs 21%; P = 0.02). During treatment, rates of hyponatraemia, hypernatraemia, hyperkalaemia, hyperglycaemia, hypertension, and gastrointestinal bleeding were similar between groups. Seventy-four infants (41%) in the hydrocortisone group and 62 (34%) in the placebo group were treated with insulin (P = 0.19). Serum sodium and mean arterial blood pressure were significantly higher in hydrocortisone-treated infants (P < 0.001 and



P = 0.022, respectively). Other outcomes included no differences in weight gain or head circumference, durations of oxygen and ventilation, pulmonary air leaks, pulmonary haemorrhage, patent ductus arteriosus, sepsis, intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity and necrotising enterocolitis. However, hydrocortisone-treated infants were less likely to receive open-label corticosteroids during the treatment period (18% vs 28%; P = 0.02) and were more likely to have a spontaneous gastrointestinal perforation (9% vs 2%; P = 0.01). Follow-up data reveal no significant differences in rates of cerebral palsy, major neurological disability, developmental delay, or rehospitalisation, or in combined rates of death or cerebral palsy, or death or major neurological disability (Watterberg 2007).

Yeh 1990: Infants in the dexamethasone group had significantly higher pulmonary compliance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 vs 8/29; P < 0.025) at two weeks of age. Nineteen infants (65%) in the placebo group and 11 (39%) in the dexamethasone group (P < 0.05) had lung injury characterised by the following: surviving infants with BPD; infants who died of intractable respiratory failure and had evidence of BPD at autopsy; and infants who died of intractable respiratory failure with clinical evidence of BPD. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and delayed somatic growth.

Yeh 1997: Infants in the dexamethasone group had a significantly lower incidence of BPD than those in the placebo group, judged at 28 postnatal days (21/132 vs 40/130, P < 0.05) or at 36 weeks' postmenstrual age (20/132 vs 37/130, P < 0.05). More infants in the dexamethasone group were extubated during the study. Data showed no difference in mortality between groups (39/130 vs 44/132); however, a higher proportion of infants in the dexamethasone group died during the late study period, probably as the result of infection. Results showed no differences between groups in duration of oxygen therapy and hospitalisation. Significantly more infants in the dexamethasone group had bacteraemia or clinical sepsis (44/132 vs 27/130; P < 0.05). Other immediate but transient side effects observed in the dexamethasone group were hyperglycaemia, hypertension, cardiac hypertrophy, hyperparathyroidism, and delay in growth rate. At 25 months of age, data revealed no significant differences in rates of blindness, developmental delay, or major neurosensory disability, or in the combined rate of death or cerebral palsy, or the combined rate of death or major neurosensory disability. However, we noted significant increases in rates of abnormal neurological examination and cerebral palsy among survivors (Yeh 1998). The follow-up rate of survivors at eight years was 92% (146/159). Although rates of cerebral palsy were not significantly higher in the dexamethasone group, overall motor performance on the Movement ABC was worse than in controls. IQ and other cognitive performance were significantly worse in the dexamethasone group. Overall, survivors in the dexamethasone group had greater major neurological disability.

DISCUSSION

Corticosteroids are potent drugs that may improve lung function in infants with bronchopulmonary dysplasia (BPD) through several different mechanisms. It has been suggested that corticosteroids might have a role to play in prevention of BPD by suppressing the inflammatory response in the lungs of infants at risk (Groneck 1995). It has been shown that infants who develop BPD have low cortisol levels following adrenocorticotrophic hormone (ACTH) stimulation during the first week of life (Watterberg 1999). To be effective in preventing BPD, corticosteroids may have to be given within the first few days of life.

This review has demonstrated that early corticosteroid treatment facilitates weaning from the ventilator. Additional advantages include increased survival without BPD at 28 days of life and at 36 weeks' postmenstrual age, reduced risks of BPD at 28 days of life and at 36 weeks' postmenstrual age, and reduced risks of late treatment with corticosteroids, patent ductus arteriosus, and retinopathy of prematurity. On the other hand, risks of gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure may be increased.

Potential hazards of corticosteroid treatment for the neonate include growth restriction, protein breakdown, cardiac hypertrophy, and possible adverse effects on development of the central nervous system and lungs (Gibson 1993; Gramsbergen 1998; Tschanz 1995; van Goudoever 1994; Weichsel 1977; Werner 1992). One study showed a significant decline in the growth of head circumference with early corticosteroid treatment (Papile 1996). Long-term follow-up results showed that early corticosteroid treatment is associated with a significant increase in risks of developmental delay and cerebral palsy, but has no significant effects on the combined outcome of death or cerebral palsy, except in the subgroup of infants treated with dexamethasone. One study in which the rate of cerebral palsy was significantly higher at two years of age used a four-week tapering course of dexamethasone, so is similar in duration to the six-week tapering course of late corticosteroids reported by Kothaia and included in the systematic review of late corticosteroids (Doyle 2014a; Kothadia 1999; Yeh 1997). However, in Yeh 1997, the numbers of surviving children with cerebral palsy declined between two and eight to nine years of age, and the difference became statistically non-significant. In the 2002 follow-up study to the 1996 Shinwell study, adverse longterm neurological outcomes were reported in children treated with only a three-day course of early dexamethasone starting within 12 hours of birth (Shinwell 1996; Shinwell 2002). This finding is of extreme importance and concern, as data show about a three-fold increased risk of cerebral palsy among survivors, including children with spastic diplegia, spastic quadriplegia, and hemiplegia. Why dexamethasone given early for a short course should have such devastating effects remains unknown. Certainly some infants would have been treated with repeat courses of dexamethasone, but this would have been more likely among control infants. Periventricular leukomalacia is an obvious cause of cerebral palsy, but studies have shown no excess of this disorder in corticosteroid-treated infants compared with controls. Despite an increase in the diagnosis of cerebral palsy, it is important to note that this does not necessarily translate into major functional disability for the children concerned.

This systematic review found that early (\leq 7 days) systemic postnatal corticosteroids for preventing BPD in preterm infants, in the regimens used, have had significant short-term and long-term effects - both beneficial and harmful. A significant problem

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



in interpreting late follow-up data is that only 13 of 32 trials of early postnatal corticosteroids have reported follow-up results; therefore, the possibility of follow-up bias and publication bias must be considered. Potential limitations of the study with a significant increase in the rate of cerebral palsy are that only 84% of surviving infants were examined, and children were assessed during early childhood (Shinwell 1996). It is important to remember that cerebral palsy had been diagnosed before the children were five years of age in most cases; diagnosing cerebral palsy with certainty before five years of age is problematic (Stanley 1982). In another study, in which the rate of cerebral palsy was significantly worse at two years of age, with 81% follow-up, the difference became non-significant at eight to nine years - an age when the diagnosis of cerebral palsy is more certain, and when the followup rate was much better (92%), illustrating the importance of age of assessment and high follow-up rates (Yeh 1997). No study was designed primarily to test effects of postnatal corticosteroids on adverse long-term neurosensory outcomes, and all studies were underpowered to detect clinically important differences in longterm neurosensory outcomes.

Subgroup analyses by type of corticosteroid revealed that most beneficial and harmful effects were attributable to dexamethasone, and that hydrocortisone had little effect in most analyses, but the power to detect beneficial or harmful effects of hydrocortisone was low for most comparisons. However, the addition of data from the latest randomised controlled trial of early hydrocortisone reported by Baud and colleagues, which is also the largest trial, has revealed some advantages for early hydrocortisone in improving rates of mortality, extubation failure, and patent ductus arteriosus (Baud 2016).

In an observational study of infants born after antenatal corticosteroid therapy, an excess of periventricular leukomalacia was evident among those whose mothers had received dexamethasone rather than betamethasone (Baud 1999). Most studies of postnatal corticosteroids used dexamethasone in high doses of 0.5 to 1.0 mg/kg/d. Other corticosteroids or lower doses of dexamethasone may prove to be safer, and emerging evidence supports the use of hydrocortisone as prophylaxis for bronchopulmonary dysplasia. Further studies are needed to compare lower doses of corticosteroids, other corticosteroids, and alternative routes of administration (e.g. inhalation) (see Cochrane Review - Shah 2017).

Quality of the evidence

Review authors assessed the quality of evidence for seven major outcomes (Summary of findings for the main comparison). We assessed the evidence as high quality for mortality at 36 weeks, gastrointestinal perforation, and cerebral palsy. We downgraded several outcomes (mortality at latest age, BPD at 36 weeks, and death or BPD at 36 weeks) by one level to moderate quality because of weak evidence for publication bias, or because of moderate heterogeneity (death or cerebral palsy).

AUTHORS' CONCLUSIONS

Implications for practice

Benefits of early postnatal corticosteroids in preterm infants at risk of developing bronchopulmonary dysplasia may not outweigh real or potential adverse effects. Early postnatal corticosteroid treatment resulted in short-term benefits, including earlier extubation and decreased risks of bronchopulmonary dysplasia and of 'death or bronchopulmonary dysplasia' at 28 days of life and at 36 weeks' postmenstrual age, but was also associated with significant short-term and long-term adverse effects. Adverse effects included short-term risk of gastrointestinal bleeding, intestinal perforation, hyperglycaemia, and hypertension, as well as long-term risks of abnormal neurological examination findings and cerebral palsy. However, the methodological quality of studies determining long-term outcomes was limited in some cases; children were assessed predominantly before school age, and no study was sufficiently powered to detect important adverse long-term neurosensory outcomes. Therefore, given the risks of potential short-term and long-term adverse effects versus potential short-term benefits, it appears appropriate to curtail early corticosteroid treatment for prevention of bronchopulmonary dysplasia.

Implications for research

Through this systematic review, we have identified a compelling need for long-term follow-up and reporting of late outcomes, especially neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. These follow-up studies should include tests of gross motor function, cognitive functioning, hearing, and visual acuity.

Future studies are needed to identify accurately infants who are at greatest risk of developing bronchopulmonary dysplasia. Future placebo-controlled trials of postnatal corticosteroids in preterm infants should include long-term neurological follow-up. Studies comparing different types, doses, and durations of corticosteroid treatment, and examining effects of inhaled corticosteroids, are urgently needed.

Short-term and longer-term effects of early hydrocortisone to prevent bronchopulmonary dysplasia require further evaluation.

ACKNOWLEDGEMENTS

None noted.

REFERENCES

References to studies included in this review

Anttila 2005 {published data only}

Anttila E, Peltonemi O, Haumont D, Herting E, ter Horst H, Heinonen K, et al. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. *European Journal of Pediatrics* 2005;**164**(8):472-81. [DOI: 10.1007/s00431-005-1645-8; PUBMED: 15864643]

Baden 1972 {published data only}

* Baden M, Bauer CR, Cole E, Klein G, Taeusch HW, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. *Pediatrics* 1972;**50**(4):526-34. [PUBMED: 4561296]

Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. *Pediatrics* 1974;**53**(6):877-83. [PUBMED: 4598934]

Batton 2012 {published data only}

Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Feasibility study of early blood pressure management in extremely preterm infants. *Journal of Pediatrics* 2012;**161**(1):65-9. [DOI: 10.1016/j.jpeds.2012.01.014; PUBMED: 22336574]

Baud 2016 {published data only}

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. PREMILOC Trial Study Group. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet* 2016;**387**(10030):1827-36. [DOI: 10.1016/ S0140-6736(16)00202-6; PUBMED: 26916176]

Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C, PREMILOC Trial Group. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. *JAMA* 2017;**317**(13):1329-37. [DOI: 10.1001/jama.2017.2692; PUBMED: 28384828]

Biswas 2003 {published data only}

Biswas S. Personal communication. email 2002.

* Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial thyroid hormone replacement in neonates. *Pediatric Research* 2003;**53**(1):48-56. [DOI: 10.1203/00006450-200301000-00011; PUBMED: 12508081]

Bonsante 2007 {published data only}

Bonsante F, Latorre G, Lacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low-dose hydrocortisone in very preterm infants: a randomized placebo-controlled trial. *Neonatology*

2007;**91**(4):217-21. [DOI: 10.1159/000098168; PUBMED: 17568152]

Efird 2005 {published data only}

Efird MM, Heerens AT, Gordon PV, Bose CL, Young DA. A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. *Journal of Perinatology* 2005;**25**(2):119-24. [DOI: 10.1038/sj.jp.7211193; PUBMED: 15329742]

Garland 1999 {published data only}

Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. *Pediatrics* 1999;**104**(1 Pt 1):91-9. [PUBMED: 10390266]

Halac 1990 {published data only}

Halac E, Halac J, Begue EF, Casañas JM, Indiveri DR, Petit JF, et al. Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. *Journal of Pediatrics* 1990;**117**(1 Pt 1):132-8. [PUBMED: 2196355]

Hochwald 2014 {published data only}

Hochwald O, Palegra G, Osiovich O. Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. *Indian Journal of Pediatrics* 2014;**81**(8):808-10. [DOI: 10.1007/s12098-013-1151-3; PUBMED: 23904065]

Kopelman 1999 {published data only}

Kopelman AE, Moise AA, Holbert D, Hegemier SE. A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. *Journal of Pediatrics* 1999;**135**(3):345-50. [PUBMED: 10484801]

Lauterbach 2006 {published data only}

Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchol J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. *Journal of Maternal-Fetal & Neonatal Medicine* 2006;**19**(7):433-8. [DOI: 10.1080/14767050600736754; PUBMED: 16923699]

Lin 1999 {published data only}

Lin YJ, Yeh TF, Hsieh WS, Chi YC, Lin HC, Lin CH. Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. *Pediatric Pulmonology* 1999;**27**(1):21-6. [PUBMED: 10023787]

Mukhopadhyay 1998 {published data only}

Mukhopadhyay K, Kumar P, Narang A. Role of early postnatal dexamethasone in respiratory distress syndrome. *Indian Pediatrics* 1998;**35**(2):117-22. [PUBMED: 9707853]

Ng 2006 {published data only}

Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, et al. A double-blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension



in preterm infants. *Pediatrics* 2006;**117**(2):367-75. [DOI: 10.1542/ peds.2005-0869; PUBMED: 16452355]

Peltoniemi 2005 {published data only}

* Peltoniemi O, Kari A, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. *Journal of Pediatrics* 2005;**146**(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040; PUBMED: 15870666]

Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari MA, et al. Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two-year follow-up. *Neonatology* 2009;**95**(3):240-7. [DOI: 10.1159/000164150; PUBMED: 18931525]

Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M, Neonatal Hydrocortisone Working Group. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. *Acta Paediatrica* 2016;**105**(2):159-64. [DOI: 10.1111/apa.13074; PUBMED: 26058477]

Rastogi 1996 {published data only}

Morales P, Rastogi A, Bez ML, Akintorin SM, Pyati S, Andes SM, et al. Effect of dexamethasone therapy on the neonatal ductus arteriosus. *Pediatric Cardiology* 1998;**19**(3):225-9. [DOI: 10.1007/ s002469900290; PUBMED: 9568218]

* Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes PS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. *Pediatrics* 1996;**98**(2 Pt 1):204-10. [PUBMED: 8692619]

Romagnoli 1999 {published data only}

Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. *Pediatrics* 2002;**109**(6):e85. [PUBMED: 12042579]

* Romagnoli C, Zecca E, Vento G, De Carolis MP, Papacci P, Tortorolo G. Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. *Intensive Care Medicine* 1999;**25**(7):717-21. [PUBMED: 10470576]

Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. *Pharmacology* 1999;**59**(5):266-74. [DOI: 28329; PUBMED: 10529659]

Sanders 1994 {published data only}

* Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. *Pediatric Research* 1994;**36**(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022; PUBMED: 7936832]

Sinkin RA. Personal communication. email 2002.

Shinwell 1996 {published data only}

Shinwell ES. Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology 1999:240-54.

Shinwell ES. Personal communication. email 2002.

Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and incidence of cerebral palsy. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 2000;**83**(3):F177-81. [PUBMED: 11040164]

* Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 1996;**74**(1):F33-7. [PUBMED: 8653433]

Sinkin 2000 {published data only}

D'Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. *Biology of the Neonate* 1999;**76**(5):266-73. [DOI: 14168; PUBMED: 10516393]

Sinkin RA. Personal communication. email 2002.

* Sinkin RA, Dweck HS, Horgan MJ, Gallaher KJ, Cox C, Maniscalco WM, et al. Early dexamethasone - attempting to prevent chronic lung disease. *Pediatrics* 2000;**105**(3 Pt 1):542-8. [PUBMED: 10699107]

Soll 1999 {published data only}

Soll RF, Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. *Pediatric Research* 1999;**45**:226A.

Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. *Pediatrics* 2001;**108**(3):741-8. [PUBMED: 11533345]

Stark 2001 {published data only}

* Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. *New England Journal of Medicine* 2001;**344**(2):95-101. [DOI: 10.1056/NEJM200101113440203; PUBMED: 11150359]

Stark AR, Carlo WA, Vohr BR, Papile L, Saha S, Bauer CR, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics 2014; Vol. 164, issue 1:34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027; PUBMED: 23992673]

Subhedar 1997 {published data only}

Subhedar NV. Personal communication. email 2002.



Subhedar NV, Bennett AJ, Wardle SP, Shaw NJ. More trials on early treatment with corticosteroids are needed. *BMJ* 2000;**320**(7239):941. [PUBMED: 10742018]

* Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 1997;**77**(3):F185-90. [PUBMED: 9462187]

Suske 1996 {published data only}

ochrane

Suske G, Oestreich K, Varnholt V, Lasch P, Kachel W. Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. *Acta Paediatrica* 1996;**85**(6):713-8. [PUBMED: 8816210]

Tapia 1998 {published data only}

Tapia JL, Ramirez R, Cifuentes J, Fabres J, Hubner ME, Bancalari A, et al. The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. *Journal of Pediatrics* 1998;**132**(1):48-52. [PUBMED: 9469999]

Vento 2004 {published data only}

Vento G, Matassa PG, Zecca E, Tortorolo L, Martelli M, De Carolis MP, et al. Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. *Pharmacology* 2004;**71**(3):113-9. [DOI: 10.1159/000077444; PUBMED: 15161992]

Wang 1996 {published data only}

* Wang JY, Yeh TF, Lin YC, Miyamura K, Holmskov U, Reid KB. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. *Thorax* 1996;**51**(9):907-13. [PUBMED: 8984701]

Wang JY, Yeh TF, Lin YJ, Chen WY, Lin CH. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. *Pediatric Pulmonology* 1997;**23**(3):193-7. [PUBMED: 9094727]

Watterberg 1999 {published data only}

Watterberg KL. Personal communication. email 2002.

* Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. *Pediatrics* 1999;**104**(6):1258-63. [PUBMED: 10585975]

Watterberg 2004 {published data only}

* Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. *Pediatrics* 2004;**114**(6):1649-57. [DOI: 10.1542/peds.2004-1159; PUBMED: 15574629]

Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. *Pediatrics* 2007;**120**(1):40-8. [DOI: 10.1542/peds.2006-3158; PUBMED: 17606560]

Yeh 1990 {published data only}

Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. *Journal of Pediatrics* 1990;**117**(2 Pt 1):273-82. [PUBMED: 2199642]

Yeh 1997 {published data only}

Lin YJ, Lin CH, Wu JM, Tsai WH, Yeh TF. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. *Acta Paediatrica* 2005;**94**(3):310-6. [PUBMED: 16028649]

Lin YJ, Yeh TF, Lin HC, Wu JM, Lin CH, Yu CY. Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. *Acta Paediatrica* 1998;**87**(10):1061-5. [PUBMED: 9825973]

Peng CT, Lin HC, Lin YJ, Tsai CH, Yeh TF. Early dexamethasone therapy and blood cell count in preterm infants. *Pediatrics* 1999;**104**(3 Pt 1):476-81. [PUBMED: 10469772]

Yeh TF, Lin I, Shieh W, Lin H, Chen J, Kao S. Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. *Pediatric Research* 1994;**35**(4):262A.

* Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. *Pediatrics* 1997;**100**(4):E3. [PUBMED: 9310536]

Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. *Pediatrics* 1998;**101**(5):E7. [PUBMED: 9565440]

Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. *New England Journal of Medicine* 2004;**350**(13):1304-13. [DOI: 10.1056/NEJMoa032089; PUBMED: 15044641]

References to studies excluded from this review

Ariagno 1987 {unpublished data only}

* Ariagno RL, Sweeney TE, Baldwin RB, Inguillo D, Martin D. Controlled trial of dexamethasone in preterm infants at risk for bronchopulmonary dysplasia: lung function, clinical course and outcome at three years (as supplied 2000). Data on file.

Ariagno RL, Sweeney TJ, Baldwin RB, Inguillo D, Martin D. Dexamethasone effects on lung function and risks in 3 week old ventilatory dependent preterm infants. *American Reviews of Respiratory Disease* 1987;**135**:A125.



Avery 1985 {published data only}

Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. *Pediatrics* 1985;**75**(1):106-11. [PUBMED: 3880879]

Brozanski 1995 {published data only}

* Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. *Journal of Pediatrics* 1995;**126**(5 Pt 1):769-76. [PUBMED: 7752005]

Gilmour CH, Sentipal-Walerius JM, Jones JG, Doyle JM, Brozanski BS, Balsan MJ, et al. Pulse dexamethasone does not impair growth and body composition of very low birth weight infants. *Journal of the American College of Nutrition* 1995;**14**(5):455-62. [PUBMED: 8522724]

Hofkosh D, Brozanski BS, Edwards DE, Williams LA, Jones JG, Cheng KP. One year outcome of infants treated with pulse dexamethasone for prevention of BPD. *Pediatric Research* 1995;**37**(4):259A.

CDTG 1991 {published data only}

* Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. *Pediatrics* 1991;**88**(3):421-7. [PUBMED: 1881718]

Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. *Pediatrics* 1995;**96**(5 Pt 1):897-906. [PUBMED: 7478833]

Jones RA, Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. *Pediatrics* 1995;**116**(2):370-8. [DOI: 10.1542/peds.2004-1818; PUBMED: 16061591]

Jones RA, Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. *Pediatrics* 2005;**116**(2):379-84. [DOI: 10.1542/peds.2004-1819; PUBMED: 16061592]

Cummings 1989 {published data only}

Cummings JJ. Personal communication. email 2002.

* Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. *New England Journal of Medicine* 1989;**320**(23):1505-10. [DOI: 10.1056/NEJM198906083202301; PUBMED: 2657423]

Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. *Pediatrics* 2005;**115**(3):681-7. [DOI: 10.1542/peds.2004-0956; PUBMED: 15741372]

Dobryansky 2012 {published data only}

Dobryansky D, Borysiuk O, Salabay Z, Dubrovna Y. Clinical effectiveness of early administration of caffeine and low-dose hydrocortisone to preterm newborns with a high risk of BPD development. *Archives of Disease in Childhood* 2012;**97**:A119. [DOI: 10.1136/archdischild-2012-302724.0405]

Doyle 2006 {published data only}

* Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Lowdose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. *Pediatrics* 2006;**117**(1):75-83. [PUBMED: 16396863]

Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. *Pediatrics* 2007;**119**(4):716-21. [DOI: 10.1542/peds.2006-2806; PUBMED: 17403842]

Durand 1995 {published data only}

Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. *Pediatrics* 1995;**95**(4):584-90. [PUBMED: 7700763]

Gaissmaier 1999 {published data only}

Gaissmaier RE, Pohlandt F. Single-dose dexamethasone treatment of hypotension in preterm infants. *Journal of Pediatrics* 1999;**134**(6):701-5. [PUBMED: 10356137]

Gross 2005 {published data only}

Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. *Pediatrics* 2005;**115**(3):681-7. [10.1542/peds.2004-0956; PUBMED: 15741372]

Harkavy 1989 {published data only}

Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilatorand oxygen-dependent infants: a controlled trial. *Journal of Pediatrics* 1989;**115**(6):979-83. [PUBMED: 2685220]

Kari 1993 {published data only}

* Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. *Archives of Disease in Childhood* 1993;**68**(5 Spec No):566-9. [PUBMED: 8323356]

Kari MA, Raivio KO, Venge P, Hallman M. Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens. *Pediatric Research* 1994;**36**(3):387-93. [DOI: 10.1203/00006450-199409000-00020; PUBMED: 7808837]

Mieskonen S, Eronen M, Malmberg LP, Turpeinen M, Kari MA, Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. *Acta Paediatrica* 2003;**92**(8):896-904. [PUBMED: 12948063]



Kazzi 1990 {published data only}

Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. *Pediatrics* 1990;**86**(5):722-7. [PUBMED: 2235226]

Kothadia 1999 {published data only}

Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. *Pediatrics* 1996;**97**(6 Pt 1):818-21. [PUBMED: 8657520]

Goldstein DJ, Waldrep EL, VanPelt JC, O'Shea TM. Developmental outcome at 5 years following dexamethasone use for very low birth weight infants. *Pediatric Research* 2000;**47**(4):310A.

* Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG 3rd, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. *Pediatrics* 1999;**104**(1 Pt 1):22-7 Erratum in: Pediatrics 2004; 114(6):1746. [PUBMED: 10390255]

Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Followup study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. *Journal of Pediatrics* 2007;**150**(4):345-50. [DOI: 10.1016/ j.jpeds.2006.12.013; PUBMED: 17382108]

O'Shea TM, Goldstein DJ, Jackson BG, Kothadia JM, Dillard RG. Randomized trial of a 42-day tapering course of dexamethasone in very low birth weight infants: neurological, medical and functional outcome at 5 years of age. *Pediatric Research* 2000;**47**(4):319A.

O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, et al. Randomized placebocontrolled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. *Pediatrics* 1999;**104**(1 Pt 1):15-21. [PUBMED: 10390254]

Washburn LK, Nixon PA, O'Shea TM. Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. *Pediatrics* 2006;**118**(4):1592-9. [DOI: 10.1542/peds.2006-0973; PUBMED: 17015551]

Kovacs 1998 {published data only}

Kovacs L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. *Acta Paediatrica* 1998;**87**(7):792-8. [PUBMED: 9722255]

Noble-Jamieson 1989 {published data only}

Noble-Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. *European Journal of Pediatrics* 1989;**148**(4):365-7. [PUBMED: 2651132]

Ohlsson 1992 {published data only}

Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. *Acta Paediatrica* 1992;**81**(10):751-6. [PUBMED: 1421877]

Papile 1998 {published data only}

* Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. *New England Journal of Medicine* 1998;**338**(16):1112-8. [DOI: 10.1056/ NEJM199804163381604; PUBMED: 9545359]

Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, et al. Dexamethasone therapy increases infection in very low birth weight infants. *Pediatrics* 1999;**104**(5):e63. [PUBMED: 10545589]

Parikh 2013 {published data only}

Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. *Journal of Pediatrics* 2013;**162**(4):685-90. [DOI: 10.1016/ j.jpeds.2012.09.054; PUBMED: 23140612]

Romagnoli 1997 {published data only}

* Romagnoli C, Vento G, Zecca E, Tortorolo G, Papacci P, De Carolis M, et al. Dexamethasone for the prevention of chronic lung disease in preterm neonates: a prospective randomized study [II desametazone nella prevenzione della patologia polmonare cronica del neonato pretermine: studio prospettico randomizzato]. *Rivista Italiana di Pediatria [Italian Journal of Pediatrics]* 1997;**24**:283-8.

Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 2002;**87**(1):F55-8. [12091294]

Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized trial. *Pharmacology* 1999;**59**(5):266-74. [PUBMED: 10529659]

Salas 2014 {published data only}

Salas G, Travaglianti M, Leone A, Couceiro C, Rodríguez S, Fariña D. Hydrocortisone for the treatment of refractory hypotension:a randomised controlled trial [Hidrocortisona para el tratamiento de hipotensión refractaria: ensayo clínico controlado y aleatorizado]. *Anales de Pediatria (Barcelona, Spain : 2003)* 2014;**80**(6):387-93. [DOI: 10.1016/ j.anpedi.2013.08.004; PUBMED: 24139558]

Scott 1997 {published data only}

Scott SM, Backstrom C, Bessman S. Effect of five days of dexamethasone therapy on ventilator dependence and adrenocorticotropic hormone-stimulated cortisol concentrations. *Journal of Perinatology* 1997;**17**(1):24-8. [PUBMED: 9069060]



Smolkin 2014 {published data only}

Smolkin T, Ulanovsky I, Jubran H, Blazer S, Makhoul IR. Experience with oral betamethasone in extremely low birthweight infants with bronchopulmonary dysplasia. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 2014;**99**(6):F517-8. [DOI: 10.1136/archdischild-2014-306619; PUBMED: 25074982]

Tsukahara 1999 {published data only}

Tsukahara H, Watanabe Y, Yasutomi M, Kobata R, Tamura S, Kimura K, et al. Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants. *Biology of the Neonate* 1999;**76**(5):283-90. [DOI: 14170; PUBMED: 10516395]

Vincer 1998 {published data only}

Vincer MJ, Allen AC. Double blind randomized controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBW <1500 grams) who are ventilator dependent at 4 weeks of age. *Pediatric Research* 1998;**43**:201A.

Walther 2003 {published data only}

Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. *Early Human Development* 2003;**74**(1):37-45. [PUBMED: 14512180]

Yaseen 1999 {published data only}

Yaseen H, Okash I, Hanif M, al-Umran K, al-Faraidy A. Early dexamethasone treatment in preterm infants treated with surfactant: a double blind controlled trial. *Journal of Tropical Pediatrics* 1999;**45**(5):304-6. [DOI: 10584476]

Additional references

Anonymous 1991

[No authors listed]. Dexamethasone for neonatal chronic lung disease. *Lancet* 1991;**338**(8773):982-3. [PUBMED: 1681347]

Arias-Camison 1999

Arias-Camison JM, Lau J, Cole CH, Frantz ID 3rd. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. *Pediatric Pulmonology* 1999;**28**(3):167-74. [PUBMED: 10495332]

Baud 1999

Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very preterm infants. *New England Journal of Medicine* 1999;**341**(16):1190-6. [DOI: 10.1056/ NEJM199910143411604; PUBMED: 10519896]

Bayley 1993

Bayley, N. Bayley Scales of Infant Development. 2nd Edition. San Antonio: The Psychological Corporation, 1993.

Bhuta 1998

Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung

disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;**79**(1):F26-33. [PUBMED: 9797621]

Doyle 2000

Doyle LW, Davis PG. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. *Journal of Paediatrics and Child Health* 2000;**36**(2):101-7. [PUBMED: 10760004]

Doyle 2010a

Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. *Neonatology* 2010;**98**(2):111-7. [DOI: 10.1159/000279992; PUBMED: 20150750]

Doyle 2010b

Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. *Neonatology* 2010;**98**(3):217-24. [DOI: 10.1159/000286210; PUBMED: 20389126]

Doyle 2010c

Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. *Neonatology* 2010;**98**(4):289-96. [DOI: 10.1159/000286212; PUBMED: 20453523]

Doyle 2014b

Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2014, Issue 5. [DOI: 10.1002/14651858.CD001145.pub3]

Doyle 2017

Doyle LW, Cheong J, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database of Systematic Reviews* 2017, Issue 10. [DOI: 10.1002/14651858.CD001145.pub4]

Egberts 1997

Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. *Pediatrics* 1997;**100**(1):E4. [PUBMED: 9200378]

Fitzhardinge 1974

Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. *Pediatrics* 1974;**53**(6):877-83. [PUBMED: 4598934]

Gibson 1993

Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by knemometry. *Archives of Disease in Childhood* 1993;**69**(5 Spec No):505-9. [PUBMED: 8285754]



GRADEpro GDT [Computer program]

GRADE Working Group, McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 21 February 2017. Hamilton (ON): GRADE Working Group, McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org.

Gramsbergen 1998

Gramsbergen A, Mulder EJH. The influence of betamethasone and dexamethasone on motor development in young rats. *Pediatric Research* 1998;**44**(1):105-10. [DOI: 10.1203/00006450-199807000-00017; PUBMED: 9667379]

Groneck 1995

Groneck P, Speer CP. Inflammatory mediators and bronchopulmonary dysplasia. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 1995;**73**(1):F1-3. [PUBMED: 7552588]

Halliday 1997

Halliday HL. A review of postnatal corticosteroids for treatment and prevention of chronic lung disease in the preterm infant. *Prenatal and Neonatal Medicine* 1997;**2**:1-12.

Halliday 1999

Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. *Biology of the Neonate* 1999;**76**(Suppl 1):29-40. [PUBMED: 10393391]

Higgins 2011

Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Mammel 1983

Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. *Lancet* 1983;**1**(8338):1356-8. [PUBMED: 6134136]

Ng 1993

Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. *Archives of Disease in Childhood* 1993;**68**(3 Spec No):330-6. [PUBMED: 8466274]

Onland 2017

Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. *Cochrane Database of Systematic Reviews* 2017, Issue 8. [DOI: 10.1002/14651858.CD002311.pub4]

Papile 1996

Papile LA, Stoll B, Donovan E, Tyson I, Bauer C, Wright L, et al. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): a multicenter, randomized, double-masked trial. *Pediatric Research* 1996;**39**:236A.

Peltoniemi 2009

Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari M A, et al. Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two-year follow-up. *Neonatology* 2009;**95**(3):240-7. [DOI: 10.1159/000164150; PUBMED: 18931525]

Peltoniemi 2016

Peltoniemi OM, Lano A, Yliherva A, Kari M A, Hallman M, Neonatal Hydrocortisone Working Group. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. *Acta Paediatrica* 2016;**105**(2):159-64. [DOI: 10.1111/apa.13074; PUBMED: 26058477]

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Romagnoli 2002

Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. *Pediatrics* 2002;**109**(6):e85. [PUBMED: 12042579]

Ryan 1996

Ryan SW, Nycyk J, Shaw NJ. Prediction of chronic neonatal lung disease on day 4 of life. *European Journal of Pediatrics* 1996;**155**(8):668-71. [PUBMED: 8839722]

Schmidt 2006

Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. *New England Journal of Medicine* 2006;**354**(20):2112-21.

Schünemann 2013

Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Available from https://gdt.gradepro.org/app/handbook/handbook.html. Updated October 2013.

Shah 2007b

Shah V, Ohlsson A, Halliday H, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. *Cochrane Database of Systematic Reviews* 2007, Issue 4. [DOI: 10.1002/14651858.CD001969.pub2]

Shah 2012a

Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. *Cochrane Database of Systematic Reviews* 2012, Issue 5. [DOI: 10.1002/14651858.CD002058.pub2]

Shah 2012b

Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. *Cochrane Database of Systematic Reviews* 2012, Issue 5. [DOI: 10.1002/14651858.CD002057.pub3]



Shah 2017

Shahh VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. *Cochrane Database of Systematic Reviews* 2017, Issue 1. [DOI: 10.1002/14651858.CD001969.pub4]

Shinwell 2002

Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 2000;**83**(3):F177-81. [PUBMED: 11040164]

Stanley 1982

Stanley FJ. Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. *Developmental Medicine and Child Neurology* 1982;**24**(1):93-4. [PUBMED: 7106413]

Stark 2014

Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. *Journal of Pediatrics* 2014;**164**(1):34-9 e2. [DOI: 10.1016/ j.jpeds.2013.07.027; PUBMED: 23992673]

Tarnow-Mordi 1999

Tarnow-Mordi W, Mitra A. Postnatal dexamethasone in preterm infants is potentially life saving, but follow up studies are urgently needed. *BMJ* 1999;**319**(7222):1385-6. [PUBMED: 10574836]

Tschanz 1995

Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. *Biology of the Neonate* 1995;**68**(4):229-45. [PUBMED: 8580214]

van Goudoever 1994

Van Goudoever JB, Wattimena JD, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJ. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. *Journal of Pediatrics* 1994;**124**(1):112-8. [PUBMED: 8283359]

Watterberg 2007

Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and developmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. *Pediatrics* 2007;**120**(1):40-8. [DOI: 10.1542/peds.2006-3158; PUBMED: 17606560]

Weichsel 1977

Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurologic hazards. *Annals* of Neurology 1977;**2**(5):364-6. [DOI: 10.1002/ana.410020503; PUBMED: 617574]

Werner 1992

Werner JC, Sicard RE, Hansen TWR, Solomon E, Cowett RM, Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. *Journal of Pediatrics* 1992;**120**(2 Pt 1):286-91. [PUBMED: 1735831]

Yeh 1998

Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow up study. *Pediatrics* 1998;**101**(5):E7. [PUBMED: 9565440]

Yeh 2004

Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. *New England Journal of Medicine* 2004;**350**(13):1304-13. [DOI: 10.1056/NEJMoa032089; PUBMED: 15044641]

References to other published versions of this review

Doyle 2014a

Doyle LW, Ehrenkranz RA, Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2014, Issue 5. [DOI: 10.1002/14651858.CD001146.pub4]

Halliday 2000

Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2000, Issue 2. [DOI: 10.1002/14651858.CD001146]

Halliday 2001

Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2001, Issue 1. [DOI: 10.1002/14651858.CD001146]

Halliday 2003b

Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2003, Issue 1. [DOI: 10.1002/14651858.CD001146]

Halliday 2010

Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: 10.1002/14651858.CD001146.pub3]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Anttila 2005

Methods	Multi-centre double-blind placebo-controlled randomised trial		
Participants	109 infants with birth weight 500 grams to 999 grams, gestation < 32 weeks, need for mechanical venti- lation and supplemental oxygen by 4 hours of age. Stratified by weight (500 grams to 749 grams vs 750 grams to 999 grams) Exclusions: life-threatening congenital anomalies or known chromosomal anomaly		
Interventions	dose was given before	4 doses of dexamethasone 0.25 mg/kg each at 12-hourly intervals or normal saline as placebo. First dose was given before 6 hours. Open-label dexamethasone was allowed when deemed necessary by attending physician, but its use was discouraged.	
Outcomes	Survival to 36 weeks without IVH (grade III to IV), PVL (echodensities after first week or periventricular cysts on ultrasound), or BPD (oxygen at 36 weeks); growth, duration of assisted ventilation and oxygen, late corticosteroid treatment, infection, hyperglycaemia, hypertension, ROP, PDA, GI bleeding and perforation, NEC		
Notes	This paper also reported a meta-analysis of early short vs early prolonged dexamethasone treatment.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation by coded vials prepared in the pharmacy at each centre	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes	
Selective reporting (re- porting bias)	Low risk	All prespecified primary and secondary outcomes reported	

Baden 1972

Methods	Double-blind placebo-controlled randomised trial
Participants	44 preterm infants < 24 hours old with respiratory distress confirmed both clinically and radiologically
Interventions	Hydrocortisone 25 mg/kg on admission and 12 hours later intravenously



Baden 1972 (Continued)	Control group given pla	acebo
Outcomes	Death, FiO ₂ , cortisol levels, and blood gases	
Notes	The oldest study, carrie	ed out in 1972. Used hydrocortisone in a very short course of treatment
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation via random numbers and sealed envelopes
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Batton 2012

Methods	Multi-centre randomised placebo-controlled trial		
Participants	Infants at 23 to 26 completed weeks' gestation with study-defined low blood pressure		
Interventions	Hydrocortisone 1 mg/k	g loading, then 0.5 mg/kg at 12-hourly intervals for 6 doses	
Outcomes	Short-term outcomes during primary hospitalisation of death, BPD (not defined), IVH grade III or IV, PVL, and NEC requiring surgery		
Notes	_		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Enrolled infants were randomised from a prespecified sequence, allocated by centre, and received treatment from an investigational pharmacist.	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	



Batton 2012 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Unclear risk	Primary outcome of the study was to determine the feasibility of a randomised trial of blood pressure management, rather than effects on bronchopulmonary dysplasia.

Methods	Multi-centre double-blind randomised controlled trial			
Participants	523 inborn infants at 24 to 27 weeks' gestational age in the first 24 hours after birth recruited from 21 French centres with NICU facilities between 25 May 2008 and 31 January 2014.			
	Exclusions: rupture of membranes at < 22 weeks' gestation; birth weight < third centile according to French sex-customised curves; severe perinatal asphyxia (Apgar score = 0–3 for longer than 5 minutes, cord blood pH < 7·00, or both) and expected to die shortly after birth; congenital malformations (birth defects or major structural abnormalities detectable prenatally); known chromosomal aberrations			
Interventions	Hydrocortisone hemisuccinate 1 mg/kg/d divided into 2 doses for 7 days, then 0.5 mg/kg/d once per day for 3 days (total dose 8.5 mg/kg)			
	Control infants were given an equivalent volume of 5% glucose placebo.			
	Open-label corticosteroids were not allowed during first 10 days of treatment.			
Outcomes	Short-term primary outcome: survival free of bronchopulmonary dysplasia (BPD) at 36 weeks' post- menstrual age. BPD was diagnosed at 36 weeks (± 3 days) without additional testing if an infant re- quired mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, or 30% or more supplemental oxygen concentration. BPD was diagnosed in infants requiring only 22% to 29% oxygen if the oxygen requirement was confirmed by a standardised oxygen-reduction test, which was completed by neonatologists masked to treatment groups.			
	Secondary outcomes: bronchopulmonary dysplasia at 36 weeks' postmenstrual age; death; surgical lig- ation of patent ductus arteriosus; air leaks; pulmonary haemorrhage; insulin requirement; late-onset sepsis (positive blood culture or symptomatic pneumonia); necrotising enterocolitis, gastrointestinal perforation; grade 3 or 4 IVH; cystic PVL; death before discharge; severe retinopathy of prematurity (re- quiring laser treatment or surgery)			
	Longer term: Children were assessed at approximately 22 months' corrected age. Children underwent a French-based developmental assessment that was standardised in the mid-1990s, and a standardised neurodevelopmental assessment based on the Amiel-Tison and Denver scales. Neurodevelopmental impairment (NDI) was defined as any disability on the standardised neurodevelopmental assessment, cerebral palsy, blindness, deafness, or a formal developmental assessment score < -1 SD (< 85).			
Notes	Study was stopped early because of lack of funding, rather than because any predetermined threshold had been reached, at approximately 2/3 of projected sample size of 786.			



Baud 2016 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera-	Low risk	Randomly assigned (1:1) via a secure study website
tion (selection bias)		Strata for 24 to 25 weeks and 26 to 27 weeks
Allocation concealment (selection bias)	Low risk	Remote electronic allocation
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding maintained by identical placebo
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Outcome assessors blinded to knowledge of treatment group at both primary hospitalisation phase and 22-month follow-up phase
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low risk for short-term outcomes, as all but 2 randomised participants have short-term outcomes reported. However, moderate risk at follow-up phase because although 93% (379/406) of long-term survivors were assessed at 22 months' corrected age, only 75% (304/406) had full neurological and develop- mental assessment.
Selective reporting (re- porting bias)	Low risk	Primary and secondary outcomes reported

Biswas 2003

Methods	Multi-centre placebo-controlled randomised trial	
Participants	253 infants < 30 weeks'	gestation, within 9 hours of birth at entry; all mechanically ventilated
Interventions	Hydrocortisone 1 mg/kg/d as continuous infusion for 5 days, then 0.5 mg/kg/d for 2 days. Also given tri- iodothyronine 6 μg/kg/d for 5 days, halving to 3 μg/kg/d for 2 days Controls given equal volume infusion of 5% dextrose	
Outcomes	Primary outcome was death or ventilator dependence at 7 days, or death or oxygen dependence at 14 days. Secondary outcomes included duration of ventilation, oxygen dependence, and hospitalisation; oxygen dependency at 36 weeks; IVH, PVL, PDA, and NEC	
Notes	Hydrocortisone combined with T3 infusion	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Randomisation by Oxford Perinatal Trials Unit
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes



Biswas 2003 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Bonsante 2007

Methods	Two-centre randomised double-blind placebo-controlled trial
Participants	70 infants with birth weight < 1000 grams or < 28 weeks' gestation, ventilator-dependent after 7 days of age, and considered to be a candidate for corticosteroids Exclusions: major anomaly likely to affect long-term neurological outcome
Interventions	Active treatment – total dose of hydrocortisone 10.5 mg/kg over 10 days Placebo group - equal volume of 0.9% saline
Outcomes	Primary outcomes: survival free of disability at 2 years of age, mortality up to 2 years of age, and neuro- logical outcome after discharge Secondary outcomes: rate of BPD, death or BPD, failure to extubate, other complications during prima- ry hospital stay including GI perforation, severe IVH (grade 3 or 4) and cystic PVL, long-term neurosen- sory impairment (blindness, deafness, developmental delay assessed by MDI on Bayley Scales, cerebral palsy), and disabilities (severe - any of severe cerebral palsy (not likely to walk), blindness, or severe de- velopmental delay (MDI < 55), moderate-moderate cerebral palsy (not walking at 2 years but likely to do so), deafness, moderate developmental delay (MDI 55 to < 70), mild-mild cerebral palsy (walking at 2 years), or mild developmental delay (MDI 70 to < 85)

Notes

Risk of bias

_

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated randomisation centrally
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias)	Low risk	Outcome assessment blind: yes



Bonsante 2007 (Continued) All outcomes

Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up reporting: yes for outcomes during primary hospital stay - 98% of surviving infants traced to 2 years of age
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Efird 2005

Methods	Randomised double-blind placebo-controlled trial
Participants	34 infants of gestation > 23 weeks and < 29 weeks, and birth weight > 500 grams and < 1000 grams en- rolled by 2 hours of age Exclusions: major malformations, chromosomal abnormalities, congenital heart disease
Interventions	Hydrocortisone intravenously at dose of 1 mg/kg every 12 hours for 2 days, followed by 0.3 mg/kg every 12 hours for 3 days Control infants received an equivalent volume of normal saline as placebo
Outcomes	Blood pressure, urine output, hyperglycaemia, mortality, durations of mechanical ventilation and hos- pital stay, BPD (oxygen at 36 weeks), infection, NEC, intestinal perforation, PDA, IVH, PVL, cortisol levels
Notes	_

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation via sequentially numbered, preassigned treatment desig- nations in sealed, opaque envelopes
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported



Methods	Multi-centre placebo-controlled randomised trial		
Participants	241 infants weighing between 500 grams and 1500 grams, received surfactant, at significant risk for BPD or death using a model to predict at 24 hours		
Interventions	3-Day course of dexamethasone beginning at 24 to 48 hours. First 2 doses were 0.4 mg/kg, third and fourth doses 0.2 mg/kg, and fifth and sixth doses 0.1 mg/kg and 0.05 mg/kg, respectively. Dexamethasone dose reduced slightly after first interim analysis (see Notes) Similar volume of normal saline was given to control infants		
Outcomes	Primary outcomes were survival without BPD defined as oxygen therapy at 36 weeks to maintain SaO ₂ above 91% and mortality. Secondary outcomes included duration of ventilation and supplemental oxygen, respiratory support at 28 days of life, length of stay for survivors, use of subsequent dexamethasone therapy, and usual complications of prematurity.		
Notes	At first interim analysis (n = 75), increased risk of GI perforation was noted in the dexamethasone group Data Monitoring Committee recommended reducing the dexamethasone dose to 4 doses of 0.25 mg/ kg/dose every 12 hours begun at 24 to 48 hours, followed by doses of 0.125 mg/kg and 0.05 mg/kg at the next two 12-hour periods, respectively.		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Low risk	Randomisation by study pharmacists at each centre	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes	
Selective reporting (re-	Low risk	All prespecified outcomes reported	

Halac 1990

Methods	Placebo-controlled randomised trial
Participants	248 infants, birth weight ≤ 1500 grams, gestation < 34 weeks, with evidence of "birth asphyxia" (1- minute Apgar score < 5, prolonged resuscitation, and metabolic acidosis (HCO ₃ < 15 mmol/L within 1 hour of birth))



Halac 1990 (Continued)

Interventions	7-Day course of dexamethasone 1 mg/kg 12-hourly beginning on first day of life		
Outcomes	Neonatal mortality, mortality to discharge, NEC, PDA, sepsis, severe IVH		
Notes	Possible exclusion of 5 deaths after randomisation, but not clear which group they came from		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera-	Low risk	Random allocation via list of random numbers	

tion (selection bias)		
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	Primary prespecified outcome of NEC was reported, as were a large number of other outcomes.

Hochwald 2014

Methods	Placebo-controlled randomised trial		
Participants	22 infants, gestational age ≤ 30 weeks or birth weight ≤ 1250 grams, and < 48 hours after birth, with an arterial catheter in place, invasive mean blood pressure < gestational age on 3 consecutive measure- ments 10 minutes apart, and after treatment with 1 or 2 boluses of 10 mL of 0.9% saline. Excluded if blood loss, hydrops, or major cardiac lesions		
Interventions	Hydrocortisone 7 mg/kg total over 48 hours, or equal volume of 0.9% saline placebo		
Outcomes	Mortality (presumably to discharge), NEC, BPD, positive blood culture, insulin treatment		
Notes	Major outcome was to determine whether hydrocortisone reduced vasopressor doses		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Method of randomisation not stated	



Hochwald 2014 (Continued)

Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Placebo-controlled
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Short-term outcomes reported for all participants
Selective reporting (re- porting bias)	Unclear risk	Only short-term outcomes reported, but major outcome of effects on vaso- pressor doses not reported

Kopelman 1999

Methods	Two-centre randomised placebo-controlled trial
Participants	70 infants < 28 weeks' gestation requiring intermittent mandatory ventilation and arterial catheterisa- tion
Interventions	Dexamethasone 0.2 mg/kg within 2 hours of delivery Control infants given an equal volume of saline
Outcomes	Ventilation Index (VI), IMV rate, mean blood pressure, incidence of PDA, need for indomethacin, number extubated during first week, usual complications of RDS
Notes	After an interim analysis showed that the incidence of IVH was much lower than expected, enrolment was stopped and analysis was limited to a comparison of ventilator settings, blood pressure, and pres- sor use during first 7 days. Outcome of successful extubation was available at only 1 hospital, where 38 infants were enrolled.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in the hospital pharmacy stratified by use of antenatal cor- ticosteroids; exact method of randomisation not stated
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes



Kopelman 1999 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes	
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported, but others reported too	-

Lauterbach 2006

Lauter Datif 2000	
Methods	Three-armed randomised controlled trial: (1) nebulised pentoxifylline, (2) intravenous dexamethasone, (3) nebulised water placebo
Participants	150 infants < 1500 grams birth weight who needed oxygen on fourth day of life, regardless of the need for assisted ventilation. Major malformations and grade 3 or 4 IVH led to exclusions.
Interventions	Dexamethasone 0.25 mg/kg/dose every 12 hours for 3 days
Outcomes	Primary endpoint BPD (oxygen dependency at 36 weeks). Secondary endpoints included PDA, IVH and PVL,
Notes	All prespecified outcomes reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer-generated randomisation table
Allocation concealment (selection bias)	Unclear risk	Not clearly stated
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Unable to blind treatment groups for comparison of dexamethasone vs nebu- lised water placebo
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Unable to blind treatment groups for comparison of dexamethasone vs nebu- lised water placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	Short-term outcomes reported for all participants
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Lin 1999

Methods Placebo-controlled randomised trial	
Participants	40 infants of 500 grams to 1999 grams with severe RDS, needing IPPV within 6 hours of birth



Lin 1999 (Continued)	
Interventions	Dexamethasone 0.25 mg/kg 12-hourly from 1 to 7 days, 0.12 mg/kg 12-hourly from 8 to 14 days, 0.05 mg/kg 12-hourly from 15 to 21 days, 0.02 mg/kg 12-hourly from 22 to 28 days Saline placebo was given to controls.
Outcomes	Mortality at 28 days; discharge, failure to extubate (during study), death or BPD (36 weeks), BPD (28 days and 36 weeks), infection (clinical), severe IVH, plasma glucose, mean blood pressure on days 2, 5, 7, and 16; weight at 2 weeks
Notes	Sequential analysis for 12 pairs. Data given for 40 infants as randomised into the 2 groups

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in a paired sequential trial. Assignment determined by pharmacist and groups stratified by birth weight: 500 grams to 999 grams, 1000 grams to 1500 grams, and 1501 grams to 1999 grams. Allocation by draw- ing lots
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Mukhopadhyay 1998

Methods	Single-centre randomised controlled trial	
Participants	19 infants < 34 weeks and < 2000 grams who could be provided with ventilation. Clinical and radi- ographic evidence of RDS; IPPV with oxygen > 30%	
Interventions	Dexamethasone 0.5 mg/kg/dose 12-hourly for 3 days starting within 6 hours of birth Control group did not receive any drug	
Outcomes	Changes in oxygen requirements, mean duration of ventilation, culture-positive sepsis, PDA, BPD (not defined), pneumothorax, mortality	
Notes	Infants were entered into the trial only if a ventilator was available. Surfactant was not given.	
Risk of bias		



Mukhopadhyay 1998 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation: method not stated
Allocation concealment (selection bias)	Unclear risk	Allocation concealment: not sure
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding of intervention: no
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Blinding of outcome measurement: no
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Ng 2006

Methods	Double-blind randomised controlled trial	
Participants	48 infants of gestation < 32 weeks and birth weight < 1500 grams who had systemic hypotension de- spite treatment with volume expanders and dopamine within the first 7 days of life Infants also had to have an indwelling arterial catheter for continuous BP monitoring. Exclusions: major or lethal congenital or chromosomal abnormalities, congenital heart defects, previ- ous postnatal systemic or inhaled corticosteroids, proven infection, NEC	
Interventions	Hydrocortisone 1 mg/kg every 8 hours for 5 days Control infants received isotonic saline as placebo for 5 days.	
Outcomes	BP, use of vasopressors, duration of ventilation, oxygen and hospital stay, PIE, pulmonary haemor- rhage, pneumothorax, hyperglycaemia, glycosuria, IVH (grade III or IV), PVL, NEC, GI perforation, sepsis, ROP (> stage II), mortality	
Notes	_	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation in blocks of 6 by computer-generated random numbers and opening numbered, sealed, opaque envelopes
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias)	Low risk	Blinding of intervention: yes



Ng 2006 (Continued) All outcomes

Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes	
Selective reporting (re- porting bias)	Low risk	Primary outcome was blood pressure, which was reported.	

Peltoniemi 2005

Methods	Multi-centre double-bli	ind randomised controlled trial	
Participants	51 infants with birth weight 501 grams to 1250 grams, gestation 23 to 30 weeks, needing med ventilation before the age of 24 hours. The subgroup 1000 grams to 1250 grams had to need mental oxygen and mechanical ventilation > 24 hours despite surfactant.		
	Exclusions: lethal malfo	ormations, suspected chromosomal abnormalities	
Interventions	Hydrocortisone 2.0 mg/kg/d intravenously 8-hourly for 2 days, 1.5 mg/kg/d 8-hourly for 2 days, 0.75 mg/kg/d 12-hourly for 6 days Control infants received isotonic saline as placebo. First dose was given before 36 hours. Use of open- label corticosteroids was discouraged.		
Outcomes	Survival without BPD (oxygen at 36 weeks), IVH (grades III or IV), cystic PVL, durations of ventilation, oxygen and hospital stay, sepsis, hyperglycaemia, hypertension, PDA, GI bleeding, GI perforation, NEC, ROP, and cortisol levels		
	Long-term outcomes: At 2 years - neurosensory impairments (blindness, deafness, developmental de- lay assessed by MDI on Bayley Scales, cerebral palsy) and disabilities (severe - any of severe cerebral palsy (not likely to walk), blindness, or severe developmental delay (MDI < 55, moderate-moderate cerebral palsy (not walking at 2 years but likely to do so), deafness, moderate developmental delay (MDI 55 to < 70), mild-mild cerebral palsy (walking at 2 years), or mild developmental delay (MDI 70 to < 85). Follow-up rate was 87% (40/46).		
	At 6 years - IQ (Wechsler Preschool and Primary Scale of Intelligence - Revised) and language (Reynell Developmental Language Scale III) were assessed, as were diagnoses of cerebral palsy, blindness, and deafness. Follow-up rate was 80% (37 of the 46 survivors).		
Notes	_		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation at each centre via identical coded syringes. Exact method of randomisation not stated. Stratified by birth weight (501 grams to 750 grams vs 750 grams to 999 grams vs 1000 grams to 1250 grams)	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	

Peltoniemi 2005 (Continued)

Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes (for primary hospital outcomes). Follow-up rates at 2 and 6 years listed above
Selective reporting (re- porting bias)	Low risk	Primary outcome was reported as specified.

Rastogi 1996

Methods	Double-blind randomised controlled trial 70 preterm infants < 12 hours old, weighing 700 grams to 1500 grams with respiratory distress syn- drome (RDS) confirmed clinically and radiologically; infants needed mechanical ventilation > 30% O ₂ and/or MAP 7 cmH ₂ O a/A < 0.25 after surfactant treatment. Exclusions: major malformations, chromosome abnormalities, severe infection, Apgar < 3 at 5 minutes	
Participants		
Interventions	Intravenous dexamethasone 0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.15 mg/kg/d for 3 days, 0.05 mg/kg/d for 3 days 0.05 mg/kg/d for 3 days Control group given saline placebo	
Outcomes	FiO ₂ , MAP, BPD (28 days and CXR), severe BPD (36 weeks), duration O ₂ , infections, deaths, pneumotho- rax, pulmonary haemorrhage, PDA, IVH, NEC, hyperglycaemia, insulin use, hypertension, ROP	
Notes	_	

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation: via a pharmacy list; stratified for birth weight
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias)	Unclear risk	Complete follow-up: yes



Rastogi 1996 (Continued) All outcomes

Selective reporting (re-	Low risk	All prespecified outcomes reported
porting bias)		

Methods	Randomised non-blinded controlled trial			
Participants	50 infants < 1251 grams or < 33 weeks, oxygen-dependent at 72 hours, and at high risk of BPD accordir to a scoring system predicting 90% risk of BPD			
Interventions		Dexamethasone 0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, and 0.125 mg/kg/d for 1 day Control group: no mention of placebo		
Outcomes	Survival to 28 days, survival to discharge, PDA, IVH (grades 3 and 4), PVL, sepsis, NEC, ROP (stages III and above), requiring ventilation at 28 days, BPD at 28 days and 36 weeks, hyperglycaemia, hyperten sion, needed late corticosteroids, growth failure, left ventricular hypertrophy			
Notes	_			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	Random allocation via random numbers, concealed in numbered sealed envelopes		
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes		
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding of intervention: no		
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Blinding of outcome measurements: no		
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes		
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported		

Sanders 1994

54114C15 1554		
Methods	Randomised double-blind controlled trial	
Participants	40 infants < 30 weeks' gestation and 12 to 18 hours old with RDS, both clinical and radiological. Infants were treated with mechanical ventilation and surfactant	



Blinding of participants

and personnel (perfor-

Blinding of outcome as-

sessment (detection bias)

Incomplete outcome data

Selective reporting (re-

mance bias) All outcomes

All outcomes

(attrition bias) All outcomes

porting bias)

Shinwell 1996 Methods

Participants

Interventions

Outcomes

Risk of bias

Notes

Trusted evidence. Informed decisions. Better health.

Low risk

Low risk

Low risk

Low risk

alies

Sanders 1994 (Continued)	Exclusions: sepsis, con sion	genital heart disease, chromosome abnormalities, need for exchange transfu-	
Interventions	Dexamethasone 0.5 mg/kg twice, 12 hours apart Control group given saline placebo		
Outcomes	MAP, FiO ₂ , mortality, extubation < 7 days, pulmonary function tests, duration IPPV, O ₂ , hospital, mortal- ity, BPD (36 weeks O ₂), late corticosteroids		
Notes	_		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in the pharmacy via sealed envelopes. Method of randomi- sation not described	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	

Blinding of intervention: yes

Complete follow-up: yes

Blinding of outcome measurement: yes

Prespecified outcomes reported, but definitions vague

248 preterm infants with birth weight 500 grams to 2000 grams, 1 to 3 days old, requiring mechanical

Exclusions: active bleeding, hypertension, hyperglycaemia, active infection, lethal congenital anom-

Mortality, survival with no O₂, mechanical ventilation at 3 and 7 days, BPD, duration in hospital, IVH,

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Multi-centre double-blind randomised controlled trial

Intravenous dexamethasone 0.25 mg/kg every 12 hours 6 times

PVL, pneumothorax, PIE, PDA, sepsis, hypertension, hyperglycaemia

ventilation with more than 40% oxygen

Controls given saline placebo



Shinwell 1996 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation, stratified by centre and birth weight, from random num- bers list in the pharmacy
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes for short-term; 84% for long-term
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Sinkin 2000

Methods	Multi-centre randomised double-blind trial
Participants	384 infants < 30 weeks' gestation with RDS by clinical and radiographic signs, needing IPPV at 12 to 18 hours of age; had received at least 1 dose of surfactant
Interventions	Dexamethasone 0.5 mg/kg at 12 to 18 hours of age, second dose 12 hours later Control group given an equal volume of placebo
Outcomes	Primary outcomes were survival, survival without oxygen at 28 days or 36 weeks, and survival without oxygen at 28 days or 36 weeks and without late corticosteroids Length of time in oxygen, on ventilation, to regain birth weight, and in hospital. Hyperglycaemia, hy- pertension, IVH, PDA, sepsis, NEC, isolated GI perforation, ROP, air leak, discharged home on oxygen
Notes	_

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in the pharmacy via labelled syringes. Stratification by cen- tre. Exact method of randomisation not stated
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes



Sinkin 2000 (Continued)

Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Soll 1999

Methods	Multi-centre randomised double-blind trial		
Participants	542 infants weighing 501 grams to 1000 grams who required assisted ventilation < 12 hours, had re- ceived surfactant by 12 hours, were physiologically stable, and had no life-threatening congenital anomalies		
Interventions	Dexamethasone 0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.10 mg/kg/d for 3 days, and 0.05 mg, kg/d for 3 days. Control infants received a similar volume of normal saline. Infants in either group could receive late postnatal corticosteroids beginning on day 14 if they were on assisted ventilation with supplemental oxygen > 30%.		
Outcomes	Primary outcome was BPD or death at 36 weeks' adjusted age. Secondary outcome measures included clinical status at 14 days and 28 days, duration of assisted ven- tilation, supplemental oxygen and hospital stay, treatment with late postnatal corticosteroids, proven sepsis, hypertension and hyperglycaemia requiring therapy, weight at 36 weeks, usual complications of prematurity		
Notes	Published as an extended abstract and presented at a clinical meeting		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in hospital pharmacies by opening opaque, sealed en- velopes. Precise method of randomisation not stated	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes	



Low risk

Soll 1999 (Continued)

Selective reporting (reporting bias) All prespecified outcomes reported

Stark 2001

Methods	Multi-centre randomised double-blind trial		
Participants	220 infants with birth weight 501 grams to 1000 grams, mechanically ventilated < 12 hours. Infants > 750 grams also needed to receive surfactant and have FiO ₂ > 0.29.		
Interventions	Dexamethasone 0.15 mg/kg/d for 3 days, then tapered over 7 days Saline placebo		
Outcomes	Death or BPD, oxygen at 28 days, PIE, late corticosteroid treatment, hypertension, hyperglycaemia, GI perforation		
Notes	Factorial design; infants also randomised to routine ventilator management or a strategy of minimal ventilator support to reduce mechanical lung injury. After enrolling 220 infants (sample size estimate was 1200), the trial was halted owing to unanticipated adverse events.		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation via numbers generated by a random, permuted block algo- rithm, stratified by birth weight
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Subhedar 1997

Methods	Randomised controlled trial - factorial design
Participants	42 preterm infants, entry at 96 hours if gestation < 32 weeks, mechanical ventilation from birth, surfac- tant treatment, and high risk of developing BPD based on score (Ryan 1996)

Subhedar 1997 (Continued)	Exclusion criteria: major congenital anomaly, structural cardiac defect, significant ductus shunting, culture-positive sepsis, IVH with parenchymal involvement, pulmonary or GI haemorrhage, abnormal coagulation, thrombocytopenia (platelets < 50,000)
Interventions	Intravenous dexamethasone at 12-hourly intervals for 6 days; 0.5 mg/kg/dose for 6 doses and 0.25 mg/ kg/dose for a further 6 doses. Inhaled NO 5 to 20 ppm for 72 hours Control groups were not given placebo
Outcomes	Mortality, BPD at 28 days and > 36 weeks with abnormal chest radiograph Duration of ventilation, time to extubation, duration of hospitalisation, maximum grade of IVH, pul- monary haemorrhage, pneumothorax, severe PDA, NEC, ROP (stage 3 or 4) Complications including ileal perforation, upper GI haemorrhage, hyperglycaemia, hypertension, sep- ticaemia
Notes	Note factorial design, which means that half of treated infants and half of control infants also received 72 hours of inhaled NO

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation by computer-generated random numbers and sealed en- velopes. Factorial design provided 4 groups: early dexamethasone, inhaled NO, both drugs together, and neither drug.
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding of intervention: no
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Blinding of outcome measurements: no
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Unclear risk	All prespecified outcomes reported

Suske 1996

Methods	Randomised controlled trial		
Participants	26 preterm infants < 2 hours old, with birth weight < 1500 grams if FiO ₂ > 0.50, or > 1500 grams birth weight with FiO ₂ > 0.70		
	Exclusions: known sepsis, cardiac anomalies, malformations of lung or CNS		
Interventions	Intravenous dexamethasone 0.5 mg/kg/d for 5 days Controls were not given placebo.		

Suske 1996 (Continued)

Outcomes

Blood gases, ventilator settings, mortality IVH, BPD (O₂ 28 days), NEC, late sepsis, PDA, ROP, air leak, duration in hospital

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation via sealed envelopes. Randomisation achieved by drawing lots
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	High risk	Blinding of intervention: no
Blinding of outcome as- sessment (detection bias) All outcomes	High risk	Blinding of outcome measurement: no
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Tapia 1998

Methods	Multi-centre double-blind placebo-controlled randomised trial 113 (4 exclusions for congenital abnormality, early sepsis, and failure to obtain follow-up data) infants with birth weight between 700 and 1600 grams, clinical and radiological diagnosis of RDS, needing me- chanical ventilation, and < 36 hours of age Exclusion criteria: life-threatening congenital malformation or chromosome abnormality, strong suspi- cion of infection at birth (maternal chorioamnionitis) or early sepsis (positive blood culture in the first 36 hours of life)		
Participants			
Interventions	Intravenous dexamethasone 0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.12 mg/kg/d for 3 days, and 0.06 mg/kg/d for 3 days Placebo group received an equivalent volume of saline solution.		
Outcomes	Primary outcomes were death before hospital discharge, BPD (oxygen need at 28 days and x-ray changes), death or BPD, and oxygen need at 36 weeks. Other outcomes included time on ventilator, time in over 40% oxygen, and time in oxygen. Major morbidity and complications included pneumothorax, PIE, PDA, pulmonary haemorrhage, pneu monia, sepsis, NEC, ROP, hypertension, hyperglycaemia, and IVH (grades I to II and III to IV).		
Notes	_		

Risk of bias



Tapia 1998 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation via ampoules of dexamethasone and saline prepared in the hospital pharmacy. Exact method of randomisation not described
Allocation concealment (selection bias)	Low risk	Blinding of randomisation: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: almost (109/113)
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Vento 2004

Methods	Randomised controlled trial		
Participants	20 infants with birth weight < 1251 grams and gestation < 33 weeks who were oxygen- and ventila- tor-dependent on fourth day of life and were at high risk of BPD by study authors' own scoring system Exclusions: none stated		
Interventions	Intravenous dexamethasone 0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, and 0.125 mg/kg/d for 1 day (total dose 2.375 mg/kg) Control group received no corticosteroid treatment.		
Outcomes	Tracheal aspirates for cell counts, pulmonary mechanics, PDA, IVH (grades III and IV), extubation during study period		
Notes	_		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation but method not stated	
Allocation concealment (selection bias)	Unclear risk	Allocation concealment: uncertain	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk Blinding of intervention: uncertain		



Vento 2004 (Continued)

Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Blinding of outcome measurement: uncertain
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Wang 1996

Mang 1990			
Methods	Double-blind randomised controlled trial		
Participants 63 infants with birth weight from 1000 grams to 1999 grams, AGA, clinical and radi to 12, age after birth)			
Interventions Dexamethasone 0.25 mg/kg 12-hourly from 1 to 7 days, 0.125 mg/kg 12-hourly from 8 to mg/kg 12-hourly from 15 to 21 days. First dose administered at < 12 hours Controls received saline placebo.			
Outcomes Oxygen requirements; PCO ₂ ; MAP; SP-A and SP-D in tracheal aspirate; failure to extubate 7th day, 14th day, and 28th day; mortality before discharge; sepsis; BPD at 28 days			
Notes	_		

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in a double-blind fashion; method not stated
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported



_

Methods	Two-centre double-blind randomised controlled trial		
Participants	40 infants weighing between 500 grams and 999 grams who were AGA and needed mechanical ventila tion < 48 hours of age		
	Exclusion criteria: maternal diabetes, congenital sepsis, SGA		
Interventions	Hydrocortisone 1.0 mg/kg/d every 12 hours for 9 days, 0.5 mg/kg/d for 3 days Control infants were given an equal volume of normal saline.		
Outcomes	Primary outcome was survival without supplemental oxygen at 36 weeks' post conception. Secondary outcomes among survivors: BPD at 36 weeks, duration of mechanical ventilation, > 40% oxygen, > 25% oxygen, hospital stay, weight and head circumference at 36 weeks		

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Random allocation at each centre by constant block design with 4 participants per block to minimise bias over time. Separate randomisation tables were used for infants exposed to antenatal corticosteroids.
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurement: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Watterberg 2004	
Methods	Multi-centre double-blind randomised controlled trial
Participants	360 infants of 500 grams to 999 grams birth weight, needing mechanical ventilation, aged 12 to 48 hours Exclusions: major congenital anomaly, congenital sepsis, postnatal corticosteroids, triplet or high- er-order gestation
Interventions	Hydrocortisone 1 mg/kg/d 12-hourly for 12 days, then 0.5 mg/kg/d for 3 days Control group infants received an equal volume of normal saline placebo.
Outcomes	Survival without BPD (oxygen at 36 weeks), physiological BPD, death before 36 weeks, death before discharge, BPD in survivors, durations of mechanical ventilation and oxygen, hospital stay, weight and



Watterberg 2004 (Continued)

Trusted evidence. Informed decisions. Better health.

	OFC at 36 weeks, PDA, infection, NEC, GI perforation, major IVH (grade 3 or 4), cystic PVL, ROP, and open-label corticosteroid therapy Longer-term outcomes included neurosensory impairments (any of cerebral palsy, blindness, deaf- ness, or developmental or motor delay, as assessed by Bayley Scales (MDI or PDI, respectively)).			
Notes	Sample size estimate was 712, but the study was stopped early because of increased incidence of apparently spontaneous GI perforation in the hydrocortisone group.			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Low risk	Random allocation, stratified by centre and birth weight (500 grams to 749 grams vs 750 grams to 999 grams), via a permuted block scheme with blocks of 6 in each stratum. Randomisation lists in each pharmacy in a sealed envelope		
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes		
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes		

Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: yes
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported

Yeh 1990

Interventions Intravence 0.05 mg/l Control ir Outcomes MAP, FiO ₂	judgement Support for judgement		
Clinically had infections Interventions Intravence 0.05 mg/l Control in Outcomes MAP, FiO ₂ sepsis, PI			
Clinically had infections Interventions Intravence 0.05 mg/l Control in Outcomes MAP, FiO ₂			
clinically had infec Interventions Intravence 0.05 mg/l	₂ , pulmonary function tests, BP, glucose, mortality, BPD, duration O ₂ , hospital, weight loss, DA, IVH (> grade I), ROP		
clinically	ous dexamethasone 0.50 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.12 mg/kg/d for 3 days, kg/d for 3 days nfants were given saline placebo.		
	57 preterm infants weighing between 700 grams and 1999 grams, < 13 hours old, with severe RDS l clinically and radiologically. They needed mechanical ventilation < 4 hours and were excluded if th had infection.		
Methods Double-b	Double-blind randomised controlled trial		

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Yeh 1990 (Continued)

Random sequence genera- tion (selection bias)	Unclear risk	Random allocation in blocks of 10 via a pharmacy list. Exact method of ran- domisation not described	
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes	
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Blinding of outcome measurements: yes	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: almost	
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported	

Yeh 1997

Methods	Multi-centre double-blind randomised controlled trial	
Participants	262 infants of birth weight < 2000 grams with RDS and requiring mechanical ventilation after birth	
Interventions	Dexamethasone 0.25 mg/kg/dose every 12 hours intravenously on days 1 to 7; 0.12 mg/kg/dose every 12 hours intravenously from days 8 to 14; 0.05 mg/kg/dose every 12 hours intravenously from days 15 to 21; and 0.02 mg/kg/dose every 12 hours intravenously from days 22 to 28 Control infants were given saline placebo.	
Outcomes	BPD judged at 28 days or at 36 weeks Extubation during the study, mortality, bacteraemia or clinical sepsis, and side effects of hypergly- caemia, hypertension, cardiac hypertrophy, hyperparathyroidism, and growth failure	
Notes	_	

```
Risk of bias
```

Bias	Authors' judgement	Support for judgement		
Random sequence genera- tion (selection bias)	Unclear risk	Random allocation via central pharmacy random number list; exact method of randomisation not described		
Allocation concealment (selection bias)	Low risk	Allocation concealment: yes		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Blinding of intervention: yes		
Blinding of outcome as- sessment (detection bias)	Low risk	Blinding of outcome measurement: yes		



Trusted evidence. Informed decisions. Better health.

Yeh 1997 (Continued) All outcomes				
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow-up: almost for short-term; 81% for long-term		
Selective reporting (re- porting bias)	Low risk	All prespecified outcomes reported		
ACTH: adrenocorticotrophic he ABA: appropriate for gestation BP: blood pressure. BPD: bronchopulmonary dysp CLD: chronic lung disease. CNS: central nervous system. CXR: chest x-ray. FiO ₂ : fraction of inspired oxyge GI: gastrointestinal. HCO ₃ : bicarbonate. IMV: intermittent mandatory v IPPV: intermittent positive-pre IVH: intraventricular haemorrh MAP: mean airway pressure. MDI: Mental Developmental Im NDI: neurodevelopmental imp NEC: necrotising enterocolitis. NO: nitric oxide. NRN: Neonatal Research Netw O ₂ : oxygen. OFC: occipito-frontal circumfe PDA: patent ductus arteriosus. PDI: Psychomotor Developme PIE: pulmonary interstitial em ppm: parts per million. PVL: periventricular leukomala RDS: respiratory distress synde ROP: retinopathy of prematuri SaO ₂ : oxygen saturation. SGA: small for gestational age. SP-A: surfactant protein-A. SP-D: surfactant protein-D. T3: triiodothyronine. VI: Ventilation Index.	al age. lasia. en. entilation. essure ventilation. age. dex. airment. ork. rence. ntal Index. physema. acia. rome. ty.			

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Ariagno 1987	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Avery 1985	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Brozanski 1995	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)

Study	Reason for exclusion
CDTG 1991	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Cummings 1989	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Dobryansky 2012	20 VLBW infants were randomised to both hydrocortisone and caffeine as active treatments, com- pared with "standard guidelines", which presumably meant no hydrocortisone or caffeine. Major outcomes reported included BPD and BPD combined with death. As caffeine reduces BPD (Schmidt 2006), the independent effect of hydrocortisone cannot be determined.
Doyle 2006	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Durand 1995	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Gaissmaier 1999	Primary outcome was need for an epinephrine infusion 12 hours after treatment. No long-term out- comes reported
Gross 2005	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Harkavy 1989	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Kari 1993	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Kazzi 1990	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Kothadia 1999	Study of late postnatal corticosteroids included in the review "'Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Kovacs 1998	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Noble-Jamieson 1989	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Ohlsson 1992	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Papile 1998	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Parikh 2013	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Romagnoli 1997	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)
Salas 2014	Recruited term infants only for a study of early hydrocortisone to treat hypotension

Study	Reason for exclusion		
Scott 1997	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)		
Smolkin 2014	Before after study only - not an RCT		
Tsukahara 1999	Not an RCT; 26 study infants and 12 historical controls		
Vincer 1998	Study of late postnatal corticosteroids included in the review "'Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)		
Walther 2003	Study of late postnatal corticosteroids included in the review "Late (> 7 days) systemic postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants" (Doyle 2017)		
Yaseen 1999	Study of early dexamethasone, but no outcomes relevant to this review were reported		

BPD: bronchopulmonary dysplasia. RCT: randomised controlled trial. VLBW: very low birth weight.

DATA AND ANALYSES

Comparison 1. Mortality

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Neonatal mortality (up to 28 days)	19	2950	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.88, 1.19]
1.1 Dexamethasone	16	2603	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.90, 1.24]
1.2 Hydrocortisone	3	347	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.50, 1.23]
2 Mortality at 36 weeks	20	3733	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.89, 1.14]
2.1 Dexamethasone	14	2487	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.94, 1.25]
2.2 Hydrocortisone	6	1246	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.65, 1.06]
3 Mortality to hospital dis- charge	30	4273	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.85, 1.07]
3.1 Dexamethasone	19	2840	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.90, 1.18]
3.2 Hydrocortisone	11	1433	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.65, 0.98]
4 Mortality at latest report- ed age	31	4373	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.85, 1.06]
4.1 Dexamethasone	20	2940	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.90, 1.16]
4.2 Hydrocortisone	11	1433	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.65, 0.99]



Analysis 1.1. Comparison 1 Mortality, Outcome 1 Neonatal mortality (up to 28 days).

Study or subgroup	Steroid Control		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
1.1.1 Dexamethasone					
Garland 1999	12/118	20/123	+	7.21%	0.63[0.32,1.22]
Halac 1990	17/130	21/118	+	8.1%	0.73[0.41,1.32]
Kopelman 1999	8/37	3/33		1.17%	2.38[0.69,8.23]
Lin 1999	5/20	4/20		1.47%	1.25[0.39,3.99]
Rastogi 1996	4/36	2/34		0.76%	1.89[0.37,9.65]
Romagnoli 1999	0/25	0/25			Not estimable
Sanders 1994	2/19	3/21		1.05%	0.74[0.14,3.95]
Shinwell 1996	31/132	22/116	-++	8.62%	1.24[0.76,2.01]
Sinkin 2000	31/189	25/195	_ + •	9.06%	1.28[0.79,2.08]
Soll 1999	65/273	50/269	+ •-	18.53%	1.28[0.92,1.78]
Stark 2001	20/111	22/109		8.17%	0.89[0.52,1.54]
Subhedar 1997	9/21	8/21		2.94%	1.13[0.54,2.35]
Suske 1996	1/14	1/12		0.4%	0.86[0.06,12.28]
Wang 1996	3/34	6/29		2.38%	0.43[0.12,1.56]
Yeh 1990	3/28	8/29		2.89%	0.39[0.11,1.32]
Yeh 1997	44/132	39/130	-+	14.46%	1.11[0.78,1.59]
Subtotal (95% CI)	1319	1284	•	87.2%	1.06[0.9,1.24]
Total events: 255 (Steroid), 234 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =13.48	, df=14(P=0.49); l ² =0%				
Test for overall effect: Z=0.72(P=0.4	47)				
1.1.2 Hydrocortisone					
Baden 1972	6/22	7/22		2.58%	0.86[0.34,2.14]
Biswas 2003	19/125	19/128		6.91%	1.02[0.57,1.84]
Bonsante 2007	2/25	9/25		3.31%	0.22[0.05,0.93]
Subtotal (95% CI)	172	175	•	12.8%	0.78[0.5,1.23]
Total events: 27 (Steroid), 35 (Cont	trol)				
Heterogeneity: Tau ² =0; Chi ² =3.83,	df=2(P=0.15); I ² =47.77%				
Test for overall effect: Z=1.05(P=0.2	29)				
Total (95% CI)	1491	1459	•	100%	1.02[0.88,1.19]
Total events: 282 (Steroid), 269 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =18.3,	df=17(P=0.37); I ² =7.09%				
Test for overall effect: Z=0.32(P=0.	75)				
Test for subgroup differences: Chi ²	²=1.52, df=1 (P=0.22), I²≕	34.16%			

Analysis 1.2. Comparison 1 Mortality, Outcome 2 Mortality at 36 weeks.

Study or subgroup	Steroid	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	I, Fixed, 95%	5 CI			M-H, Fixed, 95% CI
1.2.1 Dexamethasone									
Anttila 2005	11/53	12/56			_			2.96%	0.97[0.47,2]
Garland 1999	19/118	25/123			-+-			6.21%	0.79[0.46,1.36]
Kopelman 1999	10/37	5/33			++-			1.34%	1.78[0.68,4.68]
		Favours steroid	0.01	0.1	1	10	100	Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Lauterbach 2006	12/50	12/50		3.04%	1[0.5,2.01]
Rastogi 1996	4/36	2/34		0.52%	1.89[0.37,9.65]
Romagnoli 1999	2/25	2/25	_	0.51%	1[0.15,6.55]
Sanders 1994	2/19	7/21		1.69%	0.32[0.07,1.34]
Shinwell 1996	31/132	22/116	_ +	5.94%	1.24[0.76,2.01]
Sinkin 2000	40/189	33/195	-+	8.24%	1.25[0.83,1.89]
Soll 1999	74/273	61/269	+-	15.59%	1.2[0.89,1.6]
Stark 2001	23/111	26/109	-+-	6.66%	0.87[0.53,1.42]
Subhedar 1997	9/21	8/21	— <u>+</u>	2.03%	1.13[0.54,2.35]
Tapia 1998	17/55	18/54	<u> </u>	4.61%	0.93[0.54,1.6]
Yeh 1997	44/132	39/130	+	9.97%	1.11[0.78,1.59]
Subtotal (95% CI)	1251	1236	•	69.3%	1.08[0.94,1.25]
Total events: 298 (Steroid), 272 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =8, df=13	(P=0.84); I ² =0%				
Test for overall effect: Z=1.07(P=0.28)	1				
1.2.2 Hydrocortisone					
Baud 2016	47/255	60/266	-+-	14.9%	0.82[0.58,1.15]
Biswas 2003	19/125	19/128	<u> </u>	4.76%	1.02[0.57,1.84]
Bonsante 2007	3/25	8/25		2.03%	0.38[0.11,1.25]
Hochwald 2014	0/11	4/11		1.14%	0.11[0.01,1.85]
Watterberg 1999	3/20	3/20	+	0.76%	1[0.23,4.37]
Watterberg 2004	27/180	28/180	_ _	7.1%	0.96[0.59,1.57]
Subtotal (95% CI)	616	630	•	30.7%	0.83[0.65,1.06]
Total events: 99 (Steroid), 122 (Contr	ol)				
Heterogeneity: Tau ² =0; Chi ² =4.56, df ²	=5(P=0.47); I ² =0%				
Test for overall effect: Z=1.5(P=0.13)					
Total (95% CI)	1867	1866	•	100%	1.01[0.89,1.14]
Total events: 397 (Steroid), 394 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =15.45, d	f=19(P=0.69); l ² =0%				
Test for overall effect: Z=0.08(P=0.94)	1				
Test for subgroup differences: Chi ² =3	37 df-1 (P-0.07) 12-	70 31%			

Analysis 1.3. Comparison 1 Mortality, Outcome 3 Mortality to hospital discharge.

Study or subgroup	bgroup Steroid Control Risk Ratio		Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl	
1.3.1 Dexamethasone						
Anttila 2005	11/53	12/56		2.44%	0.97[0.47,2]	
Garland 1999	19/118	25/123	+	5.12%	0.79[0.46,1.36]	
Halac 1990	22/130	24/118	+	5.27%	0.83[0.49,1.4]	
Kopelman 1999	10/37	5/33		1.11%	1.78[0.68,4.68]	
Lin 1999	5/20	4/20		0.84%	1.25[0.39,3.99]	
Mukhopadhyay 1998	6/10	6/9		1.32%	0.9[0.45,1.79]	
Rastogi 1996	4/36	2/34		0.43%	1.89[0.37,9.65]	
Romagnoli 1999	2/25	3/25		0.63%	0.67[0.12,3.65]	
Sanders 1994	2/19	7/21	· · · · · · · · · · · · · · · · · · ·	1.39%	0.32[0.07,1.34]	
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control		



Study or subgroup	Steroid Control		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Shinwell 1996	31/132	22/116		4.9%	1.24[0.76,2.01]
Sinkin 2000	40/189	33/195	- + •	6.8%	1.25[0.83,1.89]
Soll 1999	76/273	62/269	++	13.07%	1.21[0.9,1.61]
Stark 2001	23/111	28/109	+	5.91%	0.81[0.5,1.31]
Subhedar 1997	9/21	8/21		1.67%	1.13[0.54,2.35]
Suske 1996	1/14	1/12	+	0.23%	0.86[0.06,12.28]
Tapia 1998	17/55	18/54	+	3.8%	0.93[0.54,1.6]
Wang 1996	7/34	6/29		1.36%	1[0.38,2.63]
Yeh 1990	3/28	8/29		1.65%	0.39[0.11,1.32]
Yeh 1997	46/132	42/130		8.86%	1.08[0.77,1.52]
Subtotal (95% CI)	1437	1403	•	66.8%	1.03[0.9,1.18]
Total events: 334 (Steroid), 316 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =12.7, d	f=18(P=0.81); I ² =0%				
Test for overall effect: Z=0.47(P=0.64	4)				
1.3.2 Hydrocortisone					
Baden 1972	7/22	8/22		1.67%	0.88[0.38,2]
Batton 2012	0/4	2/6	•	0.44%	0.28[0.02,4.66]
Baud 2016	48/255	67/266	-+	13.73%	0.75[0.54,1.04]
Biswas 2003	23/125	25/128		5.17%	0.94[0.57,1.57]
Bonsante 2007	4/25	10/25		2.09%	0.4[0.14,1.11]
Efird 2005	2/16	3/18		0.59%	0.75[0.14,3.94]
Hochwald 2014	0/11	4/11	•	0.94%	0.11[0.01,1.85]
Ng 2006	4/24	3/24		0.63%	1.33[0.33,5.33]
Peltoniemi 2005	2/25	3/26	• · · · · · · · · · · · · · · · · · · ·	0.62%	0.69[0.13,3.81]
Watterberg 1999	3/20	3/20	_	0.63%	1[0.23,4.37]
Watterberg 2004	31/180	32/180	_ -	6.7%	0.97[0.62,1.52]
Subtotal (95% CI)	707	726	•	33.2%	0.8[0.65,0.98]
Total events: 124 (Steroid), 160 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =6.17, d	f=10(P=0.8); I ² =0%				
Test for overall effect: Z=2.12(P=0.03	3)				
Total (95% CI)	2144	2129	•	100%	0.95[0.85,1.07]
Total events: 458 (Steroid), 476 (Cor					
Heterogeneity: Tau ² =0; Chi ² =22.59,					
Test for overall effect: Z=0.81(P=0.42					
Test for subgroup differences: Chi ² =	-	75 80%			

Analysis 1.4. Comparison 1 Mortality, Outcome 4 Mortality at latest reported age.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
1.4.1 Dexamethasone					
Anttila 2005	11/53	12/56	_	2.3%	0.97[0.47,2]
Garland 1999	19/118	25/123	+	4.82%	0.79[0.46,1.36]
Halac 1990	22/130	24/118	+	4.95%	0.83[0.49,1.4]
Kopelman 1999	10/37	5/33		1.04%	1.78[0.68,4.68]
Lauterbach 2006	12/50	12/50		2.36%	1[0.5,2.01]
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Lin 1999	5/20	4/20		0.79%	1.25[0.39,3.99]
Mukhopadhyay 1998	6/10	6/9	_	1.24%	0.9[0.45,1.79]
Rastogi 1996	4/36	2/34		0.4%	1.89[0.37,9.65]
Romagnoli 1999	2/25	3/25		0.59%	0.67[0.12,3.65]
Sanders 1994	2/19	7/21		1.31%	0.32[0.07,1.34]
Shinwell 1996	32/132	26/116	+	5.45%	1.08[0.69,1.7]
Sinkin 2000	40/189	33/195	_ + •	6.39%	1.25[0.83,1.89]
Soll 1999	76/273	62/269		12.29%	1.21[0.9,1.61]
Stark 2001	26/111	30/109		5.96%	0.85[0.54,1.34]
Subhedar 1997	11/21	9/21	+ +	1.77%	1.22[0.64,2.32]
Suske 1996	1/14	1/12		0.21%	0.86[0.06,12.28]
Tapia 1998	17/55	18/54		3.58%	0.93[0.54,1.6]
Wang 1996	7/34	6/29		1.27%	1[0.38,2.63]
Yeh 1990	3/28	8/29	i	1.55%	0.39[0.11,1.32]
Yeh 1997	53/132	50/130	_ _	9.92%	1.04[0.77,1.41]
Subtotal (95% CI)	1487	1453	•	68.19%	1.02[0.9,1.16]
Total events: 359 (Steroid), 343 (- / -
Heterogeneity: Tau ² =0; Chi ² =12.0					
Test for overall effect: Z=0.35(P=					
1.4.2 Hydrocortisone					
Baden 1972	8/22	9/22		1.77%	0.89[0.42,1.88]
Batton 2012	0/4	2/6		0.41%	0.28[0.02,4.66]
Baud 2016				0.4170	0.20[0.02,4.00]
		67/266		12 0106	0 75[0 54 1 04]
Biswas 2003	48/255	67/266		12.91%	0.75[0.54,1.04]
Biswas 2003	23/125	26/128		5.06%	0.91[0.55,1.5]
Bonsante 2007	23/125 4/25	26/128 10/25		5.06% 1.97%	0.91[0.55,1.5] 0.4[0.14,1.11]
Bonsante 2007 Efird 2005	23/125 4/25 2/16	26/128 10/25 3/18		5.06% 1.97% 0.56%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94]
Bonsante 2007 Efird 2005 Hochwald 2014	23/125 4/25 2/16 0/11	26/128 10/25 3/18 4/11		5.06% 1.97% 0.56% 0.89%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006	23/125 4/25 2/16 0/11 4/24	26/128 10/25 3/18 4/11 3/24		5.06% 1.97% 0.56% 0.89% 0.59%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005	23/125 4/25 2/16 0/11 4/24 2/25	26/128 10/25 3/18 4/11 3/24 3/26		5.06% 1.97% 0.56% 0.89% 0.59% 0.58%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999	23/125 4/25 2/16 0/11 4/24 2/25 3/20	26/128 10/25 3/18 4/11 3/24 3/26 3/20		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49%	$\begin{array}{c} 0.91[0.55,1.5]\\ 0.4[0.14,1.11]\\ 0.75[0.14,3.94]\\ 0.11[0.01,1.85]\\ 1.33[0.33,5.33]\\ 0.69[0.13,3.81]\\ 1[0.23,4.37]\\ 1[0.65,1.55]\end{array}$
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI)	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707	26/128 10/25 3/18 4/11 3/24 3/26 3/20		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (r	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control)	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49%	$\begin{array}{c} 0.91[0.55,1.5]\\ 0.4[0.14,1.11]\\ 0.75[0.14,3.94]\\ 0.11[0.01,1.85]\\ 1.33[0.33,5.33]\\ 0.69[0.13,3.81]\\ 1[0.23,4.37]\\ 1[0.65,1.55]\end{array}$
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (Heterogeneity: Tau ² =0; Chi ² =6.33	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); l ² =0%	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37] 1[0.65,1.55]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); l ² =0%	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37] 1[0.65,1.55]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (Heterogeneity: Tau ² =0; Chi ² =6.33	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); l ² =0%	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49%	$\begin{array}{c} 0.91[0.55,1.5]\\ 0.4[0.14,1.11]\\ 0.75[0.14,3.94]\\ 0.11[0.01,1.85]\\ 1.33[0.33,5.33]\\ 0.69[0.13,3.81]\\ 1[0.23,4.37]\\ 1[0.65,1.55]\end{array}$
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (Heterogeneity: Tau ² =0; Chi ² =6.33 Test for overall effect: Z=2.1(P=0.33)	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); I ² =0% .04) 2194	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180 726		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49% 31.81%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37] 1[0.65,1.55] 0.8[0.65,0.99]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (Heterogeneity: Tau ² =0; Chi ² =6.33 Test for overall effect: Z=2.1(P=0.33)	23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); I ² =0% .04) 2194 Control)	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180 726		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49% 31.81%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37] 1[0.65,1.55] 0.8[0.65,0.99]
Bonsante 2007 Efird 2005 Hochwald 2014 Ng 2006 Peltoniemi 2005 Watterberg 1999 Watterberg 2004 Subtotal (95% CI) Total events: 127 (Steroid), 163 (Heterogeneity: Tau ² =0; Chi ² =6.33 Test for overall effect: Z=2.1(P=0.23) Total (95% CI) Total events: 486 (Steroid), 506 (23/125 4/25 2/16 0/11 4/24 2/25 3/20 33/180 707 Control) 3, df=10(P=0.79); l ² =0% .04) 2194 Control) 9, df=30(P=0.86); l ² =0%	26/128 10/25 3/18 4/11 3/24 3/26 3/20 33/180 726		5.06% 1.97% 0.56% 0.89% 0.59% 0.58% 0.59% 6.49% 31.81%	0.91[0.55,1.5] 0.4[0.14,1.11] 0.75[0.14,3.94] 0.11[0.01,1.85] 1.33[0.33,5.33] 0.69[0.13,3.81] 1[0.23,4.37] 1[0.65,1.55] 0.8[0.65,0.99]

Comparison 2. Bronchopulmonary dysplasia (BPD)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 BPD (28 days of life)	17	2874	Risk Ratio (M-H, Fixed, 95% Cl)	0.87 [0.81, 0.93]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1.1 Dexamethasone	16	2621	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.79, 0.92]
1.2 Hydrocortisone	1	253	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.85, 1.18]
2 BPD (36 weeks' postmen- strual age)	24	3929	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.72, 0.87]
2.1 Dexamethasone	16	2584	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.62, 0.81]
2.2 Hydrocortisone	8	1345	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.80, 1.05]
3 BPD at 36 weeks' post- menstrual age in survivors	21	2970	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.74, 0.88]
3.1 Dexamethasone	14	1917	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.64, 0.83]
3.2 Hydrocortisone	7	1053	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.80, 1.03]
4 Late rescue with corticos- teroids	14	2483	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.68, 0.82]
4.1 Dexamethasone	10	1974	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.65, 0.80]
4.2 Hydrocortisone	4	509	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.73, 1.40]
5 Survivors who had late rescue with corticosteroids	7	895	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.67, 0.89]
5.1 Dexamethasone	6	853	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.68, 0.91]
5.2 Hydrocortisone	1	42	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.24, 0.98]
6 Survivors discharged home on oxygen	6	691	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.51, 1.03]
6.1 Dexamethasone	3	406	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.48, 1.26]
6.2 Hydrocortisone	3	285	Risk Ratio (M-H, Fixed, 95% CI)	0.66 [0.40, 1.11]

Analysis 2.1. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 1 BPD (28 days of life).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
2.1.1 Dexamethasone					
Garland 1999	73/118	76/123	+	10.36%	1[0.82,1.22]
Halac 1990	15/130	10/118	— — • —	1.46%	1.36[0.64,2.91]
Lin 1999	4/20	11/20		1.53%	0.36[0.14,0.95]
Mukhopadhyay 1998	0/10	0/9			Not estimable
Rastogi 1996	5/36	21/34	—— — —	3.01%	0.22[0.1,0.53]
Romagnoli 1999	11/25	24/25		3.34%	0.46[0.29,0.72]
		Favours steroid	0.05 0.2 1 5 20	Favours control	



Trusted evidence. Informed decisions. Better health.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Shinwell 1996	29/132	23/116	-+	3.41%	1.11[0.68,1.8]
Sinkin 2000	93/189	103/195	+	14.11%	0.93[0.77,1.13]
Soll 1999	181/273	186/269	+	26.07%	0.96[0.85,1.08]
Stark 2001	71/111	82/109	+	11.51%	0.85[0.71,1.01]
Subhedar 1997	11/21	13/21	+	1.81%	0.85[0.5,1.43]
Suske 1996	1/14	3/12		0.45%	0.29[0.03,2.4]
Tapia 1998	11/55	16/54	— • • •	2.25%	0.68[0.35,1.32]
Wang 1996	5/34	9/29		1.35%	0.47[0.18,1.26]
Yeh 1990	8/28	12/29		1.64%	0.69[0.33,1.43]
Yeh 1997	21/132	40/130	_ +	5.61%	0.52[0.32,0.83]
Subtotal (95% CI)	1328	1293	•	87.9%	0.85[0.79,0.92]
Total events: 539 (Steroid), 629 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =37.22, df=	=14(P=0); I ² =62.39%				
Test for overall effect: Z=4.11(P<0.0001	1)				
2.1.2 Hydrocortisone					
Biswas 2003	86/125	88/128	+	12.1%	1[0.85,1.18]
Subtotal (95% CI)	125	128	•	12.1%	1[0.85,1.18]
Total events: 86 (Steroid), 88 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.01(P=0.99)					
Total (95% CI)	1453	1421	•	100%	0.87[0.81,0.93]
Total events: 625 (Steroid), 717 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =39.12, df=	=15(P=0); I ² =61.65%				
Test for overall effect: Z=3.91(P<0.000)	1)				
Test for subgroup differences: Chi ² =3.0	06, df=1 (P=0.08), I ² =	67.36%			
		Favours steroid	0.05 0.2 1 5 2	20 Favours control	

Analysis 2.2. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 2 BPD (36 weeks' postmenstrual age).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
2.2.1 Dexamethasone					
Anttila 2005	11/53	15/56	+ <u> </u>	2.31%	0.77[0.39,1.53]
Garland 1999	16/118	27/123	+ <u>+</u>	4.19%	0.62[0.35,1.09]
Kopelman 1999	6/37	5/33		0.84%	1.07[0.36,3.18]
Lauterbach 2006	16/50	21/50	+	3.32%	0.76[0.45,1.28]
Lin 1999	3/20	9/20		1.42%	0.33[0.11,1.05]
Rastogi 1996	0/36	6/34	←	1.06%	0.07[0,1.24]
Romagnoli 1999	3/25	17/25		2.69%	0.18[0.06,0.53]
Sanders 1994	4/19	5/21		0.75%	0.88[0.28,2.82]
Shinwell 1996	15/132	11/116		1.85%	1.2[0.57,2.5]
Sinkin 2000	38/189	48/195	-+-	7.48%	0.82[0.56,1.19]
Soll 1999	62/273	84/269	_ + _	13.4%	0.73[0.55,0.96]
Stark 2001	47/111	49/109	_ _	7.83%	0.94[0.7,1.27]
Subhedar 1997	11/21	13/21		2.06%	0.85[0.5,1.43]
Tapia 1998	3/55	12/54	← → → →	1.92%	0.25[0.07,0.82]
Yeh 1990	8/28	12/29	· · · · · · · · · · · · · · · · · · ·	1.87%	0.69[0.33,1.43]
		Favours steroid	0.1 0.2 0.5 1 2 5 1	⁰ Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Yeh 1997	20/132	37/130	-+	5.9%	0.53[0.33,0.87]
Subtotal (95% CI)	1299	1285	•	58.89%	0.71[0.62,0.81]
Total events: 263 (Steroid), 371 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =22.14, d	lf=15(P=0.1); l ² =32.269	%			
Test for overall effect: Z=5.06(P<0.00	01)				
2.2.2 Hydrocortisone					
Baud 2016	55/255	70/266	-+-	10.85%	0.82[0.6,1.12]
Biswas 2003	59/125	56/128	-+	8.76%	1.08[0.82,1.41]
Bonsante 2007	6/25	8/25		1.27%	0.75[0.3,1.85]
Hochwald 2014	4/11	7/11		1.11%	0.57[0.23,1.41]
Ng 2006	9/24	8/24		1.27%	1.13[0.52,2.42]
Peltoniemi 2005	7/25	11/26		1.71%	0.66[0.31,1.43]
Watterberg 1999	5/20	10/20		1.58%	0.5[0.21,1.2]
Watterberg 2004	90/180	92/180	+	14.57%	0.98[0.8,1.2]
Subtotal (95% CI)	665	680	•	41.11%	0.91[0.8,1.05]
Total events: 235 (Steroid), 262 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =6.37, df	=7(P=0.5); l ² =0%				
Test for overall effect: Z=1.31(P=0.19)				
Total (95% CI)	1964	1965	•	100%	0.79[0.72,0.87]
Total events: 498 (Steroid), 633 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =34.26, d	lf=23(P=0.06); l ² =32.87	7%			
Test for overall effect: Z=4.78(P<0.00	01)				
Test for subgroup differences: Chi ² =6	5.88, df=1 (P=0.01), I ² =	85.47%			
		Favours steroid 0.1	0.2 0.5 1 2 5	¹⁰ Favours control	

Analysis 2.3. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 3 BPD at 36 weeks' postmenstrual age in survivors.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
2.3.1 Dexamethasone					
Anttila 2005	11/42	15/44		2.45%	0.77[0.4,1.48]
Garland 1999	16/99	27/98		4.54%	0.59[0.34,1.02]
Kopelman 1999	6/27	5/28		0.82%	1.24[0.43,3.6]
Lauterbach 2006	16/38	21/38		3.51%	0.76[0.48,1.22]
Rastogi 1996	0/32	6/32	◀─────	1.09%	0.08[0,1.31]
Romagnoli 1999	3/23	17/23	◀──── │	2.84%	0.18[0.06,0.52]
Sanders 1994	4/17	5/14		0.92%	0.66[0.22,2]
Shinwell 1996	15/101	11/94		1.91%	1.27[0.61,2.62]
Sinkin 2000	38/149	47/162	+	7.53%	0.88[0.61,1.27]
Soll 1999	62/199	84/208	-+	13.74%	0.77[0.59,1]
Stark 2001	47/88	49/83	+ _	8.44%	0.9[0.69,1.18]
Subhedar 1997	11/12	13/13	+ <u>+</u> _	2.17%	0.92[0.74,1.14]
Tapia 1998	3/38	12/36	↓	2.06%	0.24[0.07,0.77]
Yeh 1997	20/88	37/91	İ	6.09%	0.56[0.35,0.88]
Subtotal (95% CI)	953	964	◆	58.11%	0.73[0.64,0.83]
Total events: 252 (Steroid), 349 (Control)					
		Favours steroid	0.2 0.5 1 2	⁵ Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Heterogeneity: Tau ² =0; Chi ² =25.29), df=13(P=0.02); l ² =48.59	9%			
Test for overall effect: Z=4.7(P<0.0	001)				
2.3.2 Hydrocortisone					
Baud 2016	55/208	70/206	-+	11.77%	0.78[0.58,1.05]
Biswas 2003	59/106	56/109	-+	9.24%	1.08[0.84,1.39]
Bonsante 2007	6/22	8/17 -		1.51%	0.58[0.25,1.35]
Efird 2005	9/13	8/15		1.24%	1.3[0.72,2.36]
Hochwald 2014	4/11	5/7		1.02%	0.51[0.2,1.27]
Watterberg 1999	5/17	10/17 —		1.67%	0.5[0.22,1.15]
Watterberg 2004	90/153	92/152	-	15.44%	0.97[0.81,1.17]
Subtotal (95% CI)	530	523	•	41.89%	0.91[0.8,1.03]
Total events: 228 (Steroid), 249 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =9.46,	df=6(P=0.15); I ² =36.55%				
Test for overall effect: Z=1.48(P=0.	14)				
Total (95% CI)	1483	1487	•	100%	0.81[0.74,0.88]
Total events: 480 (Steroid), 598 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =37.44	l, df=20(P=0.01); l ² =46.58	3%			
Test for overall effect: Z=4.61(P<0.	0001)				
Test for subgroup differences: Chi ⁴	² =5.28, df=1 (P=0.02), I ² =	81.05%			
rest for subgroup differences: Chi	-5.26, ui-1 (P=0.02), I ⁻ =	Favours steroid ^{0.2}	0.5 1 2	⁵ Favours control	

Analysis 2.4. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 4 Late rescue with corticosteroids.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
2.4.1 Dexamethasone					
Anttila 2005	35/53	41/56	-+-	7.32%	0.9[0.7,1.16]
Garland 1999	68/118	81/123	-+-	14.56%	0.88[0.72,1.07]
Kopelman 1999	16/37	17/33		3.3%	0.84[0.51,1.38]
Rastogi 1996	4/36	15/34		2.83%	0.25[0.09,0.68]
Romagnoli 1999	3/25	13/25		2.39%	0.23[0.07,0.71]
Sanders 1994	3/19	3/21	+	0.52%	1.11[0.25,4.83]
Shinwell 1996	24/132	30/116	+ _	5.86%	0.7[0.44,1.13]
Sinkin 2000	48/189	69/195	+	12.47%	0.72[0.53,0.98]
Soll 1999	114/273	164/269	-	30.33%	0.68[0.58,0.81]
Stark 2001	38/111	56/109		10.37%	0.67[0.49,0.91]
Subtotal (95% CI)	993	981	♦	89.95%	0.72[0.65,0.8]
Total events: 353 (Steroid), 489 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =16.24	1, df=9(P=0.06); I ² =44.58 ⁰	%			
Test for overall effect: Z=6.44(P<0.	0001)				
2.4.2 Hydrocortisone					
Bonsante 2007	7/25	12/25		2.2%	0.58[0.28,1.23]
Ng 2006	6/24	7/24		1.28%	0.86[0.34,2.18]
Peltoniemi 2005	7/25	12/26	_	2.16%	0.61[0.29,1.29]
Watterberg 2004	35/180	24/180		4.41%	1.46[0.91,2.35]
Subtotal (95% CI)	254	255	•	10.05%	1.01[0.73,1.4]
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control	



Study or subgroup	Steroid	Control		Ri	sk Ra	itio			Weight	Risk Ratio
	n/N	n/N		M-H, F	ixed,	95% CI				M-H, Fixed, 95% Cl
Total events: 55 (Steroid), 55 (C	ontrol)									
Heterogeneity: Tau ² =0; Chi ² =6.2	21, df=3(P=0.1); l ² =51.7%									
Test for overall effect: Z=0.04(P	=0.97)									
Total (95% CI)	1247	1236			•				100%	0.75[0.68,0.82]
Total events: 408 (Steroid), 544	(Control)									
Heterogeneity: Tau ² =0; Chi ² =23	.76, df=13(P=0.03); l ² =45.2	9%								
Test for overall effect: Z=5.91(P	<0.0001)									
Test for subgroup differences: 0	Chi ² =3.72, df=1 (P=0.05), I ²	=73.11%								
		Favours steroid	0.1 0.2	0.5	1	2	5	10	Favours control	

Analysis 2.5. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 5 Survivors who had late rescue with corticosteroids.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
2.5.1 Dexamethasone					
Rastogi 1996	4/32	15/32		6.83%	0.27[0.1,0.72]
Shinwell 1996	24/101	30/94	-+	14.14%	0.74[0.47,1.18]
Sinkin 2000	47/149	64/162		27.91%	0.8[0.59,1.08]
Garland 1999	68/99	81/98	-	37.05%	0.83[0.71,0.98]
Kopelman 1999	16/27	17/28	_ _	7.6%	0.98[0.63,1.5]
Sanders 1994	3/17	1/14		- 0.5%	2.47[0.29,21.21]
Subtotal (95% CI)	425	428	◆	94.02%	0.79[0.68,0.91]
Total events: 162 (Steroid), 208 (Control	l)				
Heterogeneity: Tau ² =0; Chi ² =7.14, df=5(P=0.21); I ² =29.94%				
Test for overall effect: Z=3.26(P=0)					
2.5.2 Hydrocortisone					
Bonsante 2007	7/23	12/19		5.98%	0.48[0.24,0.98]
Subtotal (95% CI)	23	19		5.98%	0.48[0.24,0.98]
Total events: 7 (Steroid), 12 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.02(P=0.04)					
Total (95% CI)	448	447	•	100%	0.77[0.67,0.89]
Total events: 169 (Steroid), 220 (Control	l)				
Heterogeneity: Tau ² =0; Chi ² =9.35, df=6(P=0.15); I ² =35.84%				
Test for overall effect: Z=3.65(P=0)					
Test for subgroup differences: Chi ² =1.78	3, df=1 (P=0.18), l ² =4	13.94%			
		Favours steroid	0.05 0.2 1 5	²⁰ Favours control	

Analysis 2.6. Comparison 2 Bronchopulmonary dysplasia (BPD), Outcome 6 Survivors discharged home on oxygen.

Study or subgroup	Steroid n/N	Control n/N	Risk Ratio M-H, Fixed, 95% Cl			Weight	Risk Ratio M-H, Fixed, 95% Cl		
2.6.1 Dexamethasone				1					
		Favours steroid	0.01	0.1	1	10	100	Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Rastogi 1996	0/32	1/32		2.42%	0.33[0.01,7.89]
Sanders 1994	2/17	1/14		- 1.77%	1.65[0.17,16.33]
Sinkin 2000	22/149	31/162	-	47.96%	0.77[0.47,1.27]
Subtotal (95% CI)	198	208	•	52.16%	0.78[0.48,1.26]
Total events: 24 (Steroid), 33 (Control)					
Heterogeneity: Tau ² =0; Chi ² =0.69, df=2	(P=0.71); I ² =0%				
Test for overall effect: Z=1.01(P=0.31)					
2.6.2 Hydrocortisone					
Biswas 2003	15/106	19/109		30.25%	0.81[0.44,1.51]
Bonsante 2007	0/21	2/15	+	4.67%	0.15[0.01,2.83]
Watterberg 1999	4/17	8/17	-+	12.92%	0.5[0.18,1.35]
Subtotal (95% CI)	144	141	•	47.84%	0.66[0.4,1.11]
Total events: 19 (Steroid), 29 (Control)					
Heterogeneity: Tau ² =0; Chi ² =1.72, df=2	(P=0.42); I ² =0%				
Test for overall effect: Z=1.58(P=0.12)					
Total (95% CI)	342	349	•	100%	0.72[0.51,1.03]
Total events: 43 (Steroid), 62 (Control)					
Heterogeneity: Tau ² =0; Chi ² =2.57, df=5	(P=0.77); I ² =0%				
Test for overall effect: Z=1.81(P=0.07)					
Test for subgroup differences: Chi ² =0.2	1, df=1 (P=0.65), I ² =	:0%			
		Favours steroid	0.01 0.1 1 10	¹⁰⁰ Favours control	

Comparison 3. Death or bronchopulmonary dysplasia (BPD)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Death or BPD at 28 days of life	15	2546	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.88, 0.96]
1.1 Dexamethasone	14	2293	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.86, 0.96]
1.2 Hydrocortisone	1	253	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.90, 1.12]
2 Death or BPD at 36 weeks' postmenstrual age	25	3960	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.83, 0.93]
2.1 Dexamethasone	16	2581	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.80, 0.94]
2.2 Hydrocortisone	9	1379	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.82, 0.99]

Analysis 3.1. Comparison 3 Death or bronchopulmonary dysplasia (BPD), Outcome 1 Death or BPD at 28 days of life.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
3.1.1 Dexamethasone					
Garland 1999	85/118	96/123	-+	10.11%	0.92[0.8,1.07]
Kopelman 1999	0/1	0/1			Not estimable
Lin 1999	9/20	15/20		1.61%	0.6[0.35,1.04]
Rastogi 1996	9/36	23/34		2.55%	0.37[0.2,0.68]
Romagnoli 1999	11/25	24/25	+	2.58%	0.46[0.29,0.72]
Shinwell 1996	60/132	45/116	++	5.15%	1.17[0.87,1.57]
Sinkin 2000	115/189	120/195	+	12.71%	0.99[0.84,1.16]
Soll 1999	246/273	236/269	+	25.58%	1.03[0.97,1.09]
Stark 2001	91/111	104/109	+	11.29%	0.86[0.78,0.95]
Subhedar 1997	20/21	21/21	+	2.31%	0.95[0.84,1.09]
Suske 1996	2/14	4/12		0.46%	0.43[0.09,1.94]
Tapia 1998	28/55	34/54	_+ +	3.69%	0.81[0.58,1.13]
Yeh 1990	11/28	19/29	+	2.01%	0.6[0.35,1.02]
Yeh 1997	65/132	79/130	-+-	8.56%	0.81[0.65,1.01]
Subtotal (95% CI)	1155	1138	•	88.62%	0.91[0.86,0.96]
Total events: 752 (Steroid), 820 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =46.31,	df=12(P<0.0001); I ² =74	.09%			
Test for overall effect: Z=3.61(P=0)					
3.1.2 Hydrocortisone					
Biswas 2003	105/125	107/128	+	11.38%	1[0.9,1.12]
Subtotal (95% CI)	125	128	•	11.38%	1[0.9,1.12]
Total events: 105 (Steroid), 107 (Co	ntrol)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.09(P=0.9	93)				
Total (95% CI)	1280	1266	•	100%	0.92[0.88,0.96]
Total events: 857 (Steroid), 927 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =46.81,	df=13(P<0.0001); I ² =72	.23%			
Test for overall effect: Z=3.45(P=0)					
Test for subgroup differences: Chi ²	=2.69, df=1 (P=0.1), I ² =6	2.83%			
		Favours steroid 0.1	0.2 0.5 1 2 5	¹⁰ Favours control	

Analysis 3.2. Comparison 3 Death or bronchopulmonary dysplasia (BPD), Outcome 2 Death or BPD at 36 weeks' postmenstrual age.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
3.2.1 Dexamethasone					
Anttila 2005	22/53	27/56		2.5%	0.86[0.57,1.31]
Garland 1999	35/118	52/123		4.85%	0.7[0.5,0.99]
Kopelman 1999	16/37	10/33		1.01%	1.43[0.76,2.69]
Lauterbach 2006	28/50	33/50	+	3.14%	0.85[0.62,1.16]
Lin 1999	8/20	13/20		1.24%	0.62[0.33,1.15]
Rastogi 1996	4/36	8/34	• • •	0.78%	0.47[0.16,1.43]
Romagnoli 1999	5/25	19/25	↓ +	1.81%	0.26[0.12,0.59]
Sanders 1994	6/19	12/21		1.09%	0.55[0.26,1.18]
		Favours steroid	0.2 0.5 1 2	⁵ Favours control	



Study or subgroup	Steroid Control		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Shinwell 1996	46/132	33/116		3.35%	1.22[0.85,1.78]
Sinkin 2000	76/189	77/195	_ _	7.22%	1.02[0.8,1.3]
Soll 1999	135/272	143/267	-+-	13.75%	0.93[0.79,1.09]
Stark 2001	70/111	75/109	-+-	7.21%	0.92[0.76,1.11]
Subhedar 1997	20/21	21/21	-+-	2.05%	0.95[0.84,1.09]
Tapia 1998	20/55	30/54		2.88%	0.65[0.43,1]
Yeh 1990	11/28	19/29		1.78%	0.6[0.35,1.02]
Yeh 1997	64/132	76/130	-+	7.3%	0.83[0.66,1.04]
Subtotal (95% CI)	1298	1283	•	61.95%	0.87[0.8,0.94]
Total events: 566 (Steroid), 648 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =27.5, df=1	5(P=0.02); I ² =45.459	6			
Test for overall effect: Z=3.52(P=0)					
3.2.2 Hydrocortisone					
Baud 2016	102/255	130/266	-+	12.12%	0.82[0.67,0.99
Biswas 2003	82/125	81/128	_ + _	7.62%	1.04[0.86,1.24]
Bonsante 2007	9/25	17/25		1.62%	0.53[0.29,0.95
Efird 2005	11/16	11/18		0.99%	1.13[0.69,1.85]
Hochwald 2014	4/11	9/11		0.86%	0.44[0.19,1.02
Ng 2006	13/24	11/24		1.05%	1.18[0.67,2.09]
Peltoniemi 2005	9/25	12/26		1.12%	0.78[0.4,1.52]
Watterberg 1999	8/20	13/20		1.24%	0.62[0.33,1.15]
Watterberg 2004	117/180	120/180		11.43%	0.98[0.84,1.13]
Subtotal (95% CI)	681	698	•	38.05%	0.9[0.82,0.99]
Total events: 355 (Steroid), 404 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =13.52, df=	8(P=0.1); I ² =40.81%				
Test for overall effect: Z=2.22(P=0.03)					
Total (95% CI)	1979	1981	•	100%	0.88[0.83,0.93]
Total events: 921 (Steroid), 1052 (Conti	rol)				
Heterogeneity: Tau ² =0; Chi ² =41.28, df=	24(P=0.02); l ² =41.86	%			
Test for overall effect: Z=4.15(P<0.0001)				
Test for subgroup differences: Chi ² =0.3	5, df=1 (P=0.55). I ² =	0%			

Comparison 4. Failure to extubate

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Failure to extubate by third day	4	887	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.75, 0.95]
1.1 Dexamethasone	3	381	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.62, 0.86]
1.2 Hydrocortisone	1	506	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.82, 1.14]
2 Failure to extubate by sev- enth day	8	1448	Risk Ratio (M-H, Fixed, 95% CI)	0.76 [0.68, 0.85]
2.1 Dexamethasone	6	703	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.61, 0.84]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.2 Hydrocortisone	2	745	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.69, 0.94]
3 Failure to extubate by 14th day	4	443	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.62, 0.97]
4 Failure to extubate by 28th day	7	902	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.72, 0.98]

Analysis 4.1. Comparison 4 Failure to extubate, Outcome 1 Failure to extubate by third day.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
4.1.1 Dexamethasone					
Rastogi 1996	20/36	27/34		10.43%	0.7[0.5,0.98]
Shinwell 1996	54/132	71/116 -	_	28.38%	0.67[0.52,0.86]
Wang 1996	29/34	27/29		10.94%	0.92[0.77,1.09]
Subtotal (95% CI)	202	179		49.75%	0.73[0.62,0.86]
Total events: 103 (Steroid), 125 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =7.34, df=2	(P=0.03); I ² =72.74%				
Test for overall effect: Z=3.88(P=0)					
4.1.2 Hydrocortisone					
Baud 2016	127/249	136/257		50.25%	0.96[0.82,1.14]
Subtotal (95% CI)	249	257		50.25%	0.96[0.82,1.14]
Total events: 127 (Steroid), 136 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P<	<0.0001); I ² =100%				
Test for overall effect: Z=0.43(P=0.67)					
Total (95% CI)	451	436	•	100%	0.85[0.75,0.95]
Total events: 230 (Steroid), 261 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =7.73, df=3	(P=0.05); I ² =61.18%				
Test for overall effect: Z=2.8(P=0.01)					
Test for subgroup differences: Chi ² =5.5	57, df=1 (P=0.02), I ² =8	2.06%			
		Favours steroid 0.5	0.7 1 1.5	² Favours control	

Analysis 4.2. Comparison 4 Failure to extubate, Outcome 2 Failure to extubate by seventh day.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
4.2.1 Dexamethasone					
Rastogi 1996	11/36	22/34	← →───	6.13%	0.47[0.27,0.82]
Sanders 1994	15/19	14/21		3.6%	1.18[0.81,1.73]
Shinwell 1996	27/132	34/116		9.8%	0.7[0.45,1.08]
Vento 2004	3/10	8/10	↓	2.17%	0.38[0.14,1.02]
Wang 1996	22/34	23/29	+	6.72%	0.82[0.6,1.11]
Yeh 1997	54/132	75/130		20.47%	0.71[0.55,0.91]
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Subtotal (95% CI)	363	340	•	48.89%	0.71[0.61,0.84]
Total events: 132 (Steroid), 176 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =11.31, d	=5(P=0.05); I ² =55.799	%			
Test for overall effect: Z=4.1(P<0.0001	.)				
4.2.2 Hydrocortisone					
Baud 2016	101/243	132/249	_ _	35.32%	0.78[0.65,0.95]
Biswas 2003	49/125	59/128		15.79%	0.85[0.64,1.13]
Subtotal (95% CI)	368	377	•	51.11%	0.8[0.69,0.94]
Total events: 150 (Steroid), 191 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =0.21, df=	1(P=0.64); I ² =0%				
Test for overall effect: Z=2.69(P=0.01)					
Total (95% CI)	731	717	•	100%	0.76[0.68,0.85]
Total events: 282 (Steroid), 367 (Cont	rol)				- / -
Heterogeneity: Tau ² =0; Chi ² =11.33, di	=7(P=0.12); I ² =38.229	%			
Test for overall effect: Z=4.76(P<0.000	01)				
Test for subgroup differences: Chi ² =1	.12, df=1 (P=0.29), I ² =	10.4%			
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 4.3. Comparison 4 Failure to extubate, Outcome 3 Failure to extubate by 14th day.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Biswas 2003	40/125	40/128		39.04%	1.02[0.71,1.47]
Rastogi 1996	10/36	20/34 -		20.32%	0.47[0.26,0.86]
Wang 1996	17/34	19/29		20.26%	0.76[0.5,1.17]
Yeh 1990	12/28	21/29		20.38%	0.59[0.37,0.96]
Total (95% CI)	223	220	•	100%	0.77[0.62,0.97]
Total events: 79 (Steroid), 100 (C	Control)				
Heterogeneity: Tau ² =0; Chi ² =6.1	, df=3(P=0.11); I ² =50.81%				
Test for overall effect: Z=2.27(P=	=0.02)				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 4.4. Comparison 4 Failure to extubate, Outcome 4 Failure to extubate by 28th day.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Garland 1999	50/118	53/123	-+-	26.25%	0.98[0.73,1.32]
Lin 1999	8/20	11/20	+	5.56%	0.73[0.37,1.42]
Romagnoli 1999	4/25	13/25		6.57%	0.31[0.12,0.81]
Stark 2001	43/111	44/109	_ _	22.45%	0.96[0.69,1.33]
Suske 1996	1/14	3/12		1.63%	0.29[0.03,2.4]
Wang 1996	5/34	9/29		4.91%	0.47[0.18,1.26]
Yeh 1997	55/132	64/130	-	32.61%	0.85[0.65,1.11]
			_ , _ , _ , _ , _ ,		
		Favours steroid	0.05 0.2 1 5 20	Favours control	



Study or subgroup	Steroid	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI				M-H, Fixed, 95% CI		
Total (95% CI)	454	448			•			100%	0.84[0.72,0.98]
Total events: 166 (Steroid), 197	7 (Control)								
Heterogeneity: Tau ² =0; Chi ² =8.	.35, df=6(P=0.21); l ² =28.14%	þ							
Test for overall effect: Z=2.18(F	P=0.03)								
		Favours steroid	0.05	0.2	1	5	20	Favours control	

Comparison 5. Complications during primary hospitalisation

Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Infection	25	4101	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.96, 1.15]
1.1 Dexamethasone	18	2821	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.91, 1.15]
1.2 Hydrocortisone	7	1280	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.94, 1.25]
2 Hyperglycaemia	13	2167	Risk Ratio (M-H, Fixed, 95% CI)	1.33 [1.20, 1.47]
2.1 Dexamethasone	12	2117	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [1.21, 1.49]
2.2 Hydrocortisone	1	50	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.50, 1.67]
3 Hypertension	11	1993	Risk Ratio (M-H, Fixed, 95% CI)	1.85 [1.54, 2.22]
3.1 Dexamethasone	10	1943	Risk Ratio (M-H, Fixed, 95% CI)	1.84 [1.53, 2.21]
3.2 Hydrocortisone	1	50	Risk Ratio (M-H, Fixed, 95% CI)	3.0 [0.33, 26.92]
4 Hypertrophic cardiomy- opathy	1	50	Risk Ratio (M-H, Fixed, 95% CI)	4.33 [1.40, 13.37]
5 Growth failure	1	50	Risk Ratio (M-H, Fixed, 95% CI)	6.67 [2.27, 19.62]
6 Pulmonary air leak	16	3225	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.74, 1.13]
6.1 Dexamethasone	12	2041	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.66, 1.08]
6.2 Hydrocortisone	4	1184	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.75, 1.65]
7 Patent ductus arteriosus (PDA)	24	4013	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.72, 0.85]
7.1 Dexamethasone	17	2706	Risk Ratio (M-H, Fixed, 95% CI)	0.76 [0.69, 0.84]
7.2 Hydrocortisone	7	1307	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.71, 0.95]
8 Severe IVH	26	4103	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.83, 1.11]
8.1 Dexamethasone	17	2736	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.81, 1.14]
8.2 Hydrocortisone	9	1367	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.74, 1.23]



Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size
9 Severe intraventricular haemorrhage (IVH) in in- fants examined	7	1909	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.74, 1.11]
10 Periventricular leuko- malacia (PVL)	15	2807	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.78, 1.46]
10.1 Dexamethasone	8	1514	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.84, 1.81]
10.2 Hydrocortisone	7	1293	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.46, 1.40]
11 PVL in infants with cra- nial ultrasound scans	7	1841	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.79, 1.60]
12 PVL in survivors seen at follow-up	2	183	Risk Ratio (M-H, Fixed, 95% CI)	1.22 [0.60, 2.48]
13 Necrotising enterocoli- tis (NEC)	25	4050	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.74, 1.11]
13.1 Dexamethasone	15	2661	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.69, 1.13]
13.2 Hydrocortisone	10	1389	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.66, 1.37]
14 Gastrointestinal bleed- ing	12	1816	Risk Ratio (M-H, Fixed, 95% CI)	1.86 [1.35, 2.55]
14.1 Dexamethasone	10	1725	Risk Ratio (M-H, Fixed, 95% CI)	1.87 [1.35, 2.58]
14.2 Hydrocortisone	2	91	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.27, 8.74]
15 Gastrointestinal perfo- ration	16	3040	Risk Difference (M-H, Fixed, 95% CI)	0.03 [0.02, 0.05]
15.1 Dexamethasone	9	1936	Risk Difference (M-H, Fixed, 95% CI)	0.03 [0.01, 0.05]
15.2 Hydrocortisone	7	1104	Risk Difference (M-H, Fixed, 95% CI)	0.03 [0.00, 0.06]
16 Pulmonary haemor- rhage	10	1820	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.87, 1.54]
16.1 Dexamethasone	7	686	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.65, 1.45]
16.2 Hydrocortisone	3	1134	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [0.92, 2.03]
17 Any retinopathy of pre- maturity (ROP)	9	1345	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.80, 0.97]
17.1 Dexamethasone	8	1042	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.72, 0.99]
17.2 Hydrocortisone	1	303	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.84, 1.04]
18 Severe ROP	14	2577	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.66, 0.98]
18.1 Dexamethasone	8	1507	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.60, 0.99]



Outcome or subgroup ti- tle	No. of studies	No. of partici- pants	Statistical method	Effect size
18.2 Hydrocortisone	6	1070	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.63, 1.21]
19 Severe ROP in survivors	12	1575	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.64, 0.94]
19.1 Dexamethasone	10	1238	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.59, 0.95]
19.2 Hydrocortisone	2	337	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.60, 1.17]

Analysis 5.1. Comparison 5 Complications during primary hospitalisation, Outcome 1 Infection.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.1.1 Dexamethasone					
Anttila 2005	22/53	20/56		3.32%	1.16[0.72,1.87]
Garland 1999	47/118	44/123	-+	7.35%	1.11[0.8,1.54]
Halac 1990	15/130	18/118	+	3.22%	0.76[0.4,1.43]
Kopelman 1999	24/37	19/33	_ +_	3.43%	1.13[0.77,1.64]
Lin 1999	6/20	4/20		0.68%	1.5[0.5,4.52]
Rastogi 1996	1/36	3/34 -	•	0.53%	0.31[0.03,2.88]
Romagnoli 1999	8/25	7/25		1.19%	1.14[0.49,2.67]
Sanders 1994	1/19	1/21		0.16%	1.11[0.07,16.47]
Shinwell 1996	32/132	37/116	-+-	6.72%	0.76[0.51,1.14]
Sinkin 2000	13/189	11/195	— +	1.85%	1.22[0.56,2.65]
Soll 1999	109/273	107/269	+	18.39%	1[0.82,1.23]
Stark 2001	51/111	48/109	—	8.26%	1.04[0.78,1.4]
Subhedar 1997	2/21	1/21		0.17%	2[0.2,20.41]
Suske 1996	5/14	1/12			4.29[0.58,31.79]
Tapia 1998	14/55	15/54	<u> </u>	2.58%	0.92[0.49,1.71]
Wang 1996	5/34	6/29		1.1%	0.71[0.24,2.09]
Yeh 1990	1/28	1/29		0.17%	1.04[0.07,15.77]
Yeh 1997	17/132	12/130	- ++	2.06%	1.4[0.69,2.8]
Subtotal (95% CI)	1427	1394	•	61.36%	1.02[0.91,1.15]
Total events: 373 (Steroid), 355 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =9.21, c	lf=17(P=0.93); I ² =0%				
Test for overall effect: Z=0.4(P=0.69)				
5.1.2 Hydrocortisone					
Baud 2016	80/255	66/266		11.02%	1.26[0.96,1.67]
Biswas 2003	63/125	64/128	+	10.79%	1.01[0.79,1.29]
Bonsante 2007	9/25	7/25		1.19%	1.29[0.57,2.91]
Efird 2005	3/16	6/18		0.96%	0.56[0.17,1.89]
Hochwald 2014	3/11	5/11		0.85%	0.6[0.19,1.92]
Watterberg 1999	5/20	6/20		1.02%	0.83[0.3,2.29]
Watterberg 2004	80/180	75/180		12.79%	1.07[0.84,1.35]
Subtotal (95% CI)	632	648	•	38.64%	1.08[0.94,1.25]
Total events: 243 (Steroid), 229 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =4.09, c	lf=6(P=0.66); I ² =0%				
Test for overall effect: Z=1.13(P=0.2	6)				

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Study or subgroup	Steroid	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95%	% CI			M-H, Fixed, 95% Cl
Total (95% CI)	2059	2042			•			100%	1.05[0.96,1.15]
Total events: 616 (Steroid), 584	4 (Control)								
Heterogeneity: Tau ² =0; Chi ² =1	3.54, df=24(P=0.96); l ² =0%								
Test for overall effect: Z=1(P=0	.32)								
Test for subgroup differences:	Chi ² =0.38, df=1 (P=0.54), I ² =00	%					1		
		Favours steroid	0.05	0.2	1	5	20	Favours control	

Analysis 5.2. Comparison 5 Complications during primary hospitalisation, Outcome 2 Hyperglycaemia.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
5.2.1 Dexamethasone					
Anttila 2005	26/53	22/56	-+-	6.11%	1.25[0.82,1.91]
Garland 1999	39/118	22/123		6.16%	1.85[1.17,2.92]
Kopelman 1999	19/37	11/33	++	3.32%	1.54[0.87,2.74]
Rastogi 1996	24/36	18/34	-+-	5.29%	1.26[0.85,1.86]
Romagnoli 1999	7/25	0/25	+	- 0.14%	15[0.9,249.3]
Sanders 1994	8/19	6/21	_ 	1.63%	1.47[0.63,3.47]
Shinwell 1996	16/132	9/116	++	2.74%	1.56[0.72,3.4]
Sinkin 2000	55/189	39/195	-+-	10.97%	1.46[1.02,2.08]
Soll 1999	200/271	151/263	•	43.79%	1.29[1.13,1.46]
Stark 2001	52/111	44/109	+-	12.69%	1.16[0.86,1.57]
Subhedar 1997	3/21	6/21	— • 	1.71%	0.5[0.14,1.74]
Tapia 1998	9/55	7/54	 +	2.02%	1.26[0.51,3.15]
Subtotal (95% CI)	1067	1050	•	96.57%	1.35[1.21,1.49]
Total events: 458 (Steroid), 335 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =9.36, df=	11(P=0.59); I ² =0%				
Test for overall effect: Z=5.68(P<0.000	01)				
5.2.2 Hydrocortisone					
Bonsante 2007	11/25	12/25		3.43%	0.92[0.5,1.67]
Subtotal (95% CI)	25	25	•	3.43%	0.92[0.5,1.67]
Total events: 11 (Steroid), 12 (Control					
Heterogeneity: Not applicable	·/				
Test for overall effect: Z=0.28(P=0.78)					
Total (95% CI)	1092	1075	♦	100%	1.33[1.2,1.47]
Total events: 469 (Steroid), 347 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =10.64, df	f=12(P=0.56); I ² =0%				
Test for overall effect: Z=5.56(P<0.000	01)				
Test for subgroup differences: Chi ² =1.	.52, df=1 (P=0.22), l ² =	34.29%			
		Favours steroid 0.00	05 0.1 1 10 20	^D Favours control	



Analysis 5.3. Comparison 5 Complications during primary hospitalisation, Outcome 3 Hypertension.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
5.3.1 Dexamethasone					
Garland 1999	95/118	56/123		47.07%	1.77[1.43,2.19]
Rastogi 1996	1/36	1/34		0.88%	0.94[0.06,14.51]
Romagnoli 1999	2/25	0/25		0.43%	5[0.25,99.16]
Sanders 1994	0/19	0/21			Not estimable
Shinwell 1996	8/132	2/116	+ +	1.83%	3.52[0.76,16.22]
Sinkin 2000	4/189	0/195	•	- 0.42%	9.28[0.5,171.27]
Soll 1999	68/272	50/267		43.31%	1.34[0.97,1.85]
Stark 2001	30/111	4/109		3.46%	7.36[2.68,20.21]
Subhedar 1997	0/21	0/21			Not estimable
Tapia 1998	3/55	2/54		1.73%	1.47[0.26,8.47]
Subtotal (95% CI)	978	965	•	99.14%	1.84[1.53,2.21]
Total events: 211 (Steroid), 115 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =13.76, df=	7(P=0.06); I ² =49.129	6			
Test for overall effect: Z=6.57(P<0.0001)				
5.3.2 Hydrocortisone					
Bonsante 2007	3/25	1/25		0.86%	3[0.33,26.92]
Subtotal (95% CI)	25	25		0.86%	3[0.33,26.92]
Total events: 3 (Steroid), 1 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.98(P=0.33)					
Total (95% CI)	1003	990	•	100%	1.85[1.54,2.22]
Total events: 214 (Steroid), 116 (Contro					
Heterogeneity: Tau ² =0; Chi ² =14.04, df=		6			
Test for overall effect: Z=6.65(P<0.0001					
Test for subgroup differences: Chi ² =0.1	9, df=1 (P=0.66), I ² =	0%		L	
		Favours steroid 0.00	5 0.1 1 10 2	⁰⁰ Favours control	

Analysis 5.4. Comparison 5 Complications during primary hospitalisation, Outcome 4 Hypertrophic cardiomyopathy.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Romagnoli 1999	13/25	3/25		100%	4.33[1.4,13.37]
Total (95% CI)	25	25		100%	4.33[1.4,13.37]
Total events: 13 (Steroid), 3 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.55(P=0.01)					
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control	

Analysis 5.5. Comparison 5 Complications during primary hospitalisation, Outcome 5 Growth failure.

Study or subgroup	Steroid	Control		Risk Ratio M-H, Fixed, 95% Cl				Weight	Risk Ratio
	n/N	n/N							M-H, Fixed, 95% Cl
Romagnoli 1999	20/25	3/25			-	1		100%	6.67[2.27,19.62]
Total (95% CI)	25	25			-			100%	6.67[2.27,19.62]
Total events: 20 (Steroid), 3 (Control)									
Heterogeneity: Not applicable									
Test for overall effect: Z=3.44(P=0)									
		Favours steroid	0.05	0.2	1	5	20	Favours control	

Analysis 5.6. Comparison 5 Complications during primary hospitalisation, Outcome 6 Pulmonary air leak.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl	-	M-H, Fixed, 95% Cl
5.6.1 Dexamethasone					
Garland 1999	6/118	13/123		7.78%	0.48[0.19,1.22]
Lauterbach 2006	1/50	2/50		1.22%	0.5[0.05,5.34]
Mukhopadhyay 1998	4/10	3/9		1.93%	1.2[0.36,3.97]
Rastogi 1996	2/36	3/34		1.89%	0.63[0.11,3.54]
Sanders 1994	1/19	4/21 —		2.32%	0.28[0.03,2.26]
Shinwell 1996	9/132	13/116	+-	8.46%	0.61[0.27,1.37]
Sinkin 2000	29/189	25/195	-+	15.04%	1.2[0.73,1.97]
Soll 1999	34/273	24/269	+	14.77%	1.4[0.85,2.29]
Stark 2001	10/111	25/109	+	15.41%	0.39[0.2,0.78]
Subhedar 1997	3/21	1/21		- 0.61%	3[0.34,26.56]
Suske 1996	1/14	4/12		2.63%	0.21[0.03,1.67]
Tapia 1998	4/55	4/54		2.47%	0.98[0.26,3.73]
Subtotal (95% CI)	1028	1013	•	74.52%	0.85[0.66,1.08]
Total events: 104 (Steroid), 121 (Contro	l)				
Heterogeneity: Tau ² =0; Chi ² =17.46, df=1	1(P=0.09); I ² =37.01	.%			
Test for overall effect: Z=1.32(P=0.19)					
5.6.2 Hydrocortisone					
Baud 2016	5/255	7/266	+	4.19%	0.75[0.24,2.32]
Biswas 2003	16/125	13/128		7.85%	1.26[0.63,2.51]
Bonsante 2007	2/25	4/25		2.44%	0.5[0.1,2.49]
Watterberg 2004	23/180	18/180	++	11%	1.28[0.71,2.28]
Subtotal (95% CI)	585	599	•	25.48%	1.11[0.75,1.65]
Total events: 46 (Steroid), 42 (Control)					
Heterogeneity: Tau ² =0; Chi ² =1.78, df=3(P=0.62); I ² =0%				
Test for overall effect: Z=0.52(P=0.61)					
Total (95% CI)	1613	1612	•	100%	0.91[0.74,1.13]
Total events: 150 (Steroid), 163 (Contro	l)				
Heterogeneity: Tau ² =0; Chi ² =20.31, df=1	.5(P=0.16); I ² =26.14	%			
Test for overall effect: Z=0.84(P=0.4)					
Test for subgroup differences: Chi ² =1.29	9, df=1 (P=0.26), I ² =	22.39%			
		Favours steroid	0.05 0.2 1 5 20	Favours control	

Analysis 5.7. Comparison 5 Complications during primary hospitalisation, Outcome 7 Patent ductus arteriosus (PDA).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.7.1 Dexamethasone					
Anttila 2005	21/47	29/52		3.48%	0.8[0.54,1.19]
Garland 1999	17/118	34/123 -	+	4.21%	0.52[0.31,0.88]
Halac 1990	52/130	46/118	+	6.1%	1.03[0.75,1.4]
Kopelman 1999	13/37	18/33		2.41%	0.64[0.38,1.1]
Mukhopadhyay 1998	3/10	1/9	+	0.13%	2.7[0.34,21.53]
Rastogi 1996	9/36	13/34		1.69%	0.65[0.32,1.33]
Romagnoli 1999	13/25	17/25		2.15%	0.76[0.48,1.21]
Shinwell 1996	25/132	32/116		4.31%	0.69[0.43,1.09]
Sinkin 2000	89/189	109/195	-+	13.57%	0.84[0.69,1.02]
Soll 1999	92/272	117/269	+	14.88%	0.78[0.63,0.96]
Stark 2001	38/111	49/109	+	6.25%	0.76[0.55,1.06]
Subhedar 1997	3/21	4/21	+	0.51%	0.75[0.19,2.95]
Suske 1996	4/14	6/12		0.82%	0.57[0.21,1.56]
Tapia 1998	13/55	18/54		2.3%	0.71[0.39,1.3]
Vento 2004	2/10	2/10		0.25%	1[0.17,5.77]
Yeh 1990	9/28	10/29		1.24%	0.93[0.45,1.95]
Yeh 1997	14/132	34/130	+	4.33%	0.41[0.23,0.72]
Subtotal (95% CI)	1367	1339	•	68.63%	0.76[0.69,0.84]
Total events: 417 (Steroid), 539 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =14.28,	df=16(P=0.58); I ² =0%				
Test for overall effect: Z=5.32(P<0.00	001)				
5.7.2 Hydrocortisone					
Baud 2016	37/255	55/266	+	6.81%	0.7[0.48,1.03]
Biswas 2003	41/125	60/128	+	7.5%	0.7[0.51,0.96]
Bonsante 2007	8/25	9/25		1.14%	0.89[0.41,1.93]
Efird 2005	4/14	6/18 -		0.66%	0.86[0.3,2.46]
Peltoniemi 2005	9/25	19/26 —		2.36%	0.49[0.28,0.87]
Watterberg 1999	8/20	13/20		1.64%	0.62[0.33,1.15]
Watterberg 2004	94/180	89/180	+ _	11.26%	1.06[0.86,1.29]
Subtotal (95% CI)	644	663	•	31.37%	0.82[0.71,0.95]
Total events: 201 (Steroid), 251 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =11.52,	df=6(P=0.07); I ² =47.919	6			
Test for overall effect: Z=2.73(P=0.02					
·					
Total (95% CI)	2011	2002	•	100%	0.78[0.72,0.85]
Total events: 618 (Steroid), 790 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =26.6, d	f=23(P=0.27); I ² =13.529	6			
Test for overall effect: Z=5.93(P<0.00	001)				
Test for subgroup differences: Chi ² =	0.64, df=1 (P=0.42), I ² =	0%			
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 5.8. Comparison 5 Complications during primary hospitalisation, Outcome 8 Severe IVH.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.8.1 Dexamethasone					
Anttila 2005	8/53	8/56		2.4%	1.06[0.43,2.61]
Garland 1999	17/118	26/123	-+-	7.84%	0.68[0.39,1.19]
Halac 1990	31/130	20/118	++	6.46%	1.41[0.85,2.33]
Kopelman 1999	8/37	4/33		1.3%	1.78[0.59,5.38]
Lin 1999	4/20	3/20		0.92%	1.33[0.34,5.21]
Rastogi 1996	2/36	4/34		1.27%	0.47[0.09,2.41]
Romagnoli 1999	5/25	6/25		1.85%	0.83[0.29,2.38]
Sanders 1994	6/19	5/21	— <u>+</u> +—	1.46%	1.33[0.48,3.65]
Shinwell 1996	7/132	10/116	+	3.28%	0.62[0.24,1.56]
Sinkin 2000	22/189	21/195	_ + _	6.37%	1.08[0.62,1.9]
Soll 1999	38/273	50/269	-+-	15.52%	0.75[0.51,1.1]
Stark 2001	24/111	26/109	-+-	8.08%	0.91[0.56,1.48]
Suske 1996	0/14	1/12		0.5%	0.29[0.01,6.5]
Tapia 1998	6/55	8/54		2.49%	0.74[0.27,1.98]
/ento 2004	2/10	1/10		0.31%	2[0.21,18.69]
/eh 1990	9/28	6/29		1.82%	1.55[0.64,3.79]
/eh 1997	25/132	20/130	+	6.21%	1.23[0.72,2.1]
Subtotal (95% CI)	1382	1354	•	68.06%	0.96[0.81,1.14]
Fotal events: 214 (Steroid), 219 (Cor	itrol)				
Heterogeneity: Tau ² =0; Chi ² =12.21, o	df=16(P=0.73); I ² =0%				
Test for overall effect: Z=0.44(P=0.66	5)				
5.8.2 Hydrocortisone					
Batton 2012	0/4	2/6 —	•	0.64%	0.28[0.02,4.66]
Baud 2016	38/255	38/266	+	11.46%	1.04[0.69,1.58]
Biswas 2003	15/125	19/128	-+	5.78%	0.81[0.43,1.52]
Bonsante 2007	1/25	2/25		0.62%	0.5[0.05,5.17]
Efird 2005	2/16	5/18		1.45%	0.45[0.1,2.01]
Ng 2006	3/24	5/24		1.54%	0.6[0.16,2.23]
Peltoniemi 2005	3/25	4/26		1.21%	0.78[0.19,3.14]
Watterberg 1999	2/20	1/20		0.31%	2[0.2,20.33]
Watterberg 2004	33/180	29/180	-+-	8.93%	1.14[0.72,1.79]
Subtotal (95% CI)	674	693	•	31.94%	0.95[0.74,1.23
Total events: 97 (Steroid), 105 (Cont	rol)				
	f=8(P=0.86); I ² =0%				
Heterogeneity: Tau ² =0; Chi ² =3.97, d					
Heterogeneity: Tau ² =0; Chi ² =3.97, di Fest for overall effect: Z=0.38(P=0.71	L)				
est for overall effect: Z=0.38(P=0.71	د) 2056	2047	•	100%	0.96[0.83,1.11
est for overall effect: Z=0.38(P=0.7)	2056	2047	•	100%	0.96[0.83,1.11
Test for overall effect: Z=0.38(P=0.71 Total (95% CI) Total events: 311 (Steroid), 324 (Cor	2056 itrol)	2047	•	100%	0.96[0.83,1.11
	2056 htrol) df=25(P=0.91); I ² =0%	2047	•	100%	0.96[0.83,1.11]

Analysis 5.9. Comparison 5 Complications during primary hospitalisation, Outcome 9 Severe intraventricular haemorrhage (IVH) in infants examined.

Study or subgroup	Steroid	Control		R	isk Ratio			Weight	Risk Ratio	
	n/N	n/N		M-H, Fixed, 95% Cl					M-H, Fixed, 95% Cl	
Baud 2016	38/255	38/266			-			22.82%	1.04[0.69,1.58]	
Bonsante 2007	1/25	2/21				_		1.33%	0.42[0.04,4.31]	
Shinwell 1996	7/88	10/76			•			6.58%	0.6[0.24,1.51]	
Soll 1999	38/257	50/255		-	- ∎∔			30.79%	0.75[0.51,1.11]	
Stark 2001	24/111	26/109			_+ _			16.09%	0.91[0.56,1.48]	
Tapia 1998	6/48	8/50			+			4.81%	0.78[0.29,2.08]	
Watterberg 2004	33/172	29/176			+-			17.58%	1.16[0.74,1.83]	
Total (95% CI)	956	953			•			100%	0.9[0.74,1.11]	
Total events: 147 (Steroid), 163 (0	Control)				İ					
Heterogeneity: Tau ² =0; Chi ² =3.75	, df=6(P=0.71); I ² =0%				İ					
Test for overall effect: Z=0.98(P=0).33)					1	1			
		Favours steroid	0.05	0.2	1	5	20	Favours control		

Analysis 5.10. Comparison 5 Complications during primary hospitalisation, Outcome 10 Periventricular leukomalacia (PVL).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
5.10.1 Dexamethasone					
Anttila 2005	4/53	3/56		4.11%	1.41[0.33,6]
Efird 2005	0/16	3/18	+	4.65%	0.16[0.01,2.87]
Garland 1999	6/118	7/123		9.65%	0.89[0.31,2.58]
Lauterbach 2006	2/50	2/50		2.82%	1[0.15,6.82]
Romagnoli 1999	2/25	2/25		2.82%	1[0.15,6.55]
Shinwell 1996	16/132	9/116	++	13.49%	1.56[0.72,3.4]
Soll 1999	18/273	8/269		11.34%	2.22[0.98,5.01]
Stark 2001	8/111	8/79	+	13.16%	0.71[0.28,1.82]
Subtotal (95% CI)	778	736	•	62.03%	1.23[0.84,1.81]
Total events: 56 (Steroid), 42 (Control)				
Heterogeneity: Tau ² =0; Chi ² =6.07, df=	7(P=0.53); I ² =0%				
Test for overall effect: Z=1.06(P=0.29)					
5.10.2 Hydrocortisone					
Batton 2012	0/4	1/6		1.76%	0.47[0.02,9.26]
Baud 2016	4/255	10/266		13.78%	0.42[0.13,1.31]
Biswas 2003	4/125	2/128		2.78%	2.05[0.38,10.98]
Bonsante 2007	1/25	2/25		2.82%	0.5[0.05,5.17]
Ng 2006	1/24	1/24		1.41%	1[0.07,15.08]
Peltoniemi 2005	3/25	2/26		2.76%	1.56[0.28,8.56]
Watterberg 2004	8/180	9/180	+	12.67%	0.89[0.35,2.25]
Subtotal (95% CI)	638	655	•	37.97%	0.81[0.46,1.4]
Total events: 21 (Steroid), 27 (Control))				
Heterogeneity: Tau ² =0; Chi ² =3.38, df=	6(P=0.76); I ² =0%				
Test for overall effect: Z=0.76(P=0.45)					
Total (95% CI)	1416	1391		100%	1.07[0.78,1.46]
		Favours steroid 0.02	1 0.1 1 10 10	⁰⁰ Favours control	



Study or subgroup	Steroid	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl						M-H, Fixed, 95% Cl
Total events: 77 (Steroid), 69 (Co	ontrol)								
Heterogeneity: Tau ² =0; Chi ² =10	.84, df=14(P=0.7); I ² =0%								
Test for overall effect: Z=0.42(P=	=0.67)								
Test for subgroup differences: C	hi²=1.51, df=1 (P=0.22),	l ² =33.79%		1					
		Favours steroid	0.01	0.1	1	10	100	Favours control	

Analysis 5.11. Comparison 5 Complications during primary hospitalisation, Outcome 11 PVL in infants with cranial ultrasound scans.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Baud 2016	4/255	10/266	+	18.35%	0.42[0.13,1.31]
Bonsante 2007	1/23	2/20 —		4.01%	0.43[0.04,4.44]
Garland 1999	6/107	7/112		12.82%	0.9[0.31,2.58]
Shinwell 1996	16/88	9/76		18.11%	1.54[0.72,3.27]
Soll 1999	18/252	8/250	+	15.06%	2.23[0.99,5.04]
Stark 2001	8/82	8/79		15.28%	0.96[0.38,2.44]
Watterberg 2004	8/112	9/119		16.36%	0.94[0.38,2.36]
Total (95% CI)	919	922	•	100%	1.13[0.79,1.6]
Total events: 61 (Steroid), 53 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =7.31,	df=6(P=0.29); I ² =17.89%				
Test for overall effect: Z=0.65(P=0.	.52)				
		Favours steroid	0.05 0.2 1 5	²⁰ Favours control	

Analysis 5.12. Comparison 5 Complications during primary hospitalisation, Outcome 12 PVL in survivors seen at follow-up.

Study or subgroup	Steroid	Control	1	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	М-Н,	Fixed, 95% CI		M-H, Fixed, 95% Cl
Romagnoli 1999	1/23	1/1		-	25.59%	0.08[0.01,0.48]
Shinwell 1996	13/80	8/79			74.41%	1.6[0.7,3.66]
Total (95% CI)	103	80		•	100%	1.22[0.6,2.48]
Total events: 14 (Steroid), 9 (Control)						
Heterogeneity: Tau ² =0; Chi ² =9.51, df=	=1(P=0); I ² =89.48%					
Test for overall effect: Z=0.54(P=0.59)						
		Favours steroid	0.02 0.1	1 10	⁵⁰ Favours control	

Analysis 5.13. Comparison 5 Complications during primary hospitalisation, Outcome 13 Necrotising enterocolitis (NEC).

Steroid	Control	Risk Ratio	Weight	Risk Ratio
n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
8/53	8/56	+	4.37%	1.06[0.43,2.61]
6/118	8/123	+	4.4%	0.78[0.28,2.19]
9/130	17/118	_ + _	10.02%	0.48[0.22,1.04]
5/37	3/33		1.78%	1.49[0.38,5.75]
2/36	2/34		1.16%	0.94[0.14,6.33]
2/25	3/25		1.69%	0.67[0.12,3.65]
0/19	3/21 —		1.87%	0.16[0.01,2.86]
10/132	10/116	+	5.98%	0.88[0.38,2.04]
16/189	13/195		7.19%	1.27[0.63,2.57]
24/273	25/269	-+-	14.15%	0.95[0.55,1.61]
14/111	10/109		5.67%	1.37[0.64,2.96]
2/21	1/21		0.56%	2[0.2,20.41]
1/14	2/12		1.21%	0.43[0.04,4.16]
0/55	5/54		3.12%	0.09[0.01,1.58]
11/132	12/130	_ + _	6.8%	0.9[0.41,1.97]
1345	1316	•	69.97%	0.88[0.69,1.13]
ntrol)				
df=14(P=0.74); I ² =0%				
31)				
				Not estimable
17/255	12/266	+	6.6%	1.48[0.72,3.03]
16/125	15/128		8.33%	1.09[0.56,2.11]
1/25	2/25		1.12%	0.5[0.05,5.17]
2/16	2/18		1.06%	1.13[0.18,7.09]
1/11	3/11		1.69%	0.33[0.04,2.73]
2/24	3/24		1.69%	0.67[0.12,3.64]
2/25	1/26		0.55%	2.08[0.2,21.52]
2/20	2/20		1.12%	1[0.16,6.42]
7/180	14/180	-+	7.87%	0.5[0.21,1.21]
685	704	•	30.03%	0.95[0.66,1.37]
rol)				
df=8(P=0.7); I ² =0%				
'8)				
2030	2020	•	100%	0.9[0.74,1.11]
,				
	8/53 6/118 9/130 5/37 2/36 2/25 0/19 10/132 16/189 24/273 14/111 2/21 1/14 0/55 11/132 1345 ontrol) , df=14(P=0.74); l ² =0% 81) 0/4 17/255 16/125 1/25 2/16 1/11 2/24 2/25 2/20 7/180	$8/53$ $8/56$ $6/118$ $8/123$ $9/130$ $17/118$ $5/37$ $3/33$ $2/36$ $2/34$ $2/25$ $3/25$ $0/19$ $3/21$ $10/132$ $10/116$ $16/189$ $13/195$ $24/273$ $25/269$ $14/111$ $10/109$ $2/21$ $1/21$ $1/14$ $2/12$ $0/55$ $5/54$ $11/132$ $12/130$ 1345 1316 ontrol) $df=14(P=0.74); l^2=0\%$ $df=14(P=0.74); l^2=0\%$ 311 $0/4$ $0/6$ $17/255$ $12/266$ $16/125$ $15/128$ $1/25$ $2/25$ $2/16$ $2/18$ $1/11$ $3/11$ $2/20$ $2/20$ $7/180$ $14/180$ 685 704 rol) $df=8(P=0.7); l^2=0\%$ $df=8(P=0.7); l^2=0\%$ 704	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$

Analysis 5.14. Comparison 5 Complications during primary hospitalisation, Outcome 14 Gastrointestinal bleeding.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.14.1 Dexamethasone					
Anttila 2005	2/53	1/56		1.82%	2.11[0.2,22.63]
Kopelman 1999	2/37	1/33		1.98%	1.78[0.17,18.78]
Rastogi 1996	0/36	0/34			Not estimable
Shinwell 1996	28/132	12/116	—	23.88%	2.05[1.09,3.84]
Soll 1999	33/271	21/267	+∎-	39.56%	1.55[0.92,2.61]
Stark 2001	6/111	2/109		3.77%	2.95[0.61,14.28]
Subhedar 1997	2/21	0/21			5[0.25,98.27]
Tapia 1998	0/55	0/54			Not estimable
Yeh 1990	4/28	3/29	+	5.51%	1.38[0.34,5.62]
Yeh 1997	21/132	10/130		18.84%	2.07[1.01,4.22]
Subtotal (95% CI)	876	849	•	96.3%	1.87[1.35,2.58]
Total events: 98 (Steroid), 50 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =1.59, df	=7(P=0.98); I ² =0%				
Test for overall effect: Z=3.81(P=0)					
5.14.2 Hydrocortisone					
Peltoniemi 2005	2/25	1/26		1.83%	2.08[0.2,21.52]
Watterberg 1999	1/20	1/20		1.87%	1[0.07,14.9]
Subtotal (95% CI)	45	46		3.7%	1.53[0.27,8.74]
Total events: 3 (Steroid), 2 (Control)					
Heterogeneity: Tau ² =0; Chi ² =0.16, df	=1(P=0.69); I ² =0%				
Test for overall effect: Z=0.48(P=0.63	;)				
Total (95% CI)	921	895	•	100%	1.86[1.35,2.55]
Total events: 101 (Steroid), 52 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =1.8, df=	9(P=0.99); I ² =0%				
Test for overall effect: Z=3.83(P=0)					
Test for subgroup differences: Chi ² =(0.05, df=1 (P=0.83), I ² =	0%			
		Favours steroid 0.01	0.1 1 10	¹⁰⁰ Favours control	

Analysis 5.15. Comparison 5 Complications during primary hospitalisation, Outcome 15 Gastrointestinal perforation.

Study or subgroup	Steroid	Control	Risk Difference	Weight	Risk Difference	
	n/N n/N		M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI	
5.15.1 Dexamethasone						
Anttila 2005	3/53	1/56	- •	3.58%	0.04[-0.03,0.11]	
Garland 1999	12/118	7/123	+-	7.93%	0.04[-0.02,0.11]	
Kopelman 1999	3/37	0/33		2.3%	0.08[-0.02,0.18]	
Rastogi 1996	0/36	0/34	+	2.3%	0[-0.05,0.05]	
Sinkin 2000	3/189	2/195	÷	12.63%	0.01[-0.02,0.03]	
Soll 1999	31/271	20/267	+-	17.7%	0.04[-0.01,0.09]	
Stark 2001	15/111	8/109	+ -	7.24%	0.06[-0.02,0.14]	
Subhedar 1997	2/21	1/21	_ 	1.38%	0.05[-0.11,0.2]	
Yeh 1997	1/132	1/130	+	8.62%	-0[-0.02,0.02]	
Subtotal (95% CI)	968	968	•	63.68%	0.03[0.01,0.05]	
Total events: 70 (Steroid), 40 (Control)						
		Favors steroid ⁻¹	-0.5 0 0.5	¹ Favors control		



Study or subgroup	Steroid	Control	Risk Difference	Weight	Risk Difference
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Heterogeneity: Tau ² =0; Chi ² =16.12,	df=8(P=0.04); I ² =50.39%	6			
Test for overall effect: Z=2.96(P=0)					
5.15.2 Hydrocortisone					
Baud 2016	13/255	11/266	+	17.14%	0.01[-0.03,0.05]
Bonsante 2007	2/25	1/25		1.65%	0.04[-0.09,0.17]
Efird 2005	1/16	0/18		1.11%	0.06[-0.09,0.22]
Ng 2006	1/24	2/24	<u> </u>	1.58%	-0.04[-0.18,0.09]
Peltoniemi 2005	4/25	0/26		1.68%	0.16[0.01,0.31]
Watterberg 1999	1/20	1/20		1.32%	0[-0.14,0.14]
Watterberg 2004	22/180	11/180	-+-	11.85%	0.06[0,0.12]
Subtotal (95% CI)	545	559	♦	36.32%	0.03[0,0.06]
Total events: 44 (Steroid), 26 (Cont	rol)				
Heterogeneity: Tau ² =0; Chi ² =6.68, o	df=6(P=0.35); I ² =10.14%				
Test for overall effect: Z=2.29(P=0.0	2)				
Total (95% CI)	1513	1527	•	100%	0.03[0.02,0.05]
Total events: 114 (Steroid), 66 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =23.62,	df=15(P=0.07); I ² =36.49	%			
Test for overall effect: Z=3.74(P=0)					
Test for subgroup differences: Chi ²	=0.03, df=1 (P=0.87), I ² =	0%			

Analysis 5.16. Comparison 5 Complications during primary hospitalisation, Outcome 16 Pulmonary haemorrhage.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
5.16.1 Dexamethasone					
Garland 1999	9/118	12/123		14.58%	0.78[0.34,1.79]
Rastogi 1996	2/36	3/34 —		3.83%	0.63[0.11,3.54]
Sanders 1994	0/1	0/1			Not estimable
Shinwell 1996	0/1	0/1			Not estimable
Stark 2001	18/111	18/109	-	22.54%	0.98[0.54,1.78]
Subhedar 1997	2/21	2/21		2.48%	1[0.16,6.45]
Tapia 1998	10/55	7/54		8.76%	1.4[0.58,3.42]
Subtotal (95% CI)	343	343	-	52.19%	0.97[0.65,1.45]
Total events: 41 (Steroid), 42 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =1.16, di	f=4(P=0.88); I ² =0%				
Test for overall effect: Z=0.14(P=0.89	9)				
5.16.2 Hydrocortisone					
Baud 2016	19/255	17/266		20.65%	1.17[0.62,2.19]
Biswas 2003	15/125	9/128		11.03%	1.71[0.78,3.76]
Watterberg 2004	18/180	13/180	+	16.13%	1.38[0.7,2.74]
Subtotal (95% CI)	560	574		47.81%	1.36[0.92,2.03]
Total events: 52 (Steroid), 39 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =0.55, df	f=2(P=0.76); I ² =0%				
Test for overall effect: Z=1.53(P=0.13	3)				
		Favours steroid 0.1	0.2 0.5 1 2 5	¹⁰ Favours control	



Study or subgroup	Steroid	Control			Ri	sk Rat	io		Weight		Risk Ratio
	n/N	n/N			М-Н, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Total (95% CI)	903	917				•	•			100%	1.16[0.87,1.54]
Total events: 93 (Steroid), 81 (C	Control)										
Heterogeneity: Tau ² =0; Chi ² =3.	03, df=7(P=0.88); I ² =0%										
Test for overall effect: Z=1.03(P	P=0.3)										
Test for subgroup differences:	Chi ² =1.38, df=1 (P=0.24), I ²	=27.78%									
		Favours steroid	0.1	0.2	0.5	1	2	5	10	Favours control	

Analysis 5.17. Comparison 5 Complications during primary hospitalisation, Outcome 17 Any retinopathy of prematurity (ROP).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
5.17.1 Dexamethasone					
Anttila 2005	14/45	22/49	-+	6.5%	0.69[0.41,1.18]
Rastogi 1996	5/36	8/34		2.54%	0.59[0.21,1.63]
Sanders 1994	10/19	11/21	<u> </u>	3.23%	1[0.56,1.81]
Sinkin 2000	96/189	116/195	-	35.26%	0.85[0.71,1.02]
Suske 1996	2/14	6/12 -		2%	0.29[0.07,1.16]
Tapia 1998	7/55	8/54		2.49%	0.86[0.33,2.2]
Yeh 1990	5/28	4/29		1.21%	1.29[0.39,4.33]
Yeh 1997	23/132	22/130	+	6.85%	1.03[0.6,1.75]
Subtotal (95% CI)	518	524	•	60.08%	0.84[0.72,0.99]
Total events: 162 (Steroid), 197 (Contr	ol)				
Heterogeneity: Tau ² =0; Chi ² =4.66, df=	7(P=0.7); l ² =0%				
Test for overall effect: Z=2.13(P=0.03)					
5.17.2 Hydrocortisone					
Watterberg 2004	122/153	128/150	-	39.92%	0.93[0.84,1.04]
Subtotal (95% CI)	153	150	•	39.92%	0.93[0.84,1.04]
Total events: 122 (Steroid), 128 (Contr	ol)				
Heterogeneity: Not applicable					
Test for overall effect: Z=1.28(P=0.2)					
Total (95% CI)	671	674	•	100%	0.88[0.8,0.97]
Total events: 284 (Steroid), 325 (Contr	ol)				
Heterogeneity: Tau ² =0; Chi ² =6.15, df=8	8(P=0.63); I ² =0%				
Test for overall effect: Z=2.47(P=0.01)					
Test for subgroup differences: Chi ² =1.	14, df=1 (P=0.29), I ² =	12.14%			
		Eavours steroid	0.1 0.2 0.5 1 2 5 10	Eavours control	

Favours steroid 0.1 0.2 0.5 1 2 5 10 Favours control

Analysis 5.18. Comparison 5 Complications during primary hospitalisation, Outcome 18 Severe ROP.

Study or subgroup	Steroid	Control		Risk Ratio	Weight	Risk Ratio
	n/N n/N			M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.18.1 Dexamethasone						
Anttila 2005	3/45	4/49	-		- 2.15%	0.82[0.19,3.45]
Garland 1999	12/118	17/123		· · · · · · · · · · · · · · · · · · ·	9.34%	0.74[0.37,1.47]
		Favours steroid	0.2	0.5 1 2	⁵ Favours control	



_

Trusted evidence. Informed decisions. Better health.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Kopelman 1999	4/37	5/33		2.96%	0.71[0.21,2.44]
Romagnoli 1999	9/25	8/25		4.49%	1.13[0.52,2.44]
Shinwell 1996	10/132	8/116	+	4.78%	1.1[0.45,2.69]
Soll 1999	32/273	49/269		27.69%	0.64[0.43,0.97]
Stark 2001	18/111	24/109	+	13.58%	0.74[0.42,1.28]
Subhedar 1997	2/21	0/21		0.28%	5[0.25,98.27]
Subtotal (95% CI)	762	745	•	65.26%	0.77[0.6,0.99]
Total events: 90 (Steroid), 115 (Contro	ι)				
Heterogeneity: Tau ² =0; Chi ² =3.83, df=7	7(P=0.8); I ² =0%				
Test for overall effect: Z=2.02(P=0.04)					
5.18.2 Hydrocortisone					
Baud 2016	4/255	2/200		1.1%	2 00[0 20 11 20]
	4/255	2/266 4/25			2.09[0.39,11.29]
Bonsante 2007	3/25			2.24%	0.75[0.19,3.01]
Ng 2006	1/24	2/24		1.12%	0.5[0.05,5.15]
Peltoniemi 2005	1/25	1/26		0.55%	1.04[0.07,15.74]
Watterberg 1999	4/20	6/20		3.37%	0.67[0.22,2.01]
Watterberg 2004	41/180	47/180		26.36%	0.87[0.61,1.26]
Subtotal (95% CI)	529	541		34.74%	0.87[0.63,1.21]
Total events: 54 (Steroid), 62 (Control)					
Heterogeneity: Tau ² =0; Chi ² =1.53, df=5	5(P=0.91); I ² =0%				
Test for overall effect: Z=0.82(P=0.41)					
Total (95% CI)	1291	1286	•	100%	0.81[0.66,0.98]
Total events: 144 (Steroid), 177 (Contr	ol)				
Heterogeneity: Tau ² =0; Chi ² =5.68, df=1	L3(P=0.96); I ² =0%				
Test for overall effect: Z=2.12(P=0.03)					
Test for subgroup differences: Chi ² =0.3	36, df=1 (P=0.55), I ² =	0%			
		Favours steroid	0.2 0.5 1 2 5	Favours control	

Analysis 5.19. Comparison 5 Complications during primary hospitalisation, Outcome 19 Severe ROP in survivors.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
5.19.1 Dexamethasone					
Garland 1999	12/99	17/98	-+-	9.33%	0.7[0.35,1.39]
Kopelman 1999	4/27	5/28		2.68%	0.83[0.25,2.77]
Rastogi 1996	5/32	8/32	+	4.37%	0.63[0.23,1.71]
Shinwell 1996	10/101	8/94		4.53%	1.16[0.48,2.82]
Soll 1999	32/194	49/204		26.09%	0.69[0.46,1.02]
Stark 2001	18/80	24/80	-+-	13.11%	0.75[0.44,1.27]
Subhedar 1997	2/12	0/13	+	- 0.26%	5.38[0.28,101.96]
Suske 1996	2/13	6/11		3.55%	0.28[0.07,1.13]
Tapia 1998	7/38	8/36	— · · · ·	4.49%	0.83[0.33,2.05]
Yeh 1990	5/25	4/21		2.38%	1.05[0.32,3.42]
Subtotal (95% CI)	621	617	•	70.79%	0.75[0.59,0.95]
Total events: 97 (Steroid), 129 (Control)	I				
Heterogeneity: Tau ² =0; Chi ² =5.33, df=9	(P=0.8); I ² =0%				
Test for overall effect: Z=2.38(P=0.02)					
		Favours steroid ^{0.}	01 0.1 1 10 1	⁰⁰ Favours control	



Study or subgroup	Steroid	Control		Risk Ratio		Weight	Risk Ratio	
	n/N	n/N	M-H	Fixed, 95% CI			M-H, Fixed, 95% Cl	
5.19.2 Hydrocortisone								
Watterberg 1999	4/17	6/17	_	-+		3.28%	0.67[0.23,1.95]	
Watterberg 2004	41/153	47/150		-		25.93%	0.86[0.6,1.22]	
Subtotal (95% CI)	170	167		•		29.21%	0.83[0.6,1.17]	
Total events: 45 (Steroid), 53 (Contro	ol)							
Heterogeneity: Tau ² =0; Chi ² =0.19, df	=1(P=0.67); I ² =0%							
Test for overall effect: Z=1.06(P=0.29))							
Total (95% CI)	791	784		•		100%	0.77[0.64,0.94]	
Total events: 142 (Steroid), 182 (Cont	trol)							
Heterogeneity: Tau ² =0; Chi ² =5.82, df	=11(P=0.89); I ² =0%							
Test for overall effect: Z=2.58(P=0.01))							
Test for subgroup differences: Chi ² =0	0.25, df=1 (P=0.61), I ² =0	%						
		Favours steroid 0	0.01 0.1	1 10	100	Favours control		

Comparison 6. Long-term follow-up

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Bayley Mental Developmental In- dex (MDI) <-2 SD	3	842	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.78, 1.29]
2 Bayley MDI <-2 SD in tested sur- vivors	3	528	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.79, 1.25]
3 Bayley Psychomotor Developmen- tal Index (PDI) <-2 SD	3	842	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [0.85, 1.60]
4 Bayley PDI <-2 SD in tested sur- vivors	3	528	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [0.87, 1.57]
5 Developmental delay (criteria not specified)	1	248	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [1.08, 2.61]
6 Developmental delay (criteria not specified) in tested survivors	1	159	Risk Ratio (M-H, Fixed, 95% CI)	1.94 [1.30, 2.88]
7 Blindness	8	939	Risk Ratio (M-H, Fixed, 95% CI)	2.01 [0.74, 5.50]
8 Blindness in survivors assessed	8	585	Risk Ratio (M-H, Fixed, 95% CI)	2.16 [0.80, 5.86]
9 Deafness	8	721	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.39, 3.37]
10 Deafness in survivors assessed	8	476	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.40, 3.29]
11 Cerebral palsy	13	1973	Risk Ratio (IV, Fixed, 95% CI)	1.42 [1.06, 1.91]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size	
11.1 Dexamethasone	7	921	Risk Ratio (IV, Fixed, 95% CI)	1.75 [1.20, 2.55]	
11.2 Hydrocortisone	6	1052	Risk Ratio (IV, Fixed, 95% CI)	1.05 [0.66, 1.66]	
12 Death before follow-up in trials assessing cerebral palsy	13	1973	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.78, 1.05]	
12.1 Dexamethasone	7	921	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.81, 1.21]	
12.2 Hydrocortisone	6	1052	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.64, 1.02]	
13 Death or cerebral palsy	13	1973	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.91, 1.16]	
13.1 Dexamethasone	7	921	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [1.00, 1.37]	
13.2 Hydrocortisone	6	1052	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.71, 1.05]	
14 Cerebral palsy in survivors as- sessed	13	1328	Risk Ratio (M-H, Fixed, 95% CI)	1.45 [1.11, 1.90]	
14.1 Dexamethasone	7	586	Risk Ratio (M-H, Fixed, 95% CI)	1.82 [1.29, 2.57]	
14.2 Hydrocortisone	6	742	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.65, 1.58]	
15 Major neurosensory disability (variable criteria - see individual studies)	7	1703	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.89, 1.33]	
15.1 Dexamethasone	4	772	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [1.03, 1.83]	
15.2 Hydrocortisone	3	931	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.64, 1.14]	
16 Death before follow-up in trials assessing major neurosensory dis- ability (variable criteria)	6	1182	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.81, 1.17]	
16.1 Dexamethasone	4	772	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.82, 1.25]	
16.2 Hydrocortisone	2	410	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.58, 1.28]	
17 Death or major neurosensory dis- ability (variable criteria)	7	1703	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.87, 1.08]	



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
17.1 Dexamethasone	4	772	Risk Ratio (M-H, Fixed, 95% Cl)	1.13 [0.99, 1.30]
17.2 Hydrocortisone	3	931	Risk Ratio (M-H, Fixed, 95% Cl)	0.82 [0.69, 0.97]
18 Major neurosensory disability in survivors examined (variable crite- ria)	8	1178	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.89, 1.28]
18.1 Dexamethasone	4	469	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [1.05, 1.77]
18.2 Hydrocortisone	4	709	Risk Ratio (M-H, Fixed, 95% Cl)	0.84 [0.65, 1.10]
19 Abnormal neurological exam (variable criteria - see individual studies)	5	829	Risk Ratio (M-H, Fixed, 95% CI)	1.81 [1.33, 2.47]
20 Death before follow-up in trials assessing abnormal neurological ex- am (variable criteria)	6	1350	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.75, 1.07]
20.1 Dexamethasone	5	829	Risk Ratio (M-H, Fixed, 95% Cl)	0.97 [0.79, 1.21]
20.2 Hydrocortisone	1	521	Risk Ratio (M-H, Fixed, 95% Cl)	0.75 [0.54, 1.04]
21 Death or abnormal neurological exam (variable criteria)	5	829	Risk Ratio (M-H, Fixed, 95% Cl)	1.23 [1.06, 1.42]
22 Abnormal neurological exam in tested survivors (variable criteria)	5	508	Risk Ratio (M-H, Fixed, 95% Cl)	1.89 [1.41, 2.52]
23 Intellectual impairment (IQ < 70)	2	90	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [0.57, 3.31]
24 Intellectual impairment (IQ < 70) in survivors assessed	2	76	Risk Ratio (M-H, Fixed, 95% CI)	1.12 [0.47, 2.65]
25 "Major neurosensory impair- ment" - blindness or deafness	1	50	Risk Ratio (M-H, Fixed, 95% Cl)	0.6 [0.16, 2.25]
26 "Major neurosensory impair- ment" - blindness or deafness - in survivors assessed	1	45	Risk Ratio (M-H, Fixed, 95% CI)	0.57 [0.16, 2.12]
27 Behaviour abnormalities	1	50	Risk Ratio (M-H, Fixed, 95% Cl)	0.6 [0.16, 2.25]
28 Behaviour abnormalities in 3- year-old survivors assessed	1	46	Risk Ratio (M-H, Fixed, 95% CI)	0.6 [0.16, 2.22]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
29 Abnormal EEG	2	306	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.66, 2.33]
30 Abnormal EEG in tested survivors	2	146	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.61, 2.08]
31 Rehospitalisation in infancy	3	672	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.68, 1.08]
32 Rehospitalisation in infancy in survivors	3	430	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.71, 1.07]

Analysis 6.1. Comparison 6 Long-term follow-up, Outcome 1 Bayley Mental Developmental Index (MDI) <-2 SD.

Study or subgroup	Steroid	Control		I	Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Fixed, 95	% CI			M-H, Fixed, 95% CI
Stark 2001	35/111	25/109				-		26.73%	1.37[0.89,2.13]
Watterberg 2004	34/180	47/180		-				49.79%	0.72[0.49,1.07]
Yeh 1997	26/132	22/130						23.48%	1.16[0.7,1.95]
Total (95% CI)	423	419				•		100%	1[0.78,1.29]
Total events: 95 (Steroid), 94 (Cor	ntrol)								
Heterogeneity: Tau ² =0; Chi ² =4.99	, df=2(P=0.08); I ² =59.96%								
Test for overall effect: Z=0.01(P=0	.99)								
		Favours steroid	0.5	0.7	1	1.5	2	Favours control	

Analysis 6.2. Comparison 6 Long-term follow-up, Outcome 2 Bayley MDI <- 2 SD in tested survivors.

Study or subgroup	Steroid	Control			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95%	% CI			M-H, Fixed, 95% Cl
Stark 2001	35/76	25/67					_	28.15%	1.23[0.83,1.83]
Watterberg 2004	34/126	47/126						49.78%	0.72[0.5,1.04]
Yeh 1997	26/63	22/70				•		22.07%	1.31[0.83,2.07]
Total (95% CI)	265	263		-		-		100%	1[0.79,1.25]
Total events: 95 (Steroid), 94 (Contr	rol)								
Heterogeneity: Tau ² =0; Chi ² =5.49, d	lf=2(P=0.06); I ² =63.58%								
Test for overall effect: Z=0.02(P=0.9	8)								
		Favours steroid	0.5	0.7	1	1.5	2	Favours control	

Analysis 6.3. Comparison 6 Long-term follow-up, Outcome 3 Bayley Psychomotor Developmental Index (PDI) <- 2 SD.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Stark 2001	21/111	22/109		36.2%	0.94[0.55,1.6]
Watterberg 2004	26/180	23/180		37.51%	1.13[0.67,1.9]
Yeh 1997	25/132	16/130		- 26.29%	1.54[0.86,2.75]
Total (95% CI)	423	419		100%	1.17[0.85,1.6]
Total events: 72 (Steroid), 61 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =1.5	3, df=2(P=0.46); I ² =0%				
Test for overall effect: Z=0.97(P=	=0.33)				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.4. Comparison 6 Long-term follow-up, Outcome 4 Bayley PDI <-2 SD in tested survivors.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Stark 2001	21/76	22/67		38%	0.84[0.51,1.39]
Watterberg 2004	26/126	23/126		37.37%	1.13[0.68,1.87]
Yeh 1997	25/63	16/70		24.63%	1.74[1.02,2.94]
Total (95% CI)	265	263		100%	1.17[0.87,1.57]
Total events: 72 (Steroid), 61 (C	Control)				
Heterogeneity: Tau ² =0; Chi ² =3.	84, df=2(P=0.15); I ² =47.94%				
Test for overall effect: Z=1.05(P	9=0.29)				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.5. Comparison 6 Long-term follow-up, Outcome 5 Developmental delay (criteria not specified).

Study or subgroup	Steroid	Control		F	lisk Rati	0		Weight	Risk Ratio	
	n/N	n/N		м-н,	Fixed, 9	5% CI			M-H, Fixed, 95% Cl	
Shinwell 1996	44/132	23/116			-	+		- 100%	1.68[1.08,2.61]	
Total (95% CI)	132	116			-			- 100%	1.68[1.08,2.61]	
Total events: 44 (Steroid), 23 (Contro	ι)									
Heterogeneity: Tau ² =0; Chi ² =0, df=0(I	P<0.0001); I²=100%									
Test for overall effect: Z=2.32(P=0.02)								_		
		Favours steroid	0.5	0.7	1	1.5	2	Favours control		

Analysis 6.6. Comparison 6 Long-term follow-up, Outcome 6 Developmental delay (criteria not specified) in tested survivors.

Study or subgroup Shinwell 1996	Steroid	Steroid Control			isk Rat	io		Weight	Risk Ratio
	n/N	M-H, Fixed, 95% CI						M-H, Fixed, 95% Cl	
	44/79	23/80						— 100%	1.94[1.3,2.88]
		Favours steroid	0.5	0.7	1	1.5	2	Favours control	



Study or subgroup	Steroid n/N	Control n/N	Risk Ratio M-H, Fixed, 95% Cl	Weight	Risk Ratio M-H, Fixed, 95% Cl
Total (95% CI) Total events: 44 (Steroid), 23 (Control)	79	80		100%	1.94[1.3,2.88]
Heterogeneity: Not applicable					
Test for overall effect: Z=3.26(P=0)					
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.7. Comparison 6 Long-term follow-up, Outcome 7 Blindness.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Peltoniemi 2005	0/25	0/26			Not estimable
Romagnoli 1999	2/25	1/25	+	- 17.88%	2[0.19,20.67]
Sanders 1994	0/19	0/21			Not estimable
Shinwell 1996	3/132	1/116	•	19.04%	2.64[0.28,25]
Stark 2001	1/111	0/109		9.02%	2.95[0.12,71.55]
Subhedar 1997	0/21	0/21			Not estimable
Watterberg 1999	0/13	0/13			Not estimable
Yeh 1997	5/132	3/130		54.06%	1.64[0.4,6.73]
Total (95% CI)	478	461		100%	2.01[0.74,5.5]
Total events: 11 (Steroid), 5 (Control)					
Heterogeneity: Tau ² =0; Chi ² =0.19, df=	3(P=0.98); I ² =0%				
Test for overall effect: Z=1.36(P=0.17)					
		Favours steroid	0.05 0.2 1 5 2	20 Favours control	

Analysis 6.8. Comparison 6 Long-term follow-up, Outcome 8 Blindness in survivors assessed.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
Peltoniemi 2005	0/17	0/18			Not estimable
Romagnoli 1999	2/23	1/22		18.97%	1.91[0.19,19.63]
Sanders 1994	0/17	0/14			Not estimable
Shinwell 1996	3/79	1/80	+	- 18.44%	3.04[0.32,28.59]
Stark 2001	1/76	0/67		9.85%	2.65[0.11,63.96]
Subhedar 1997	0/10	0/11			Not estimable
Watterberg 1999	0/10	0/8			Not estimable
Yeh 1997	5/63	3/70		52.74%	1.85[0.46,7.44]
Total (95% CI)	295	290		100%	2.16[0.8,5.86]
Total events: 11 (Steroid), 5 (Control)					
Heterogeneity: Tau ² =0; Chi ² =0.16, df=3	(P=0.98); I ² =0%				
Test for overall effect: Z=1.51(P=0.13)					
		Favours steroid	0.05 0.2 1 5 20	Favours control	

Analysis 6.9. Comparison 6 Long-term follow-up, Outcome 9 Deafness.

Study or subgroup	Steroid	Control			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H	, Fixed, 95% CI			M-H, Fixed, 95% CI
Baden 1972	0/22	0/22						Not estimable
Peltoniemi 2005	1/25	0/26					8.12%	3.12[0.13,73.06]
Romagnoli 1999	0/25	2/25					41.39%	0.2[0.01,3.97]
Sanders 1994	0/19	0/21						Not estimable
Shinwell 1996	1/132	0/116					8.81%	2.64[0.11,64.16]
Stark 2001	2/111	2/109			e		33.41%	0.98[0.14,6.85]
Subhedar 1997	1/21	0/21			+		8.28%	3[0.13,69.7]
Watterberg 1999	0/13	0/13						Not estimable
Total (95% CI)	368	353			-		100%	1.14[0.39,3.37]
Total events: 5 (Steroid), 4 (Control)								
Heterogeneity: Tau ² =0; Chi ² =2.34, df=4	(P=0.67); I ² =0%							
Test for overall effect: Z=0.25(P=0.81)								
		Favours steroid	0.01	0.1	1 10	100	Favours control	

Analysis 6.10. Comparison 6 Long-term follow-up, Outcome 10 Deafness in survivors assessed.

Study or subgroup	Steroid	Control		Risk Rat	tio		Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% CI				M-H, Fixed, 95% CI
Baden 1972	0/13	0/12						Not estimable
Peltoniemi 2005	1/17	0/18			•		7.94%	3.17[0.14,72.8]
Romagnoli 1999	0/23	2/22					41.67%	0.19[0.01,3.78]
Sanders 1994	0/17	0/14						Not estimable
Shinwell 1996	1/79	0/80			•		8.11%	3.04[0.13,73.46]
Stark 2001	2/75	2/67					34.48%	0.89[0.13,6.17]
Subhedar 1997	1/10	0/11			+		7.81%	3.27[0.15,72.23]
Watterberg 1999	0/10	0/8						Not estimable
Total (95% CI)	244	232		-	►		100%	1.14[0.4,3.29]
Total events: 5 (Steroid), 4 (Control)								
Heterogeneity: Tau ² =0; Chi ² =2.65, df=4	(P=0.62); I ² =0%							
Test for overall effect: Z=0.24(P=0.81)								
		Favours steroid	0.01	0.1 1	10	100	Favours control	

Analysis 6.11. Comparison 6 Long-term follow-up, Outcome 11 Cerebral palsy.

Study or subgroup	Steroid Control		Risk Ratio	Weight	Risk Ratio
n/N		n/N	IV, Fixed, 95% CI		IV, Fixed, 95% CI
6.11.1 Dexamethasone					
Romagnoli 1999	2/25	3/25		2.95%	0.67[0.12,3.65]
Sanders 1994	3/19	1/21		- 1.8%	3.32[0.38,29.23]
Shinwell 1996	38/132	12/116	— -	23.78%	2.78[1.53,5.07]
Sinkin 2000	4/32	1/27		- 1.88%	3.38[0.4,28.42]
Stark 2001	11/111	12/109	+	14.24%	0.9[0.42,1.95]
Subhedar 1997	0/21	2/21		0.96%	0.2[0.01,3.93]
		Favours steroid	0.05 0.2 1 5 20	Favours control	



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	IV, Fixed, 95% CI		IV, Fixed, 95% CI
Yeh 1997	17/132	9/130	+	14.37%	1.86[0.86,4.02]
Subtotal (95% CI)	472	449	•	59.97%	1.75[1.2,2.55]
Total events: 75 (Steroid), 40 (Control)				
Heterogeneity: Tau ² =0; Chi ² =9.13, df=	6(P=0.17); I ² =34.27%				
Test for overall effect: Z=2.9(P=0)					
6.11.2 Hydrocortisone					
Baden 1972	2/22	1/22		1.58%	2[0.2,20.49]
Baud 2016	12/255	10/266		12.65%	1.25[0.55,2.85]
Bonsante 2007	2/25	2/25		2.42%	1[0.15,6.55]
Peltoniemi 2005	2/25	0/26		0.96%	5.19[0.26,103.07]
Watterberg 1999	1/13	2/13		1.65%	0.5[0.05,4.86]
Watterberg 2004	16/180	18/180	+	20.78%	0.89[0.47,1.69]
Subtotal (95% CI)	520	532		40.03%	1.05[0.66,1.66]
Total events: 35 (Steroid), 33 (Control)				
Heterogeneity: Tau ² =0; Chi ² =2.24, df=	5(P=0.81); I ² =0%				
Test for overall effect: Z=0.2(P=0.84)					
Total (95% CI)	992	981	•	100%	1.42[1.06,1.91]
Total events: 110 (Steroid), 73 (Contro	ol)				
Heterogeneity: Tau ² =0; Chi ² =14.18, df	=12(P=0.29); I ² =15.37	%			
Test for overall effect: Z=2.37(P=0.02)					
Test for subgroup differences: Chi ² =2.	81, df=1 (P=0.09), I ² =	64.41%			
		Favours steroid	0.05 0.2 1 5 20	Favours control	

Analysis 6.12. Comparison 6 Long-term follow-up, Outcome 12 Death before follow-up in trials assessing cerebral palsy.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
6.12.1 Dexamethasone					
Romagnoli 1999	2/25	3/25		1.17%	0.67[0.12,3.65]
Sanders 1994	2/19	7/21		2.59%	0.32[0.07,1.34]
Shinwell 1996	32/132	26/116		10.77%	1.08[0.69,1.7]
Sinkin 2000	11/32	7/27	++	2.95%	1.33[0.6,2.94]
Stark 2001	26/111	30/109	+	11.77%	0.85[0.54,1.34]
Subhedar 1997	11/21	9/21		3.5%	1.22[0.64,2.32]
Yeh 1997	53/132	50/130	_ + _	19.6%	1.04[0.77,1.41]
Subtotal (95% CI)	472	449		52.34%	0.99[0.81,1.21]
Total events: 137 (Steroid), 132 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =4.23,	df=6(P=0.65); I ² =0%				
Test for overall effect: Z=0.08(P=0.9	93)				
6.12.2 Hydrocortisone					
Baden 1972	8/22	9/22		3.5%	0.89[0.42,1.88]
Baud 2016	48/255	67/266		25.51%	0.75[0.54,1.04]
Bonsante 2007	4/25	10/25	+	3.89%	0.4[0.14,1.11]
Peltoniemi 2005	2/25	3/26	+	1.14%	0.69[0.13,3.81]
Watterberg 1999	3/13	2/13	· · · · · · · · · · · · · · · · · · ·	0.78%	1.5[0.3,7.55]
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control	



Study or subgroup	Steroid	Control		Risk Rat	tio		Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl				M-H, Fixed, 95% CI	
Watterberg 2004	33/180	33/180		-+	-		12.84%	1[0.65,1.55]
Subtotal (95% CI)	520	532		•			47.66%	0.81[0.64,1.02]
Total events: 98 (Steroid), 124 (Control)							
Heterogeneity: Tau ² =0; Chi ² =3.6	62, df=5(P=0.6); I ² =0%							
Test for overall effect: Z=1.78(P	=0.08)							
Total (95% CI)	992	981		•			100%	0.9[0.78,1.05]
Total events: 235 (Steroid), 256	(Control)							
Heterogeneity: Tau ² =0; Chi ² =9.8	87, df=12(P=0.63); I ² =0%							
Test for overall effect: Z=1.3(P=	0.19)							
Test for subgroup differences: C	Chi ² =1.7, df=1 (P=0.19), I ² =4	1.14%						
		Favours steroid	0.1 0.2	0.5 1	2	5 10	Favours control	

Favours steroid Favours control

Analysis 6.13. Comparison 6 Long-term follow-up, Outcome 13 Death or cerebral palsy.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
6.13.1 Dexamethasone					
Romagnoli 1999	4/25	6/25		1.81%	0.67[0.21,2.08]
Sanders 1994	5/19	8/21		2.3%	0.69[0.27,1.75]
Shinwell 1996	70/132	38/116	-+	12.23%	1.62[1.19,2.2]
Sinkin 2000	15/32	8/27	- + +	2.62%	1.58[0.79,3.15]
Stark 2001	37/111	42/109	-+	12.81%	0.87[0.61,1.23]
Subhedar 1997	11/21	11/21		3.32%	1[0.56,1.78]
Yeh 1997	70/132	59/130	+	17.97%	1.17[0.91,1.5]
Subtotal (95% CI)	472	449	◆	53.06%	1.17[1,1.37]
Total events: 212 (Steroid), 172 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =10.31,	df=6(P=0.11); l ² =41.8%	1			
Test for overall effect: Z=2.01(P=0.0	4)				
6.13.2 Hydrocortisone					
Baden 1972	10/22	10/22		3.02%	1[0.52,1.91]
Baud 2016	60/255	77/266		22.78%	0.81[0.61,1.09]
Bonsante 2007	6/25	12/25	+	3.63%	0.5[0.22,1.12]
Peltoniemi 2005	4/25	3/26		0.89%	1.39[0.34,5.58]
Watterberg 1999	4/13	4/13		1.21%	1[0.32,3.17]
Watterberg 2004	49/180	51/180	-+	15.41%	0.96[0.69,1.34]
Subtotal (95% CI)	520	532	•	46.94%	0.86[0.71,1.05]
Total events: 133 (Steroid), 157 (Co	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =3.02, d	lf=5(P=0.7); I ² =0%				
Test for overall effect: Z=1.45(P=0.1	5)				
		001		1000/	
Total (95% CI)	992	981	•	100%	1.03[0.91,1.16]
Total events: 345 (Steroid), 329 (Co	•				
Heterogeneity: Tau ² =0; Chi ² =19.08,		/0			
Test for overall effect: Z=0.44(P=0.6		00.07%			
Test for subgroup differences: Chi ² =	=5.67, df=1 (P=0.02), l ² =				
		Favours steroid 0.1	0.2 0.5 1 2 5	¹⁰ Favours control	

Analysis 6.14. Comparison 6 Long-term follow-up, Outcome 14 Cerebral palsy in survivors assessed.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
6.14.1 Dexamethasone					
Romagnoli 1999	2/23	3/22		4.07%	0.64[0.12,3.46]
Sanders 1994	3/17	1/14		1.45%	2.47[0.29,21.21]
Shinwell 1996	38/79	12/80		15.81%	3.21[1.81,5.67]
Sinkin 2000	4/21	1/20		1.36%	3.81[0.46,31.23]
Stark 2001	11/76	12/67	+	16.91%	0.81[0.38,1.71]
Subhedar 1997	0/10	2/11		3.17%	0.22[0.01,4.06]
Yeh 1997	17/72	9/74	+	11.77%	1.94[0.93,4.07]
Subtotal (95% CI)	298	288	•	54.54%	1.82[1.29,2.57]
Total events: 75 (Steroid), 40 (Control)					
Heterogeneity: Tau ² =0; Chi ² =12.39, df=	=6(P=0.05); I ² =51.56%	6			
Test for overall effect: Z=3.41(P=0)					
6.14.2 Hydrocortisone					
Baden 1972	2/13	1/12		1.38%	1.85[0.19,17.84]
Baud 2016	12/194	10/185		13.57%	1.14[0.51,2.58]
Bonsante 2007	2/19	2/14		3.05%	0.74[0.12,4.61]
Peltoniemi 2005	2/17	0/18		0.64%	5.28[0.27,102.58]
Watterberg 1999	1/10	2/8		2.95%	0.4[0.04,3.66]
Watterberg 2004	16/126	18/126	_ _	23.86%	0.89[0.48,1.66]
Subtotal (95% CI)	379	363		45.46%	1.01[0.65,1.58]
Total events: 35 (Steroid), 33 (Control)					
Heterogeneity: Tau ² =0; Chi ² =2.51, df=5	5(P=0.78); I ² =0%				
Test for overall effect: Z=0.06(P=0.95)					
Total (95% CI)	677	651	•	100%	1.45[1.11,1.9]
Total events: 110 (Steroid), 73 (Contro	l)				, -
Heterogeneity: Tau ² =0; Chi ² =19.22, df=	=12(P=0.08); I ² =37.57	%			
Test for overall effect: Z=2.72(P=0.01)					
Test for subgroup differences: Chi ² =4.1	14, df=1 (P=0.04), I ² =	75.84%			
<u> </u>		Favours steroid 0.01	0.1 1 10	100 Favours control	

Analysis 6.15. Comparison 6 Long-term follow-up, Outcome 15 Major neurosensory disability (variable criteria - see individual studies).

Study or subgroup	Steroid	Control	F	lisk Ratio	Weight	Risk Ratio	
	n/N	n/N	М-Н,	Fixed, 95% CI		M-H, Fixed, 95% CI	
6.15.1 Dexamethasone							
Shinwell 1996	18/132	11/116		++	8.32%	1.44[0.71,2.92]	
Stark 2001	40/111	30/109		+	21.52%	1.31[0.88,1.94]	
Subhedar 1997	1/21	4/21			2.84%	0.25[0.03,2.05]	
Yeh 1997	28/132	16/130		 +	11.46%	1.72[0.98,3.03]	
Subtotal (95% CI)	396	376		•	44.15%	1.37[1.03,1.83]	
Total events: 87 (Steroid), 61 (Contro	l)						
Heterogeneity: Tau ² =0; Chi ² =3.21, df	=3(P=0.36); I ² =6.49%						
Test for overall effect: Z=2.14(P=0.03))						
		Favours steroid	0.05 0.2	1 5 20	Favours control		



Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
6.15.2 Hydrocortisone						
Baud 2016	14/255	21/266	_ + +	14.61%	0.7[0.36,1.34]	
Bonsante 2007	4/25	3/25		2.13%	1.33[0.33,5.36]	
Watterberg 2004	49/180	55/180		39.1%	0.89[0.64,1.23]	
Subtotal (95% CI)	460	471	•	55.85%	0.86[0.64,1.14]	
Total events: 67 (Steroid), 79 (Contro	l)					
Heterogeneity: Tau ² =0; Chi ² =0.84, df=	=2(P=0.66); I ² =0%					
Test for overall effect: Z=1.06(P=0.29)	1					
Total (95% CI)	856	847	•	100%	1.08[0.89,1.33]	
Total events: 154 (Steroid), 140 (Cont	rol)					
Heterogeneity: Tau ² =0; Chi ² =9.21, df=	=6(P=0.16); I ² =34.86%					
Test for overall effect: Z=0.79(P=0.43)	1					
Test for subgroup differences: Chi ² =5	.15, df=1 (P=0.02), I ² =	80.59%				
		Favours steroid	0.05 0.2 1 5 20	Favours control		

Analysis 6.16. Comparison 6 Long-term follow-up, Outcome 16 Death before follow-up in trials assessing major neurosensory disability (variable criteria).

Study or subgroup Study or Study or Study	teroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
6.16.1 Dexamethasone					
Shinwell 1996	32/132	26/116		17.26%	1.08[0.69,1.7]
Stark 2001	26/111	30/109		18.88%	0.85[0.54,1.34]
Subhedar 1997	11/21	9/21		5.61%	1.22[0.64,2.32]
Yeh 1997	53/132	50/130	_ _	31.42%	1.04[0.77,1.41]
Subtotal (95% CI)	396	376	•	73.18%	1.02[0.82,1.25]
Total events: 122 (Steroid), 115 (Control)					
Heterogeneity: Tau ² =0; Chi ² =1.01, df=3(P=0	.8); I ² =0%				
Test for overall effect: Z=0.16(P=0.88)					
6.16.2 Hydrocortisone					
Bonsante 2007	4/25	10/25	+	6.24%	0.4[0.14,1.11]
Watterberg 2004	33/180	33/180	+	20.58%	1[0.65,1.55]
Subtotal (95% CI)	205	205		26.82%	0.86[0.58,1.28]
Total events: 37 (Steroid), 43 (Control)					
Heterogeneity: Tau ² =0; Chi ² =2.63, df=1(P=0	.1); I ² =61.97%				
Test for overall effect: Z=0.75(P=0.46)					
Total (95% CI)	601	581	•	100%	0.97[0.81,1.17]
Total events: 159 (Steroid), 158 (Control)					
Heterogeneity: Tau ² =0; Chi ² =4.18, df=5(P=0	.52); I ² =0%				
Test for overall effect: Z=0.27(P=0.79)					
Test for subgroup differences: Chi ² =0.54, df	=1 (P=0.46), I ² =	0%			
		Favours steroid	0.2 0.5 1 2 5	Favours control	

Analysis 6.17. Comparison 6 Long-term follow-up, Outcome 17 Death or major neurosensory disability (variable criteria).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
6.17.1 Dexamethasone					
Shinwell 1996	50/132	37/116		10.72%	1.19[0.84,1.68]
Stark 2001	66/111	61/109		16.75%	1.06[0.85,1.33]
Subhedar 1997	12/21	13/21	+	3.54%	0.92[0.56,1.52]
Yeh 1997	81/132	66/130	+	18.09%	1.21[0.97,1.5]
Subtotal (95% CI)	396	376	◆	49.09%	1.13[0.99,1.3]
Total events: 209 (Steroid), 177 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =1.37, d	f=3(P=0.71); I ² =0%				
Test for overall effect: Z=1.77(P=0.08	3)				
6.17.2 Hydrocortisone					
Baud 2016	62/255	88/266		23.43%	0.73[0.56,0.97]
Bonsante 2007	8/25	13/25		3.54%	0.62[0.31,1.22]
Watterberg 2004	82/180	88/180		23.94%	0.93[0.75,1.16]
Subtotal (95% CI)	460	471	•	50.91%	0.82[0.69,0.97]
Total events: 152 (Steroid), 189 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =2.6, df=	=2(P=0.27); I ² =23.04%				
Test for overall effect: Z=2.33(P=0.02	2)				
Total (95% CI)	856	847	•	100%	0.97[0.87,1.08]
Total events: 361 (Steroid), 366 (Cor	ntrol)				
Heterogeneity: Tau ² =0; Chi ² =11.59, o	df=6(P=0.07); I ² =48.24%	6			
Test for overall effect: Z=0.49(P=0.63	3)				
Test for subgroup differences: Chi ² =	8.52, df=1 (P=0), I ² =88.	27%			
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.18. Comparison 6 Long-term follow-up, Outcome 18 Major neurosensory disability in survivors examined (variable criteria).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl	
6.18.1 Dexamethasone						
Shinwell 1996	18/79	11/80	++	7.57%	1.66[0.84,3.28]	
Stark 2001	40/76	30/67		22.08%	1.18[0.84,1.65]	
Subhedar 1997	1/10	4/11		2.64%	0.28[0.04,2.07]	
Yeh 1997	28/72	16/74		10.93%	1.8[1.07,3.03]	
Subtotal (95% CI)	237	232	◆	43.22%	1.36[1.05,1.77]	
Total events: 87 (Steroid), 61 (Con	trol)					
Heterogeneity: Tau ² =0; Chi ² =4.54,	df=3(P=0.21); I ² =33.98%					
Test for overall effect: Z=2.3(P=0.0	2)					
6.18.2 Hydrocortisone						
Baud 2016	14/194	21/185	+	14.89%	0.64[0.33,1.21]	
Bonsante 2007	4/19	3/14		2.39%	0.98[0.26,3.71]	
Peltoniemi 2005	3/23	2/22		1.42%	1.43[0.26,7.78]	
Watterberg 2004	49/126	55/126		38.09%	0.89[0.66,1.2]	
Subtotal (95% CI)	362	347	•	56.78%	0.84[0.65,1.1]	
		Favours steroid	0.05 0.2 1 5 20	Favours control		



Study or subgroup	Steroid	Control		F	lisk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% Cl					M-H, Fixed, 95% CI
Total events: 70 (Steroid), 81 (0	Control)								
Heterogeneity: Tau ² =0; Chi ² =1.	3, df=3(P=0.73); I ² =0%								
Test for overall effect: Z=1.28(F	2=0.2)								
Total (95% CI)	599	579			•			100%	1.07[0.89,1.28]
Total events: 157 (Steroid), 142	2 (Control)								
Heterogeneity: Tau ² =0; Chi ² =1	1.53, df=7(P=0.12); I ² =39.29	%							
Test for overall effect: Z=0.68(F	P=0.5)								
Test for subgroup differences:	Chi ² =6.4, df=1 (P=0.01), l ² =8	34.37%							
		Favours steroid	0.05	0.2	1	5	20	Favours control	

Analysis 6.19. Comparison 6 Long-term follow-up, Outcome 19 Abnormal neurological exam (variable criteria - see individual studies).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% Cl
	n/N	n/N	M-H, Fixed, 95% Cl		
Sanders 1994	7/19	4/21	+	7.26%	1.93[0.67,5.58]
Shinwell 1996	39/132	12/116		24.41%	2.86[1.57,5.19]
Sinkin 2000	7/32	6/27		12.44%	0.98[0.38,2.58]
Stark 2001	20/111	17/109		32.78%	1.16[0.64,2.08]
Yeh 1997	25/132	12/130		23.11%	2.05[1.08,3.91]
Total (95% CI)	426	403	•	100%	1.81[1.33,2.47]
Total events: 98 (Steroid), 51 (0	Control)				
Heterogeneity: Tau ² =0; Chi ² =6.	.17, df=4(P=0.19); I ² =35.16%				
Test for overall effect: Z=3.75(F	P=0)				
		Favours steroid	0.2 0.5 1 2	⁵ Favours control	

Analysis 6.20. Comparison 6 Long-term follow-up, Outcome 20 Death before follow-up in trials assessing abnormal neurological exam (variable criteria).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
6.20.1 Dexamethasone						
Sanders 1994	2/19	7/21 -	+	3.57%	0.32[0.07,1.34]	
Shinwell 1996	32/132	26/116	+	14.87%	1.08[0.69,1.7]	
Sinkin 2000	11/32	7/27	++	4.08%	1.33[0.6,2.94]	
Stark 2001	26/111	30/109	+	16.26%	0.85[0.54,1.34]	
Yeh 1997	50/132	48/130	_ _	25.98%	1.03[0.75,1.4]	
Subtotal (95% CI)	426	403	•	64.77%	0.97[0.79,1.21]	
Total events: 121 (Steroid), 118 (Cor	ntrol)					
Heterogeneity: Tau ² =0; Chi ² =3.56, d	f=4(P=0.47); I ² =0%					
Test for overall effect: Z=0.24(P=0.8)	1)					
6.20.2 Hydrocortisone						
Baud 2016	48/255	67/266		35.23%	0.75[0.54,1.04]	
Subtotal (95% CI)	255	266	▲ · · · · · · · · · · · · · · · · · · ·	35.23%	0.75[0.54,1.04]	
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control		



Study or subgroup	Steroid	Control		Ris	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N		M-H, Fi	ixed,	95% CI	I			M-H, Fixed, 95% CI
Total events: 48 (Steroid), 67 (Con	trol)									
Heterogeneity: Not applicable										
Test for overall effect: Z=1.74(P=0.	08)									
Total (95% CI)	681	669			•				100%	0.89[0.75,1.07]
Total events: 169 (Steroid), 185 (Co	ontrol)									
Heterogeneity: Tau ² =0; Chi ² =5.54,	df=5(P=0.35); I ² =9.75%)								
Test for overall effect: Z=1.22(P=0.	22)									
Test for subgroup differences: Chi	² =1.76, df=1 (P=0.18), I	2=43.34%				ı				
		Favours steroid	0.1 0.2	0.5	1	2	5	10	Favours control	

Analysis 6.21. Comparison 6 Long-term follow-up, Outcome 21 Death or abnormal neurological exam (variable criteria).

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Sanders 1994	9/19	11/21	+	6.04%	0.9[0.48,1.69]
Shinwell 1996	71/132	38/116		- 23.4%	1.64[1.21,2.23]
Sinkin 2000	18/32	13/27	+	8.16%	1.17[0.71,1.92]
Stark 2001	46/111	47/109		27.43%	0.96[0.71,1.31]
Yeh 1997	75/132	60/130		34.97%	1.23[0.97,1.56]
Total (95% CI)	426	403	•	100%	1.23[1.06,1.42]
Total events: 219 (Steroid), 169	(Control)				
Heterogeneity: Tau ² =0; Chi ² =6.8	86, df=4(P=0.14); I ² =41.73%				
Test for overall effect: Z=2.72(P	=0.01)				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.22. Comparison 6 Long-term follow-up, Outcome 22

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% Cl
	n/N	n/N	M-H, Fixed, 95% CI		
Sanders 1994	7/17	4/14		8.47%	1.44[0.53,3.93]
Shinwell 1996	39/79	12/80		- 23.03%	3.29[1.87,5.8]
Sinkin 2000	7/21	6/20		11.87%	1.11[0.45,2.74]
Stark 2001	20/76	17/68	_	34.66%	1.05[0.6,1.84]
Yeh 1997	25/63	12/70		21.96%	2.31[1.27,4.21]
Total (95% CI)	256	252	•	100%	1.89[1.41,2.52]
Total events: 98 (Steroid), 51 (Co	ontrol)				
Heterogeneity: Tau ² =0; Chi ² =9.9	4, df=4(P=0.04); I ² =59.78%				
Test for overall effect: Z=4.28(P<	0.0001)				
		Favours steroid	0.2 0.5 1 2 5	Favours control	

Analysis 6.23. Comparison 6 Long-term follow-up, Outcome 23 Intellectual impairment (IQ < 70).

Study or subgroup	Steroid	Control		R	isk Ratio			Weight	Risk Ratio	
	n/N	n/N		м-н,	Fixed, 95	% CI			M-H, Fixed, 95% CI	
Romagnoli 1999	3/25	3/25			-			44.12%	1[0.22,4.49]	
Sanders 1994	6/19	4/21				1		55.88%	1.66[0.55,4.99]	
Total (95% CI)	44	46					-	100%	1.37[0.57,3.31]	
Total events: 9 (Steroid), 7 (Control)										
Heterogeneity: Tau ² =0; Chi ² =0.28, df=	1(P=0.59); I ² =0%									
Test for overall effect: Z=0.69(P=0.49)										
		Favours steroid	0.2	0.5	1	2	5	Favours control		

Analysis 6.24. Comparison 6 Long-term follow-up, Outcome 24 Intellectual impairment (IQ < 70) in survivors assessed.

Study or subgroup	Study or subgroup Steroid Co			R	isk Ratio	b		Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI						M-H, Fixed, 95% Cl	
Romagnoli 1999	3/23	3/22			-			41.14%	0.96[0.22,4.24]	
Sanders 1994	6/17	4/14					_	58.86%	1.24[0.43,3.53]	
Total (95% CI)	40	36						100%	1.12[0.47,2.65]	
Total events: 9 (Steroid), 7 (Contro)									
Heterogeneity: Tau ² =0; Chi ² =0.08, o	df=1(P=0.78); I ² =0%									
Test for overall effect: Z=0.26(P=0.8	3)			1						
		Favours steroid	0.2	0.5	1	2	5	Favours control		

Analysis 6.25. Comparison 6 Long-term follow-up, Outcome 25 "Major neurosensory impairment" - blindness or deafness.

Study or subgroup	Steroid	Control		Ri	sk Ratio)		Weight	Risk Ratio
	n/N	n/N		M-H, F	ixed, 95	% CI			M-H, Fixed, 95% Cl
Romagnoli 1999	3/25	5/25		-				100%	0.6[0.16,2.25]
Total (95% CI)	25	25						100%	0.6[0.16,2.25]
Total events: 3 (Steroid), 5 (Control)									
Heterogeneity: Not applicable									
Test for overall effect: Z=0.76(P=0.45)									
		Eavours storoid	0.2	0.5	1	2	5	Eavours control	

Favours steroid 0.2 0.5 1 2 5 Favours control

Analysis 6.26. Comparison 6 Long-term follow-up, Outcome 26 "Major neurosensory impairment" - blindness or deafness - in survivors assessed.

Study or subgroup	Steroid	Control		R	isk Rat	io		Weight	Risk Ratio
	n/N	n/N		м-н, і	Fixed, 9	5% CI			M-H, Fixed, 95% Cl
Romagnoli 1999	3/23	5/22						100%	0.57[0.16,2.12]
		Favours steroid	0.2	0.5	1	2	5	Favours control	



Study or subgroup	Steroid	Control		Ri	isk Rati	o		Weight	Risk Ratio
	n/N	n/N		М-Н, Р	ixed, 9	5% CI			M-H, Fixed, 95% CI
Total (95% CI)	23	22						100%	0.57[0.16,2.12]
Total events: 3 (Steroid), 5 (Control)									
Heterogeneity: Not applicable									
Test for overall effect: Z=0.83(P=0.4)									
		Favours steroid	0.2	0.5	1	2	5	Favours control	

Analysis 6.27. Comparison 6 Long-term follow-up, Outcome 27 Behaviour abnormalities.

Study or subgroup	Steroid	Control		Ris	sk Rati	0		Weight	Risk Ratio
	n/N	n/N		M-H, Fi	ixed, 9	5% CI			M-H, Fixed, 95% CI
Romagnoli 1999	3/25	5/25						100%	0.6[0.16,2.25]
Total (95% CI)	25	25						100%	0.6[0.16,2.25]
Total events: 3 (Steroid), 5 (Control)									
Heterogeneity: Not applicable									
Test for overall effect: Z=0.76(P=0.45)									
		Favours steroid	0.2	0.5	1	2	5	Favours control	

Analysis 6.28. Comparison 6 Long-term follow-up, Outcome 28 Behaviour abnormalities in 3-year-old survivors assessed.

Study or subgroup	Steroid	Control		R	isk Rati	0		Weight	Risk Ratio
	n/N	n/N		м-н, і	ixed, 9	5% CI			M-H, Fixed, 95% Cl
Romagnoli 1999	3/23	5/23						100%	0.6[0.16,2.22]
Total (95% CI)	23	23						100%	0.6[0.16,2.22]
Total events: 3 (Steroid), 5 (Control)									
Heterogeneity: Not applicable									
Test for overall effect: Z=0.76(P=0.44)									
		Favours steroid	0.2	0.5	1	2	5	Favours control	

Analysis 6.29. Comparison 6 Long-term follow-up, Outcome 29 Abnormal EEG.

Study or subgroup	Steroid	Control		F	Risk Ratio	,		Weight	Risk Ratio
	n/N	n/N		м-н,	Fixed, 95	% CI			M-H, Fixed, 95% Cl
Baden 1972	4/22	0/22				+		3.2%	9[0.51,157.78]
Yeh 1997	15/132	15/130			-			96.8%	0.98[0.5,1.93]
Total (95% CI)	154	152			•			100%	1.24[0.66,2.33]
Total events: 19 (Steroid), 15 (Co	ontrol)								
Heterogeneity: Tau ² =0; Chi ² =2.29	9, df=1(P=0.13); I ² =56.37%								
Test for overall effect: Z=0.67(P=	0.5)								
		Favours steroid	0.005	0.1	1	10	200	Favours control	

Analysis 6.30. Comparison 6 Long-term follow-up, Outcome 30 Abnormal EEG in tested survivors.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Baden 1972	4/12	0/1	+	- 5.75%	1.38[0.11,17.11]
Yeh 1997	15/63	15/70		94.25%	1.11[0.59,2.09]
Total (95% CI)	75	71	-	100%	1.13[0.61,2.08]
Total events: 19 (Steroid), 15 (Con	trol)				
Heterogeneity: Tau ² =0; Chi ² =0.03,	df=1(P=0.87); I ² =0%				
Test for overall effect: Z=0.38(P=0.	.7)	_		_	
		Favours steroid	0.1 0.2 0.5 1 2 5 10	Favours control	

Analysis 6.31. Comparison 6 Long-term follow-up, Outcome 31 Rehospitalisation in infancy.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Romagnoli 1999	10/25	15/25	+	14.83%	0.67[0.37,1.19]
Watterberg 2004	65/180	67/180	— <u>—</u>	66.24%	0.97[0.74,1.27]
Yeh 1997	12/132	19/130 —		18.93%	0.62[0.31,1.23]
Total (95% CI)	337	335	-	100%	0.86[0.68,1.08]
Total events: 87 (Steroid), 101	(Control)				
Heterogeneity: Tau ² =0; Chi ² =2.	38, df=2(P=0.3); I ² =15.81%				
Test for overall effect: Z=1.28(P	2=0.2)				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

Analysis 6.32. Comparison 6 Long-term follow-up, Outcome 32 Rehospitalisation in infancy in survivors.

Study or subgroup	Steroid	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Romagnoli 1999	10/23	15/22 -		15.28%	0.64[0.37,1.1]
Watterberg 2004	65/126	67/126		66.78%	0.97[0.77,1.23]
Yeh 1997	12/63	19/70 -	•	17.94%	0.7[0.37,1.33]
Total (95% CI)	212	218		100%	0.87[0.71,1.07]
Total events: 87 (Steroid), 101 (Cont	trol)				
Heterogeneity: Tau ² =0; Chi ² =2.5, df=	=2(P=0.29); l ² =19.88%				
Test for overall effect: Z=1.3(P=0.19))				
		Favours steroid	0.5 0.7 1 1.5 2	Favours control	

APPENDICES

Appendix 1. Standard search methods

PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh]))



Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or randomly or trial or clinical trial)

CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)

The Cochrane Library: (infant or newborn or neonate or neonatal or premature or preterm or very low birth weight or low birth weight or VLBW or LBW)

Appendix 2. Previous search methods

For previous versions of this review, we sought randomised controlled trials of postnatal corticosteroid therapy from the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 8), MEDLINE (1966 to August 2013), handsearching of paediatric and perinatal journals, and examination of previous review articles and information received from practising neonatologists. We searched MEDLINE using the terms: adrenal cortex hormones or dexamethasone or betamethasone or hydrocortisone or steroids or corticosteroids, limits randomised controlled trials, human, all infant: birth to 23 months. We contacted the authors of all studies, when possible, to confirm details of reported follow-up studies, or to obtain any information about long-term follow-up when none had been reported.

Appendix 3. Risk of bias tool

We used the standard methods of Cochrane and Cochrane Neonatal to assess the methodological quality (to meet the validity criteria) of the trials. For each trial, we sought information regarding the method of randomisation, and of blinding and reporting of all outcomes for all infants enrolled in the trial. We assessed each criterion as having low, high, or unclear risk. Two review authors separately assessed each study. We resolved disagreements by discussion. We added this information to the table 'Characteristics of included studies'. We evaluated the following issues and entered findings into the 'Risk of bias' table.

1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?

For each included study, we categorised the method used to generate the allocation sequence as:

a. low risk (any truly random process e.g. random number table; computer random number generator);

b. high risk (any non-random process e.g. odd or even date of birth; hospital or clinic record number); or

c. unclear risk.

2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?

For each included study, we categorised the method used to conceal the allocation sequence as:

a. low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);

b. high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or

c. unclear risk.

3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention adequately prevented during the study?

For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We categorised methods as:

a. low risk, high risk, or unclear risk for participants; and

b. low risk, high risk, or unclear risk for personnel;

4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately prevented at the time of outcome assessment?

For each included study, we categorised the methods used to blind outcome assessment. We assessed blinding separately for different outcomes or classes of outcomes. We categorised the methods as:

a. low risk for outcome assessors;

b. high risk for outcome assessors; or



c. unclear risk for outcome assessors.

5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were incomplete outcome data adequately addressed?

For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with total randomised participants), reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or were related to outcomes. When trial authors reported or supplied sufficient information, we re-included missing data in the analyses. We categorised methods as:

a. low risk (< 20% missing data);

b. high risk (\geq 20% missing data); or

c. unclear risk.

6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?

For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:

a. low risk (when it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);

b. high risk (when not all of the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); or

c. unclear risk.

7. Other sources of bias. Was the study apparently free of other problems that could put it at high risk of bias?

For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a potential source of bias related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as:

a. low risk;

b. high risk; or

c. unclear risk

If needed, we explored the impact of the level of bias by undertaking sensitivity analyses.

WHAT'S NEW

Date	Event	Description
23 January 2018	Amended	Additional data was incorrectly presented in table 1.3.2. It has been removed. The text of the review remains unchanged, as it did not reflect this error.

HISTORY

Protocol first published: Issue 3, 1998 Review first published: Issue 3, 1998



Date	Event	Description
10 July 2017	New citation required and conclusions have changed	Made changes to conclusions regarding hydrocortisone during first week of life
2 July 2017	New search has been performed	Updated searches 21 February 2017; updated text and data in May 2017, and again in July 2017. Added data from new studies (Baud 2016; Hochwald 2014). Also added data from 2 arms of a 3- arm study (Lauterbach 2006), which was not included in earlier reviews
8 January 2014	New citation required but conclusions have not changed	Added data from a pilot study of hydrocortisone for blood pres- sure support (Batton 2012). Made minor changes to discussion of another study (Stark 2001) with full publication of follow-up data (2013)
7 September 2013	New search has been performed	Updated searches 22 August 2013
5 November 2009	Amended	Edited reference citation (Peltoniemi 2005)
10 November 2008	New citation required but conclusions have not changed	Made substantive updates
10 September 2008	New search has been performed	This review updates the existing review, "Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants," which was published in the Cochrane Library (2003, Issue 1).
		This update includes data from a total of 28 trials, 12 of which provided long-term follow-up data.
10 April 2008	Amended	Converted to new review format
11 November 2002	New citation required and conclusions have changed	Made substantive amendments
11 November 2002	New search has been performed	This review updates the existing review, "Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants," which was published in the Cochrane Library (2001, Issue 1).
		Included in this update are additional long-term neurodevelop- mental follow-up data from 7 trials: Data for Baden 1972 and Ro- magnoli 1999 were published in full reports; data for Subhedar 1997 were published as a letter to the editor; data for Stark 2001 were obtained from a presented and published abstract; and da- ta for Sanders 1994, Sinkin 2000, and Watterberg 1999 were pro- vided by trial investigators. Also included 2 trials reporting short- term outcome data: Halac 1990 and Biswas 2003
		Although early steroid treatment facilitates extubation and re- duces risk of chronic lung disease, long-term follow-up studies indicate potentially increased risk of adverse neurosensory out- comes. Furthermore, short-term complications such as gastroin- testinal bleeding, intestinal perforation, hyperglycaemia, hyper- tension, hypertrophic cardiomyopathy, and growth failure are in- creased by early steroid treatment.



CONTRIBUTIONS OF AUTHORS

Lex Doyle collated data concerning long-term neurosensory outcomes; he assisted Henry Halliday and Richard Ehrenkranz in identifying all studies, synthesising the data, and writing earlier versions of this review. Richard Ehrenkranz assisted Henry Halliday in identifying all studies, synthesising the data, and writing earlier versions of this review. Henry Halliday identified all studies, synthesised the data, and wrote earlier versions of this review. Doyle in identifying all studies in the most recent literature search, synthesising the data, and writing the current version of this review.

DECLARATIONS OF INTEREST

Lex Doyle was Chief Investigator in the DART study, a randomised controlled trial of low-dose, short-course dexamethasone in ventilatordependent infants that was funded by the National Health and Medical Research Council of Australia.

Henry Halliday (HLH) is a retired neonatologist. He is joint Editor-in-Chief of the journal *Neonatology* and sits on many Data Monitoring and Trial Steering Committees for various neonatal/perinatal trials. He has received support in the past for co-ordinating the OSECT study (2000), for which AstraZeneca (Sweden) supplied metered-dose inhalers of budesonide and placebo. HLH also acts as a consultant for Chiesi Farmiceutici (Italy), a company that sells two neonatal drugs - Curosurf (a surfactant to treat respiratory distress syndrome) and Peyona (a caffeine preparation to treat apnoea of prematurity).

SOURCES OF SUPPORT

Internal sources

- Action Research UK Grant to study effects of postnatal steroids, UK.
- Action Research UK Grant to study long-term follow-up, UK.

External sources

• National Health and Medical Research Council, Australia.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We added the methods and plan for 'Summary of findings' tables and GRADE recommendations, which were not included in the original protocol nor in the last version of this review. For the 2017 update, we changed the title to "Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants."

INDEX TERMS

Medical Subject Headings (MeSH)

Administration, Inhalation; Anti-Inflammatory Agents [adverse effects] [*therapeutic use]; Bronchopulmonary Dysplasia [*prevention & control]; Cerebral Palsy [epidemiology]; Chronic Disease; Dexamethasone [adverse effects] [*therapeutic use]; Drug Administration Schedule; Glucocorticoids [adverse effects] [*therapeutic use]; Hydrocortisone [adverse effects] [*therapeutic use]; Infant, Low Birth Weight; Infant, Premature; Intestinal Perforation [epidemiology]; Oxygen Inhalation Therapy [statistics & numerical data]; Randomized Controlled Trials as Topic; Time Factors

MeSH check words

Humans; Infant, Newborn